AUTHOR INDEX

Abboud CN, *see* Rapoport AP
Abdy A, *see* Fox SM
Abel U, *see* Kaufmann M
Abeloff MD, *see* Saphner T
Abigerges D, *see* Gandia D
Ablin AR, *see* Gaynon PS
Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer, 44
Abrahamsen AF, *see* Abrahamsen JF
Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaløy S, Høst H. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age, 255
Abrams J, *see* Kornblith AB
Abrams RA, *see* Bierman PJ
Abromowitch M, *see* Hudson MM
Acuña LR, *see* Perez JE
Adams GL, *see* Adelstein DJ
Adams JD, *see* Trimble EL
Adelstein DJ, Kalish LA, Adams GL, Wagner H Jr, Oken MM, Remick SC, Mansour EG, Haselow RE. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group pilot study, 2136
Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung K-Y, Alt D, Fryer JG. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program, 1957
Ahmed T, *see* Feldman EJ
Aisenberg AC. Primary large-cell lymphoma of the mediastinum (editorial), 2291
Aisner J, Wiernik PH, Pearl P. Pregnancy outcome in patients treated for Hodgkin's disease, 507
— *see* Antman K
— *see* Chahinian AP
— *see* Kornblith AB
Ajani JA. In rectal carcinoma, colostomy or no colostomy: Is this the question? (letter), 193
—, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction, 22
Alberti D, *see* Robins HI
Alberts DS, *see* Feldman EJ
Albo VC, *see* Gaynon PS
Alcalá A, *see* Bladé J
Alcaraz JE, *see* Kimura E
Alexander E III, *see* Loeffler JS
Alexanian R, *see* Moulopoulos LA
Alexieva-Figusch J, *see* Foekens JA
Allegra CJ, *see* Grem JL
Allen J, *see* Packer RJ
Allen PK, *see* Dimopoulos MA
Allhoff EP, *see* de Riese WTW
Allingstrup L, *see* Ovesen L
Allison DC, *see* Lin PP
Alonso C, *see* Bladé J
— *see* Estorch M
Alt D, *see* Ahlgren JD
Altman SJ, *see* Rivkin SE
Altomonte V, *see* Kennedy MJ
Alvord WG, *see* Curti BD
— *see* Janik J
Amadori S, Testi AM, Aricò M, Comelli A, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L, Mandelli F for the Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia, 1046
— *see* Martelli M
American Society of Clinical Oncology Committee on Patient Advocacy. The physician as the patient's advocate (editorial), 1011
Ammirati M, *see* Black KL
Anasetti C, *see* Weaver CH
Andersen A, *see* Abrahamsen JF
Andersen J, *see* Cassileth PA
Anderson GL, *see* Bearman SI
Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, Bensinger WI, Martin PJ, Storb R, Sullivan KM, Hansen JA, Thomas ED. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience, 2342
Anderson JR, Armitage JO, Weisenburger DD. More on follicular lymphomas (letter), 1834
—, Jenkin RDT, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia PF, Exelby PR, Siegel S, Meadows AT, Hammond GD. Long-term follow-up of patients treated with COMP or LSA_2L_2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group, 1024
—, Roberson PK. Assessing secondary malignancy risk (letter), 1005
—, Vose JM, Bierman PJ, Weisenburger DD, Sanger WG, Pierson J, Bast M, Armitage JO. Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group, 218
Anderson JR, *see* Parker BA
— *see* Vose JM
Anderson KC, *see* Freedman AS
— *see* Tepler I
Andersson BS, *see* Giralt SA
Ando Y, *see* Minami H
Andreeff M, *see* Schwartz MA
Andrews JC, *see* Robertson JM
Andrien JM, *see* Focan C
Andriole GL. Serum prostate-specific antigen: Expanding

its role as a measure of treatment response in patients with prostate cancer (editorial), 596
Anselmino L, *see* Xu F-J
Antin J, *see* Wheeler C
Antin JH, *see* Shulman LN
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, Baker LH. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas, 1276
— *see* Chahinian AP
— *see* Wheeler C
Antman KH, *see* Sugarbaker DJ
— *see* Tepler I
Antoine E, *see* Khayat D
Appelbaum F, *see* Weaver CH
Appelbaum FR, *see* Anderson JE
— *see* Petersen FB
— *see* Weaver CH
Applewhite A, *see* Meyers PA
Arboleda J, *see* Kimura E
Arbuck S, *see* Reichman BS
Arbuck SG, *see* Grem JL
— *see* Trimble EL
Archimbaud E, *see* Quesnel B
Ardalan B. An alternate method to overcoming central venous catheter blockage in patients receiving high-dose fluorouracil and leucovorin: In reply (letter), 1434
—, Flores MRC. A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin (letter), 384
Argalia G, *see* Giovagnoni A
Aricò M, *see* Amadori S
Arilla MJ, *see* Sanz MA
Arioka H, *see* Karato A
Ariyan S, *see* Buzaid AC
Arlin Z, *see* Feldman EJ
Armand JP, *see* Cvitkovic E
Armand J-P, *see* Gandia D
— *see* Rousselet G
Armitage JO, *see* Anderson JR
— *see* Bierman PJ
— *see* Vose JM
— *see* Williams CD
Arnold A, *see* Murray N
Aronson FR, *see* Atkins MB
— *see* Sosman JA
— *see* Sparano JA
Arrighini A, *see* Garaventa A
Arusell RM, *see* Dinapoli RP
Arzoomanian RZ, *see* Robins HI
Ascari E, *see* Gobbi PG
Ashenhurst JB, *see* Cobleigh MA
Ashley S, *see* Paterson AHG
Ashmun RA, *see* Pappo AS
Asmar L, *see* Pappo AS
Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations, 1780
Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group, *see* Amadori S
Astori C, *see* Lazzarino M
Ater J, *see* Packer RJ
Athmann LM, *see* Loprinzi CL
Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, Trochanowski B, Lin S, Toomasi F, Brennan M. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer, 425
Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, Sosman JA, Boldt DH, Doroshow JH, Aronson FR, Sznol M. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma, 661
— *see* Sosman JA
— *see* Sparano JA
Atkinson JB, *see* Matthay KK
Atzpodien J, *see* de Riese WTW
Auclerc G, *see* Khayat D
Ault K, *see* Wheeler C
Australia New Zealand Breast Cancer Trials Group, *see* Coates A
Avanzini P, *see* Gobbi PG
Averbuch SD, *see* Nussbaum SR
Avvisati G, *see* Martelli M
Ayash L, *see* Tepler I
— *see* Wheeler C
Ayers D, *see* Gajjar AJ
Ayoub J, *see* Murray N
Azli N, *see* Cvitkovic E
— *see* Rousselet G

Bacci G, *see* Picci P
Bachouchi M, *see* Cvitkovic E
— *see* Rousselet G
Backstrom L, *see* Pullen J
Badger C, *see* Weaver CH
Bagnulo S, *see* Garaventa A
Baier M, *see* Feldman EJ
— *see* List AF
Baillet F, *see* Housset M
Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, Sheinfeld J, Russo P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study, 598
— *see* Seidman AD
Baker LH, *see* Antman K
Baker RR, *see* Lin PP
Baker SP, *see* Savarese DMF
Bakker W, *see* Giaccone G
Balcerzak SP, *see* Antman K
— *see* Gandara DR
— *see* Grunberg SM

Baldini N, *see* Picci P
Balis FM, *see* Savarese DMF
Balmanno K, *see* Newell DR
Bander NH, *see* Oosterwijk E
Banzet P, *see* Khayat D
Bär BMAM, Schattenberg A, Mensink EJBM, Van Kessel AAG, Smetsers TFCM, Knops GHJN, Linders EHP, De Witte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation, 513
Barber G, *see* Jakacki RI
Barcos M, *see* Parker BA
Barlogie B, *see* Antman K
Barlow JF, *see* Witzig TE
Barnard D, *see* Woods WG
Barnes P, *see* Zerbini C
Barnes R, *see* Gilbert L
Barnicle M, *see* Cella DF
Bartolucci A, *see* Johnson DH
Baskind P, *see* Feldman EJ
Bass D, *see* Johnson DH
Bast M, *see* Anderson JR
Bast RC Jr, *see* Peters WP
— *see* Xu F-J
Bataille R, *see* Moreau P
Batchelor D, *see* Kruit WHJ
Bates S, *see* Wilson WH
Bauters F, *see* Facon T
— *see* Quesnel B
Bayssas M, *see* Burris H
Bazex PA, *see* Khayat D
Beard CJ, *see* Kirn D
Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation, 1729
Beauduin M, *see* D'Hondt V
— *see* Razavi D
Becker DP, *see* Black KL
Beckwith JB, *see* Green DM
Beex LVAM, *see* van Holten-Verzantvoort ATM
Begg C, *see* Seidman AD
Begg CB, *see* McCormick B
Behm FG, *see* Pui C-H
— *see* Sandoval C
Beijnen JH, *see* Huizing MT
Beitler JJ, *see* Wadler S
Belasco J, *see* Horowitz ME
Bell B, *see* Furman WL
Belloni PA, *see* Pastorino U
Benassi MS, *see* Picci P
Bengala C, *see* Tondini C
Benhammouda A, *see* Khayat D
Benjamin D, *see* Woods WG
Bennett JM, *see* Cassileth PA
— *see* Cummings FJ
Bensinger W, *see* Radich JP
— *see* Weaver CH
Bensinger WI, *see* Anderson JE
— *see* Petersen FB
Benson AB III, *see* Cobleigh MA
Benyunes MC, *see* Petersen FB
Berchier MC, *see* Sculier JP
Berchuck A, *see* Xu F-J
Berezin F, *see* Vokes EE
Berg SL, *see* Savarese DMF
Berinstein NL, Reis MD, Ngan BY, Sawka CA, Jamal HH, Kuzniar B. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma, 1344
Berkery R, *see* Reichman BS
Berná L, *see* Estorch M
Bernasconi C, *see* Lazzarino M
Bernhardt B, *see* Cooper MR
Berthold F, *see* Brodeur GM
Bertino JR. Ode to methotrexate: Karnofsky Memorial Lecture, 5
Besalduch J, *see* Bladé J
Besses C, *see* Bladé J
Beutler E, *see* Saven A
Beveridge RA, *see* Grem JL
— *see* Kennedy MJ
Bey P, *see* Tournade MF
Bianco A, *see* Perez JE
Bianco J, *see* Weaver CH
Bierer BE, *see* Wheeler C
Bierman PJ, Vose JM, Leichner PK, Quadri SM, Armitage JO, Klein JL, Abrams RA, Dicke KA, Vriesendorp HM. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease, 698
— *see* Anderson JR
— *see* Vose JM
Bigner DD, *see* Schold SC Jr
Bijvoet OLM, *see* van Holten-Verzantvoort ATM
Bilezikian JP, *see* Nussbaum SR
Binder RA, *see* Grem JL
Bjarnason GA, *see* Hrushesky WJM
Bjergaard JP, *see* Quesnel B
Black KL, Ciacci JD, Ammirati M, Selch MT, Becker DP. Clinical trial of *Serratia marcescens* extract and radiation therapy in patients with malignant astrocytoma, 1746
Black PMcL, *see* Loeffler JS
Blackburn GL, *see* Chlebowski RT
Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, González-Brito G, Hernández-Martín J, Fernández-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura MV, Font L, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé J. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients, 1165
Blake K, *see* Freedman AS
Blanchard CG, *see* Remick SC
Blättler WA, *see* Grossbard ML
Blendowski C, *see* Cella DF

Bleyer WA, *see* Gaynon PS
Blijham G, *see* van Holten-Verzantvoort ATM
Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration, 467
Bloom JR, Fobair P, Gritz E, Wellisch D, Spiegel D, Varghese A, Hoppe R. Psychosocial outcomes of cancer: A comparative analysis of Hodgkin's disease and testicular cancer, 979
Blum R, *see* Johnson DH
Blum RH, *see* Edmonson JH
Bodis S, Henry-Amar M, Bosq J, Burgers JMV, Mellink WAM, Dietrich P-Y, Dupouy N, Noordijk EM, Raemaekers JMM, Thomas J, Eghbali H, Régnier R, Tanguy A, Verdonck L, Michel J, Zittoun R, Kerkhofs H, Hayat M. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols, 225
Boiocchi M, *see* Carbone A
Bokemeyer C, Schmoll H-J. Secondary neoplasms following treatment of malignant germ cell tumors, 1703
Boldt DH, *see* Atkins MB
— *see* Sosman JA
Bolhuis RLH, *see* Kruit WHJ
Bolognia JL, *see* Buzaid AC
Bonadonna G, *see* Tondini C
Bonenkamp JJ, *see* Hermans J
Boni L, *see* Garaventa A
Bonomi A, *see* Cella DF
Bonomi P, *see* Cella DF
— *see* Johnson DH
Bookman MA, *see* Reed E
Boon MC, *see* Hermans J
Boracchi P, *see* Silvestrini R
Borel C, *see* Khayat D
Borner MM, Sartor O. Response to "More is not always better: A case for low-dose leucovorin": In reply (letter), 1435
—, Sartor O. More is not always better: A case for low-dose leucovorin (letter), 382
Borowitz MJ, *see* Pui C-H
— *see* Winick NJ
Bosl GJ, *see* Bajorin DF
— *see* Seidman AD
Bosq J, *see* Bodis S
Botet J, *see* Kemeny N
Botet JF, *see* Smith JW
Boucheix C, *see* Fière D
Boulden T, *see* Hudson MM
Boussen H, *see* Cvitkovic E
Boveri E, *see* Lazzarino M
Bowman LC, *see* Marina NM
— *see* Sandoval C
Bowman WP, *see* Winick NJ
Boyer C, *see* Xu F-J
Boyett J, *see* Pullen J
Boyett JM, *see* Packer RJ
Bozeman P, *see* Hudson MM
Brady A, *see* Weissman D
— *see* Weissman DE
Braly PS, *see* Christen RD
Brand A, *see* Weijl NI
Brand E, Davidson SA. Dodging the dogma (letter), 587
Brandhorst JS, *see* Hoover HC Jr
Brandwein J, *see* Crump M
Brannon J, *see* Cella DF
Brault P, *see* Quesnel B
Braun T, *see* Grunberg SM
Braun TJ, *see* Gandara DR
Breed WP, *see* Carde P
Breeden ES, *see* Murphy BR
Brenckman WD Jr, *see* Laufman LR
Brennan M, *see* Atiq OT
Brennan MF, *see* Smith JW
Brenner DE, *see* Waterhouse DM
Breslow NE, *see* Green DM
Brice P, *see* Marolleau JP
Bridges JD, *see* Gray JR
Broder S, *see* Pluda JM
Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look AT, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment, 1466
Bron D, *see* Carde P
Brooks JSJ, *see* Edmonson JH
Brouillard M, *see* Facon T
Broustet A, *see* Fière D
Browman GP, Levine MN, Hodson DI, Sathya J, Russell R, Skingley P, Cripps C, Eapen L, Girard A. The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life Instrument for clinical trials of radiation therapy in locally advanced head and neck cancer, 863
Brown B, *see* Pryzant RM
Brown LD, *see* Dinapoli RP
Bruckner H, *see* Wadler S
Bruera E, *see* Finn JW
Brühmüller S, *see* Wolfrom C
Brunat-Mentigny M, *see* Pein F
Brunel P, *see* Housset M
Brunnert K, *see* Kaufmann M
Brusamolino E, *see* Lazzarino M
— *see* Tura S
Bryant G, *see* Wilson WH
Buchanan G, *see* Winick NJ
Buchanan GR, *see* Kamen BA
— *see* Winick N
— *see* Winick NJ
Buckley J, *see* Woods WG
Buckley JD, *see* Wells RJ
Buckman RA, *see* Vandenberg TA
Buckner CD, *see* Anderson JE

— *see* Petersen FB
— *see* Radich JP
— *see* Weaver CH
Buckner JC, *see* Dinapoli RP
Budd A, *see* Kemeny N
Budman D, *see* Peters WP
Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study, 161
— *see* Laufman LR
Bundy BN, *see* Stehman FB
Bunt AMG, *see* Hermans J
Buonanno MC, *see* Lazzarino M
Burdach S, Jürgens H, Peters C, Nürnberger W, Mauz-Körholz C, Körholz D, Paulussen M, Pape H, Dilloo D, Koscielniak E, Gadner H, Göbel U. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma, 1482
— *see* Ladenstein R
Bureau G, *see* Sculier JP
Bürger D, *see* Tournade MF
Burger PC, *see* Schold SC Jr
Burgers JMV, *see* Bodis S
Burgers M, *see* Tournade MF
Burgers MJV, *see* Carde P
Burghouts JThM, *see* Giaccone G
Burleson WD, *see* Hazuka MB
Burnham NL, *see* Loprinzi CL
Burns RC, *see* Campbell KA
Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, LeBail N, Von Hoff D. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion, 950
Burris HA III, *see* Rothenberg ML
Burroughs JN, *see* Reyno LM
Busson A, *see* Carde P
Busson P, *see* Cvitkovic E
— *see* Rousselet G
Butow PN, *see* Dunn SM
Buyse M, Piedbois P. Meta-analyses, use and misuse (letter), 382
— *see* Pastorino U
Buzaid AC, Sandler AB, Mani S, Curtis AMcB, Poo W-J, Bolognia JL, Ariyan S. Role of computed tomography in the staging of primary melanoma, 638
Buzzard IM, *see* Chlebowski RT
Buzzoni R, *see* Tondini C
Byers RM, *see* Dimery IW
Byrne M, *see* Levi JA

Cabanillas F, *see* Dimopoulos MA
— *see* Robertson LE
Caffier H, *see* Kaufmann M
Caguioa P, *see* Hesketh P
Cahn JY, *see* Fière D
Caillou B, *see* Carde P
Cain JM, *see* Seewaldt V
Cairncross JG, *see* Schold SC Jr
Caldora P, *see* Picci P
Caliendo G, *see* Sosman JA
Calvert AH, *see* Newell DR
Calzone KA, *see* Waterhouse DM
Campa T, *see* Formelli F
Campanacci M, *see* Picci P
Campbell KA, Burns RC, Sitzmann JV, Lipsett PA, Grochow LB, Niederhuber JE. Regional chemotherapy devices: Effect of experience and anatomy on complications, 822
Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma, 623
Cancer and Leukemia Group B, *see* Kornblith AB
Canellos G, *see* Cooper MR
— *see* Shulman LN
Canellos GP, Demetri GD. Myelosuppression and "conventional" chemotherapy: What price, what benefit? (editorial), 1
— *see* Freedman AS
— *see* Kirn D
— *see* Kornblith AB
Canetta R, *see* Reichman BS
— *see* Trimble EL
Canetta RM, *see* Reyno LM
Cannistra SA, *see* Tepler I
Canon J-L, *see* D'Hondt V
Cantor AB, *see* Douglass EC
— *see* Mendenhall NP
Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M. Human immunodeficiency virus–associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression, 1674
Carcangiu ML, *see* Magriples U
Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJV, Noordijk EM, Tanguy A, Meerwaldt JH, Le Fur R, Somers R, Kluin-Nelemans HC, Busson A, Breed WP, Bron D, Holdrinet A, Rutten, EHJM, Michiels JJ, Regnier R, Debusscher L, Musella R, Fargeot P, Thyss A, Cattan A, Rigal-Huguet F, Roth S, Caillou B, Dupouy N, Henry-Amar M. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group, 2258
Carella A, *see* Williams CD
Carey R, *see* Bajorin DF
Carey TE, *see* Vlock DR
Caride VJ, *see* Cooper DL
Carli M, *see* Garaventa A
— *see* Tournade MF
Carlsen NLT, *see* Brodeur GM
Carpio N, *see* Sanz MA
Carrera CJ, *see* Saven A
Carrió I, *see* Estorch M
Carroll AJ, *see* Pui C-H
Carson DA, *see* Saven A

Carstensen J, *see* Stål O
Carswell EA, *see* Oosterwijk E
Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial, 148
Case D Jr, *see* Parker BA
Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein M, Oken MM. Autologous bone marrow transplant in acute myeloid leukemia in first remission, 314
Castel V, *see* Brodeur GM
Castleberry RP, *see* Brodeur GM
Catalano G, *see* Cascinu S
Cates C, *see* Kim S
Catino A, *see* Lorusso V
Cattan A, *see* Carde P
Cavanna L, *see* Gobbi PG
Cazzola A, *see* Picci P
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor S IV, Thomas CR Jr, Harris J. The functional assessment of cancer therapy scale: Development and validation of the general measure, 570
Cellerino R, *see* Giovagnoni A
Cha SS, *see* Pisansky TM
Chabner BA, *see* Goldspiel BR
— *see* Wilson WH
Chabot G, *see* Gandia D
Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE II, Aisner J, Ellison RR, Leone L, Vogelzang NJ, Green MR. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B, 1559
Chamberlain MC, Dirr L. Involved-field radiotherapy and intra-ommaya methotrexate/cytarabine in patients with AIDS-related lymphomatous meningitis, 1978
— *see* Kim S
Chambers J, *see* Khojasteh A
Champlin RE, *see* Giralt SA
Chang AY, *see* Johnson DH
Chappell RJ, *see* Gaynon PS
Chase E, *see* Dana BW
Chastagnier P, *see* Méresse V
Chatelain C, *see* D'Hondt V
Chatelut E, *see* Kim S
Chaudhry V, *see* Rowinsky EK
Chauvin F, *see* Ladenstein R
Chen A, *see* Grem JL
Chen K-Y, *see* Dugan M
Chen Y-C, *see* Cheng A-L
Cheng A-L, Su I-J, Chen Y-C, Lee T-C, Wang C-H. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors, 109
Cheson BD, *see* Wilson WH
Cheung N-KV, *see* Kushner BH
Chiesa G, *see* Pastorino U
Chilcote RR, *see* Anderson JR
Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP, Martino S, Khandekar JD, York RM, Jeffery RW, Elashoff RM, Wynder EL for the Women's Intervention Nutrition Study. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer, 2072
Choi P, *see* Dugan M
Chollet P, *see* Fumoleau P
Chow C, *see* Savarese DMF
Choy D, *see* Dugan M
Chretien Y, *see* Housset M
Christen RD, McClay EF, Plaxe SC, Yen SSC, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinsky DR, Freddo JL, Braly PS, O'Quigley J, Howell SB. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin, 2417
Christian MC, *see* Trimble EL
Churchill WH, *see* Wheeler C
Ciacci JD, *see* Black KL
Civin CI, *see* Pui C-H
Clamon G, Clamon L. Relationship between tumor area, tumor volume, and criteria of response in clinical trials (letter), 1005
Clamon GH. Response migration: Area versus volume for tumore response assessment: In reply (letter), 1839
Clamon L, *see* Clamon G
Clamond GH, *see* Antman K
Clark EB, *see* Schwartz CL
Clarke-Pearson DL, *see* Xu F-J
Clavel M, *see* Steward WP
Clendennin NJ, *see* Laufman LR
Clerici M, *see* Formelli F
— *see* Pastorino U
Cleton FJ, *see* van Holten-Verzantvoort ATM
— *see* Weijl NI
Clift R, *see* Weaver CH
Clift RA, *see* Petersen FB
Closon MT, *see* Fumoleau P
Closon MTh, *see* Focan C
Coates A, Forbes J, Simes RJ for the Australian New Zealand Breast Cancer Trials Group. Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer (letter), 2050
Coates AS, *see* Gelber RD
Cobleigh MA, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB III, Rademaker AW, Ashenhurst JB, Wade JL III, Wolter J. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer, 474
Coccia P, *see* Vose JM
Coccia PF, *see* Anderson JR
— *see* Tubergen DG
Cochran A, *see* Morton DL
Cody R, *see* Wahl RL
Cohen A, *see* Kemeny N
Cohen C, *see* Wadler S
Cohen CJ, *see* Segna RA
Cohen HJ, *see* Asselin BL

Cohen JD, *see* Robins HI
Colardelle F, *see* Housset M
Cole D, *see* Weber J
Coleman CN, *see* Recht A
Collier MA, *see* Laufman LR
Collins J, *see* Reichman BS
Colominas P, *see* Bladé J
Coltman C, *see* Dana BW
Coluzzi S, *see* Martelli M
Colvin OM, *see* Cassileth PA
Come S, *see* Abner AL
Come SE, *see* Recht A
Comelli A, *see* Amadori S
Com-Nougué C, *see* Tournade MF
Coniglio D, *see* Peters WP
Conlon KC, *see* Curti BD
Connolly JL, *see* Abner AL
— *see* Healey EA
Connors JM, *see* O'Reilly SE
Constine LC, *see* Schwartz CL
Constine LS, *see* Rapoport AP
Conti JA, *see* Kemeny N
Cook EF, *see* Healey EA
Cook G, *see* Burris H
Cooper BA, *see* Antman K
Cooper DL, Caride VJ, Zloty M, Germino J, Farber LR, Hoffer PB. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy, 1092
Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study, 155
— *see* Kornblith AB
— *see* Parker BA
Cooper RM, *see* Antman K
Copeland B, *see* Saven A
Coppola DJ, *see* Asselin BL
Coradini D, *see* Silvestrini R
Coral F, *see* Freedman AS
— *see* Grossbard ML
Cork A, *see* Robertson LE
Corn B, *see* Curran WJ Jr
Cornblath DR, *see* Rowinsky EK
Cornelison TL, *see* Reed E
Corson JM, *see* Chahinian AP
— *see* Sugarbaker DJ
Costa A, *see* Formelli F
Costanzi JJ, *see* Rivkin SE
Courbon B, *see* Méresse V
Couture F, *see* Crump M
Cowan KH, *see* Gilbert L
— *see* Saverese DMF
Cox E, *see* Fox SM
Cox JD, *see* Jacobs JP
Coy P, *see* Murray N
Coze C, *see* Ladenstein R
CPT-11 Gastrointestinal Cancer Study Group, *see* Shimada Y
Crabtree WN, *see* de Riese WTW
Craft AW, *see* Skinner R
Crawford DE, *see* Bukowski RM
Crawford ED, *see* Bajorin DF
Crawford J, *see* Johnson DH
Crawford SW, *see* Anderson JE
Creasman WT, *see* Stehman FB
Creekmore SP, *see* Curti BD
— *see* Janik J
Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87, 279
Cripps C, *see* Browman GP
Crist W, *see* Pullen J
Crist WM, *see* Pappo AS
— *see* Pui C-H
— *see* Rivera GK
Crowley J, *see* Antman K
— *see* Gandara DR
— *see* Grunberg SM
Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Gilewski T, Hudis C, Gulati S, Norton L. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer, 1144
Crown JPA, *see* Reichman BS
Crowther D, *see* Steward WP
Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DMC, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe SB, Keating A. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant, 704
Cuevas MA, *see* Perez JE
Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death, 29
Cunningham D, *see* Hill M
Curley T, *see* Scher HI
— *see* Seidman AD
Curran WJ Jr, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Corn B, Nelson DF. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: A report of Radiation Therapy Oncology Group 83-02, 857
Currie V, *see* Reichman BS
Curti BD. Adoptively transferred anti–CD3-activated T cells for human tumor immunotherapy: In reply (letter), 1836
—, Longo DL, Ochoa AC, Conlon KC, Smith JW II, Alvord WG, Creekmore SP, Fenton RG, Gause BL, Holmlund J, Janik JE, Ochoa J, Rice PA, Sharfman WH, Sznol M, Urba WJ. Treatment of cancer pa-

tients with ex vivo anti–CD3-activated killer cells and interleukin-2, 652
Curtis AMcB, *see* Buzaid AC
Curtis RE, *see* Travis LB
Cvitkovic E, Bachouchi M, Boussen H, Busson P, Rousselet G, Mahjoubi R, Flores P, Tursz T, Armand JP, Azli N. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: A review of 255 consecutive cases, 2434
— *see* Rousselet G
Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase I dose-escalation trial of iodine 131–labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma, 2021

Da Costa L, *see* Gandia D
d'Ablaing G III, *see* Stehman FB
Dabouis G, *see* Sculier JP
Dahlberg S, *see* Dana BW
Daidone MG, *see* Silvestrini R
Dalesio O, *see* Giaccone G
Dalton W, *see* List AF
Daly L, *see* Xu F-J
Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy, 644
d'Angelo T, *see* Gilbert L
D'Angio GJ, *see* Green DM
Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer, 751
Dantis L, *see* Schwartz MA
Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer, 1873
Davidson NE, *see* Kennedy MJ
Davidson SA, *see* Brand E
Davis TE, *see* Cummings FJ
De Bernardi B, *see* Brodeur GM
— *see* Garaventa A
De Brier F, *see* Razavi D
De Cervens C, *see* Méresse V
De Forni M, *see* Gandia D
de Koning HYWCM, *see* Foekens JA
de Kraker J, *see* Tournade MF
de la Rubia J, *see* Sanz MA
De Lena M, *see* Lorusso V
— *see* Perez JE
De Palo G, *see* Formelli F
de Riese WTW, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, Atzpodien J, Kirchner H. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma, 1804
De Valck C, *see* Méresse V
de Vathaire F, *see* Rousselet G
De Witte T, *see* Bär BMAM
Dear K, *see* Cooper MR
DeBoer G, *see* Shepherd FA
Debusscher L, *see* Carde P
Deeg J, *see* Weaver CH
DeFelice JM, *see* Spiers ASD
DeFusco PA, *see* Wolmark N
Deisseroth AB, *see* Giralt SA
Dekker AW, *see* Lockhorst HM
Del Giglio A, *see* Giralt SA
Delanian S, *see* Housset M
DeLap RJ, *see* Marshall JL
Delemarre JFM, *see* Tournade MF
— *see* van Leeuwen FE
Delgado FM, *see* Fumoleau P
Delgado MAG, *see* Fumoleau P
Delozier T, *see* Fumoleau P
Delvaux N, *see* Razavi D
Demard F, *see* Dassonville O
Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer, 1418
Demeter J, Lehoczky D. Splenectomy and the risk of developing leukemia (letter), 2287
Demetri G, *see* Tepler I
Demetri GD, *see* Canellos GP
Denicoff AM, *see* Savarese DMF
Department of Veteran Affairs Laryngeal Cancer Study Group, *see* Vlock DR
Derde M-P, *see* Razavi D
Dershaw DD, *see* Seidman AD
Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes, 777
DeSombre K, *see* Xu F-J
DeSwarte J, *see* Woods WG
Deutsch TA, *see* Cobleigh MA
Dewey H, *see* Hesketh P
D'Hondt V, Weynants P, Humblet Y, Guillaume T, Canon J-L, Beauduin M, Duprez P, Longueville J, Müll R, Chatelain C, Symann M. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study, 2063
Di Cataldo A, *see* Garaventa A
Di Fronzo G, *see* Silvestrini R
Di Mauro MG, *see* Formelli F
di Montezemolo LC, *see* Garaventa A
Di Renzo N, *see* Gobbi PG
Di Tullio MT, *see* Garaventa A
Diasio RB, *see* Sparano JA
Dicato M, *see* Focan C
Dicke KA, *see* Bierman PJ
Dietrich P-Y, *see* Bodis S
Dilloo D, *see* Burdach S
Dilmanian FA, *see* Warrell RP Jr
Dimery IW, Peters LJ, Goepfert H, Morrison WH, Byers

RM, Guillory C, McCarthy K, Weber RS, Hong WK. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma, 1919
Dimitrov N, *see* Wolmark N
Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum β_2-microglobulin in Hodgkin's disease, 1108
— *see* Moulopoulos LA
Dinapoli RP, Brown LD, Arusell RM, Earle JD, O'Fallon JR, Buckner JC, Scheithauer BW, Krook JE, Tschetter LK, Maier JA, Pfeifle DM, Gesme DH Jr. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma, 1316
DiPersio JF, *see* Rapoport AP
Dirr L, *see* Chamberlain MC
Divgi CR, *see* Czuczman MS
— *see* Oosterwijk E
— *see* Schwartz MA
Dixon P, *see* Murray N
d'Oleire F, *see* Robins HI
Dölken G, *see* Finke J
Dombernowsky P, *see* Pedersen-Bjergaard J
Domingo A, *see* Bladé J
Donaldson SS, *see* Hancock SL
— *see* Hudson MM
Donehower RC, *see* Peereboom DM
— *see* Rowinsky EK
Doney K, *see* Petersen FB
Donfrancesco A, *see* Garaventa A
Donohue JP, *see* Fox EP
— *see* Murphy BR
Dony K, *see* Weaver CH
Dooley WC, *see* Lin PP
Doroshow J, *see* Sosman JA
Doroshow JH, *see* Antman K
— *see* Atkins MB
— *see* Sparano JA
Dorr R, *see* List AF
Dose AM, *see* Loprinzi CL
Dottino PR, *see* Segna RA
Douglass E, *see* Marina NM
Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study, 96
— *see* Gajjar AJ
— *see* Heideman RL
Dowlatshahi K, *see* Cobleigh MA
Driesschaert P, *see* Focan C
Dropcho EJ, *see* Schold SC Jr
Dubbelman AC, *see* Huizing MT
Duerst RA, *see* Rapoport AP
Duffy J, *see* Loprinzi CL
Dufmats M, *see* Stål O
Dufour B, *see* Housset M
Dugan M, Choy D, Ngai A, Sham J, Choi P, Shiu W, Leung T, Teo P, Prasad U, Lee S, Villalon A, Tan BC, Chen K-Y, Hsu M-M, Vootiprux V, Dy E, Hoffman A, Reisman A, Neal J. Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in southeast Asia: An Asian-Oceanian Clinical Oncology Association Group study, 70
Duggan D, *see* Cooper MR
Duhamel A, *see* Facon T
Dunn SM, Butow PN, Tattersall MHN, Jones QJ, Sheldon JS, Taylor JJ, Sumich MD. General information tapes inhibit recall of the cancer consultation, 2279
—, Patterson PU, Butow PN, Smartt HH, McCarthy WH, Tattersall MHN. Cancer by another name: A randomized trial of the effects of euphemism and uncertainty in communicating with cancer patients, 989
Dupouy N, *see* Bodis S
— *see* Carde P
Duprez P, *see* D'Hondt V
DuRoss DJ, *see* Robertson JM
Durr ED, *see* Pisansky TM
Dutcher JP, *see* Sparano JA
Dworzanin LM, *see* Robertson JM
Dy E, *see* Dugan M

Eapen L, *see* Browman GP
Earle JD, *see* Dinapoli RP
— *see* Pisansky TM
Eastern Cooperative Oncology Group, *see* Grossman SA
Eastman AY, *see* Remick SC
Eberlein T, *see* Abner AL
Eberly S, *see* Rapoport AP
Eckardt J, *see* Burris H
Eckardt JR, *see* Rothenberg ML
Eckberg K, *see* Cella DF
Edelstein M, *see* Cassileth PA
Eder JP, *see* Wheeler C
Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas, 1269
— *see* Saphner T
Efird J, *see* Willett CG
Eggermont AMM, *see* Kruit WHJ
Eghbali H, *see* Bodis S
Egorin MJ, *see* Reyno LM
Eguchi K, *see* Karato A
Einhorn LH. Curable neoplasms and the ethics of clinical trials (editorial), 593
— *see* Fox EP
— *see* Fox SM
— *see* Johnson DH
— *see* Murphy BR
Einzig A, *see* Sparano JA
Eisenhauer EA, *see* Peereboom DM
— *see* Vandenberg TA
Elashoff RM, *see* Chlebowski RT
Elias A, *see* Antman K
— *see* Wheeler C
Elias AD, *see* Tepler I
Eliel MR, *see* van Leeuwen FE
Eliseo L, *see* Grossbard ML
Ellerton J, *see* Cooper MR

Ellison NM, *see* Ahlgren JD
Ellison RR, *see* Chahinian AP
Elomaa I, *see* Blomqvist C
Elson P, *see* Taylor CD
Elwood LJ, *see* Gilbert L
Enns RE, *see* Kimura E
Ensign LG, *see* Heyn R
Ensminger WD, *see* Robertson JM
Epstein CL, *see* Grossbard ML
Ercolani P, *see* Giovagnoni A
Ernest ML, *see* Sosman JA
— *see* Sparano JA
Essner R, *see* Morton DL
Estapé J, *see* Bladé J
Estey E, *see* Gandhi V
— *see* Kurzrock R
— *see* Quesnel B
Estorch M, Carrió I, Martínez-Duncker D, Berná L, Torres G, Alonso C, Ojeda B. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies, 1264
Ettinger D, *see* Johnson DH
Ettinger DS, *see* Grossman SA
— *see* Rowinsky EK
Ettinghausen SE, *see* Weber J
European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group, *see* Paridaens R
Evans AE, *see* Brodeur GM
Evans WE, *see* Rodman JH
Evans WK, *see* Murray N
— *see* Shepherd FA
Ewel CH, *see* Janik J
Exelby PR, *see* Anderson JR

Fabbri N, *see* Picci P
Facada A, *see* Hesketh P
Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, Bauters F, Fenaux P. Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases, 1553
Fair WR, *see* Bajorin DF
— *see* Seidman AD
Fairclough D, *see* Hudson MM
Fairclough DL, *see* Gajjar AJ
— *see* Heideman RL
Falkson G, *see* Cummings FJ
Falletta JM, *see* Katz JA
Faragher D, *see* Cooper MR
Farber LR, *see* Cooper DL
Fargeot P, *see* Carde P
Farmer ER, *see* Kennedy MJ
Farvacques C, *see* Razavi D
Faura MV, *see* Bladé J
Favrot M, *see* Brodeur GM
Fedeli A, *see* Cascinu S
Fedeli SL, *see* Cascinu S
Federico M, *see* Gobbi PG
Fefer A, *see* Petersen FB
Feierabend C, *see* Robins HI
Feld R, *see* Murray N
— *see* Shepherd FA
Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng Y-M, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia, 2002
Fenaux P, *see* Facon T
— *see* Quesnel B
Fengler R, *see* Wolfrom C
Fenton RG, *see* Curti BD
— *see* Janik J
Fernández-Calvo J, *see* Bladé J
Ferrara J, *see* Wheeler C
Ferrari S, *see* Picci P
Ferree CR, *see* Mendenhall NP
Fiacchini M, *see* Tura S
Fields S, *see* Burris H
Fière D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant J-P, Varet B, Broustet A, Cahn JY, Rigal-Huguet F, Witz F, Michaux J-L, Michallet M, Reiffers J for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy, 1990
Figge DC, *see* Seewaldt V
Figlin RA, *see* Vogelzang NJ
Fine HA, *see* Loeffler JS
Finegold M, *see* Douglass EC
Fink KI, *see* Atkins MB
Finke J, Slanina J, Lange W, Dölken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma, 1668
Finkelstein DM, *see* Grossman SA
Finklestein JZ, *see* Gaynon PS
Finlay J, *see* Packer RJ
Finn JW, Walsh TD, MacDonald N, Bruera E, Krebs LU, Shepard KV. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer, 967
Finn R, *see* Czuczman MS
Finn RD, *see* Oosterwijk E
— *see* Schwartz MA
Firgaira FA, *see* Seshadri R
Firket P, *see* Pastorino U
Fischbach AJ, *see* Curran WJ Jr
Fischkoff S, Martin K. Response to "More is not always better: A case for low-dose leucovorin" (letter), 1434
Fisher B. Thoughts from a journey: The 1993 ASCO Presidential Address, 2297
— *see* Wolmark N
Fisher ER, *see* Wolmark N
Fisher L, *see* Petersen FB
Fisher LD, *see* Anderson JE
Fisher RI, *see* Atkins MB
— *see* Dana BW
— *see* Sosman JA
— *see* Sparano JA

Fisher SG, *see* Sosman JA
— *see* Vlock DR
Fisherman J, *see* Reichman BS
Fisherman JS, *see* Trimble EL
Fleming TR, *see* Moertel CG
Fleuren GJ, *see* Oosterwijk E
Flores MRC, *see* Ardalan B
Flores P, *see* Cvitkovic E
Foa R. Does interleukin-2 have a role in the management of acute leukemia?, 1817
Fobair P, *see* Bloom JR
Focan C, Andrien JM, Closon MTh, Dicato M, Driesschaert P, Focan-Henrard D, Lemaire M, Lobelle JP, Longree L, Ries F. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial, 1253
Focan-Henrard D, *see* Focan C
Foekens JA, van Putten WLJ, Portengen H, de Koning HYWCM, Thirion B, Alexieva-Figusch J, Klijn JGM. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis, 899
Fojo A, *see* Wilson WH
Font L, *see* Bladé J
Fontanesi J, *see* Heideman RL
Fontanillas M, *see* Bladé J
Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report, 1118
— *see* Rowinsky EK
Forbes J, *see* Coates A
Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A, Veronesi U. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations, 2036
Formento JL, *see* Dassonville O
Foshag LJ, *see* Morton DL
Fossa SD, *see* Kelly WK
Fowble B, *see* Gilchrist KW
Fowler WC Jr, *see* Stehman FB
Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections, 1294
Fox SM, Einhorn LH, Cox E, Powell N, Abdy A. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy, 2391
Francoual M, *see* Dassonville O
Frankel L, *see* Pullen J
Franks R, *see* Khayat D
Frappaz D, *see* Ladenstein R
Fraumeni JF Jr, *see* Travis LB
Fred C, *see* Schag CAC
Freddo JL, *see* Christen RD
Freedman AS, Nadler LM. Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? (editorial), 1841
—, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Grossbard M, Robertson MJ, Blake K, Coral F, Canellos GP, Ritz J, Nadler LM. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study, 931
Frei E III, Freireich EJ. The clinical cancer researcher—Still an embattled species, 1639
— *see* Tepler I
Freimann JH Jr, *see* Danhauser LL
Freireich EJ, *see* Frei E III
French Group on Therapy for Adult Acute Lymphoblastic Leukemia, *see* Fière D
Fridman M, *see* Silber JH
Friedman MA, *see* Trimble EL
Friedman N, *see* Lin PP
Frisard B, *see* Shulman LN
Fryer JG, *see* Ahlgren JD
Frytak S, *see* Edmonson JH
Fuks Z, *see* Yahalom J
Fukuoka M, *see* Furuse K
Fuller L, *see* Dimopoulos MA
— *see* Moulopoulos LA
Fumoleau P, Delgado FM, Delozier T, Monnier A, Delgado MAG, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy, 1245
Fung CY, *see* Willett CG
Furman W, *see* Marina NM
Furman WL, Strother D, McClain K, Bell B, Leventhal B, Pratt CB. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A Pediatric Oncology Group study, 2205
— *see* Rodman JH
Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, Kusunoki Y, Takifuji N, Okunaka T, Konaka C, Wada H, Hayata Y for the Japan Lung Cancer Photodynamic Therapy Study Group. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer, 1852
Futatsuki K, *see* Shimada Y
Futscher B, *see* List AF

Gabrilove JL, *see* Seidman AD
Gadner H, *see* Burdach S
— *see* Ladenstein R
Gajjar AJ, Heideman RL, Douglass EC, Kun LE, Kovnar EH, Sanford RA, Fairclough DL, Ayers D, Look AT. Relation of tumor-cell ploidy to survival in children with medulloblastoma, 2211
Galili N, *see* Ito Y
Gallagher RE. All-*trans*-retinoic acid in acute promyelocytic leukemia: Let's get on with finding out how good it is (letter), 589
Gallagher SC, *see* LeVeque FG

Gamis AS, Haake R, McGlave P, Ramsay NKC. Unrelated-donor bone marrow transplantation for Philadelphia chromosome–positive chronic myelogenous leukemia in children, 834
Gampe M, *see* Kaufmann M
Gams RA, *see* Vogel CL
Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP. Evaluation of cisplatin intensity in metastatic non–small-cell lung cancer: A phase III study of the Southwest Oncology Group, 873
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy, 116
Gandia D, Abigerges D, Armand J-P, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P. CPT-11–induced cholinergic effects in cancer patients (letter), 196
Ganz PA, *see* Schag CAC
Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, di Montezemolo LC, Di Tullio MT, Bagnulo S, Mancini A, Carli M, Pession A, Arrighini A, Di Cataldo A, Tamaro P, Iasonni V, Taccone A, Rogers D, Boni L. Localized but unresectable neuroblastoma: Treatment and outcome of 145 cases, 1770
— *see* Ladenstein R
García-Conde J, *see* Bladé J
Garcia-Giralt E, *see* Fumoleau P
Gargano G, *see* Lorusso V
Garin-Chesa P, *see* Czuczman MS
Gause BL, *see* Curti BD
Gauthier F, *see* Tournade MF
Gaynes L, *see* Tepler I
— *see* Wheeler C
Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, Chappell RJ, Sather HN, Hammond GD. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group Study CCG-106, 2234
Gaynor E, *see* Bukowski RM
Gee TS, *see* Schwartz MA
Gelber RD, Goldhirsch A, Coates AS for the International Breast Cancer Study Group. Adjuvant therapy for breast cancer: Understanding the overview, 580
— *see* Zerbini C
Geller NL, *see* Bajorin DF
— *see* Scher HI
Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: A 10-year follow-up study, 66
Gelman RS, *see* Recht A
Gelmon KA, *see* O'Reilly SE
Gerdes H, *see* Smith JW
Germino J, *see* Cooper DL
Gerstner JB, *see* Witzig TE
Gertz BJ, *see* Nussbaum SR
Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia, 914
Gesme DH Jr, *see* Dinapoli RP
Geyer R, *see* Packer RJ
Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JThM, Bakker W, Koolen MGJ, Vendrik CPJ, Roozendaal KJ, Planting AST, van Zandwijk N, ten Velde GJM, Splinter TAW. Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial, 1230
Gianni L, *see* Peereboom DM
Giardini R, *see* Tondini C
Gilbert C, *see* Peters WP
Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, Lazarous DF, Pierce L, d'Angelo T, Moscow JA, Townsend AJ, Cowan KH. A pilot study of pi-class glutathione S-transferase expression in breast cancer: Correlation with estrogen receptor expression and prognosis in node-negative breast cancer, 49
Gilchrist GS, *see* Tubergen DG
Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG IV. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node–positive breast cancer: A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients, 1929
Gilchrist TL, *see* Danhauser LL
Gilewski T, *see* Crown J
Gilewski TA, *see* Reichman BS
Gill G, *see* Levi JA
Gill I, *see* Grunberg SM
Gilliland DG, *see* Wheeler C
Ginsberg RJ, *see* Shepherd FA
Giovagnoni A, Piga A, Argalia G, Giuseppetti GM, Ercolani P, Cellerino R. Inadequacy of ultrasonography for monitoring response to treatment of liver metastases, 2451
Giovannini M, *see* Martelli M
Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia, 1055
Girard A, *see* Browman GP
Gisselbrecht C, *see* Fière D
— *see* Marolleau JP
Giuliano M, *see* Amadori S
Giuseppetti GM, *see* Giovagnoni A
Gjedde SB, *see* Pedersen-Bjergaard J
Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer, 973
Glatstein E, Rosenthal DI. Photodynamic therapy: Shining light where it is needed (editorial), 1844
— *see* Horowitz ME
— *see* Weitman SD
Glicksman A, *see* Douglass EC
Gloghini A, *see* Carbone A
Gluck L, *see* Minasian LM
Glusman J, *see* Nussbaum SR
Gobbi PG, Pieresca C, Federico M, Di Renzo N, Narni F, Iannitto E, Grignani G, Cavanna L, Avanzini P, Par-

tesotti G, Pitini V, Ascari E, Silingardi V, Mauri C. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group, 712
— *see* Tura S
Göbel U, *see* Burdach S
Goepfert H, *see* Dimery IW
Goey SH, *see* Kruit WHJ
Gold JE. Adoptively transferred anti–CD3-activated T cells for human tumor immunotherapy (letter), 1836
Goldberg G, *see* Wadler S
Goldberg RM, *see* Loprinzi CL
Goldhirsch A, *see* Gelber RD
Goldmacher VS, *see* Grossbard ML
Goldspiel B, *see* Grem JL
Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW, O'Shaughnessy JA, Wittes RE, Chabner BA. Paclitaxel administration using portable infusion pumps (letter), 2287
Goldstone AH, *see* Williams CD
Goldwein JW, *see* Jakacki RI
Gomis F, *see* Sanz MA
Gonchoroff NJ, *see* Witzig TE
Gonin R, *see* Tepler I
González-Brito G, *see* Bladé J
Goodman H, *see* Tepler I
Goodman M, *see* Cella DF
Gordon B, *see* Vose JM
Goswitz MS, *see* Jacobs JP
Gottlieb AJ, *see* Parker BA
Gottlieb RJ, *see* Ahlgren JD
Goudier MJ, *see* Fumoleau P
Goutsou M, *see* Chahinian AP
Graham M, *see* Czuczman MS
Graham MC, *see* Schwartz MA
Gralla RJ, *see* Pisters KMW
Grant CS, *see* Witzig TE
Gray G, *see* Cella DF
Gray JR, Bridges JD, Sobczak ML. Response migration: Area versus volume for tumor response assessment (letter), 1839
Gray R, *see* Cummings FJ
— *see* Gilchrist KW
Greco FA, *see* Hande KR
— *see* Johnson DH
— *see* Thompson DS
— *see* Waits TM
Green DM, Breslow NE, D'Angio GJ. The treatment of children with unilateral Wilms' tumor (editorial), 1009
—, Breslow NE, Beckwith JB, Takashima J, Kelalis P, D'Angio GJ. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: A report from the National Wilms' Tumor Study, 91
Green MR, *see* Chahinian AP
— *see* Lilenbaum RC
— *see* Parker BA
— *see* Vogel CL
Green S, *see* Rivkin SE
— *see* Williams CD
Greenwald C, *see* Hudson MM
Greer BE, *see* Seewaldt V
Greer J, *see* List AF
Greer JP, *see* Waits TM
Gregory WM, *see* Lambert HE
Greifenberg B, *see* Steward WP
Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, Weiss RB, McAtee N, Chen A, Goldspiel B, Sover E, Allegra CJ. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma, 1737
Grier HE, *see* West DC
Griffin JP, *see* Miller AA
Grignani G, *see* Gobbi PG
Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non–small-cell lung cancer: How much benefit is enough? 1866
Gritz E, *see* Bloom JR
Grochow LB, *see* Campbell KA
— *see* Rowinsky EK
Groshen S, *see* Rosen PP
Grossbard M, *see* Freedman AS
Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, Nadler LM. Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms, 726
Grossman NJ, *see* Gaynon PS
Grossman SA. Cancer pain or "total" cancer pain?: In reply (letter), 1198
—, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS for the Eastern Cooperative Oncology Group. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis, 561
Grunberg SM. The center responds to the fringe (letter), 1837
—, Crowley J, Livingston R, Gill I, Williamson SK, O'Rourke T, Braun T, Marshall ME, Weick JK, Balcerzak SP, Martino RL. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non–small-cell lung cancer: A Southwest Oncology Group study, 1598
— *see* Gandara DR
Guaspari A, *see* Laufman LR
Gucalp R, *see* Atkins MB
Guglielmi C, *see* Martelli M
Guillaume T, *see* D'Hondt V
Guillory C, *see* Dimery IW
Guinan EC, *see* Wheeler C
Guinot M, *see* Sanz MA
Gulati S, *see* Crown J
Gulati SC, *see* Thorne AC
— *see* Yahalom J
Gunn H, *see* Weber J
Gutterman JU, *see* Ajani JA
— *see* Danhauser LL

Haake R, *see* Gamis AS
Habrand JL, *see* Tournade MF
Haddad R, *see* Shepherd FA
Haeberlen V, *see* Heyn R
Hagemeister FB, *see* Dimopoulos MA
Hagenbeek A, *see* Carde P
Hainsworth JD, *see* Hande KR
— *see* Thompson DS
— *see* Waits TM
Hakes TB, *see* Reichman BS
Hakimian D, *see* Tallman MS
Haller DG, *see* Moertel CG
Halperin EC, *see* Schold SC Jr
Hamasaki V, *see* Vokes EE
Hamilton JM, *see* Grem JL
Hamilton N, *see* Crown J
Hammond GD, *see* Anderson JR
— *see* Gaynon PS
— *see* Tubergen DG
— *see* Wells RJ
— *see* Woods WG
Hancock ML, *see* Pui C-H
Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents, 1208
Hande KR. Pharmacologic-based dosing of carboplatin: A better method (editorial), 2295
—, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide, 374
— *see* Thompson DS
Hankey BF, *see* Travis LB
Hanna MG Jr, *see* Hoover HC Jr
Hannibal J, *see* Ovesen L
Hannisdal E, *see* Abrahamsen JF
Hansen JA, *see* Anderson JE
— *see* Petersen FB
— *see* Radich JP
— *see* Weaver CH
Hansen M, *see* Pedersen-Bjergaard J
Hansen OP, *see* Ovesen L
Hanson J, *see* Paterson AHG
Haraf D, *see* Vokes EE
Harker WG, *see* Bukowski RM
Harousseau JL, *see* Moreau P
— *see* Quesnel B
Harris J, *see* Cella DF
— *see* Cummings FJ
Harris JR, *see* Abner AL
— *see* Healey EA
— *see* Recht A
Harris M, *see* Pullen J
Harris RE, *see* Campbell LA
Harrison M, *see* Crown J
Hartmann O, *see* Ladenstein R
— *see* Méresse V
Hartmann R, *see* Wolfrom C
Harvey S, *see* Tepler I
Harvey V, *see* Levi JA
Haselow RE, *see* Adelstein DJ
Hass GM, *see* Xu F-J
Hatfield AK, *see* Loprinzi CL
Hatschek T, *see* Stål O
Hauri PJ, *see* Silberfarb PM
Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate (letter), 197
Hawkins MJ, *see* Trimble EL
Hayat M, *see* Bodis S
— *see* Carde P
Hayata Y, *see* Furuse K
Hayes D, *see* Abner AL
Hayn R, *see* Trimble EL
Haynes H, *see* Wadler S
Hazuka MB, Burleson WD, Stroud DN, Leonard CE, Lillehei KO, Kinzie JJ. Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy, 369
Head DR, *see* Sandoval C
Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: Clinical characteristics and impact on prognosis, 1545
Healey JH, *see* Meyers PA
Heath DD, *see* Christen RD
Heaton D, *see* Sandoval C
Hedborg F, *see* Brodeur GM
Heelan R, *see* Reichman BS
Heelan RT, *see* Pisters KMW
— *see* Warrell RP Jr
Heideman RL, Douglass EC, Krance RA, Fontanesi J, Langston JA, Sanford RA, Kovnar EH, Ochs J, Kuttesch J, Jenkins JJ, Fairclough DL, Kun LE. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas, 1458
— *see* Gajjar AJ
Heiss C, *see* Robins HI
Helle L, *see* Blomqvist C
Heller G, *see* Meyers PA
Helvie M, *see* Wahl RL
Henderson C, *see* Kornblith AB
Henderson IC, *see* Peters WP
Henry-Amar M, *see* Bodis S
— *see* Carde P
Henze G, *see* Wolfrom C
Herait P, *see* Gandia D
Herdt J, *see* Wilson WH
Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials, 1441
— *see* van Holten-Verzantvoort ATM
Hernández-Martín J, *see* Bladé J
Herndon JE, *see* Schold SC Jr
Herndon JE II, *see* Chahinian AP
— *see* Kornblith AB
Herr H, *see* Bajorin DF
Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, Parker K, Nylen P, Woodworth T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma, 1682
Hess JL, *see* Shivdasani RA
Heuson JC, *see* Paridaens R

Heyn R, Haeberlen V, Newton WA, Ragab AH, Raney RB, Tefft M, Wharam M, Ensign LG, Maurer HM for the Intergroup Rhabdomyosarcoma Study Committee. Second malignant neoplasms in children treated for rhabdomyosarcoma, 262
Hickish T, *see* Hill M
Hietanen P, *see* Blomqvist C
Hilfrich J, *see* Kaufmann M
Hill M, Cunningham D, MacVicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma, 2273
Hillig M, *see* Savarese DMF
Hillner BE, *see* Desch CE
— *see* Smith TJ
Hilsenbeck SG, *see* Rothenberg ML
Hinds MS, *see* Bearman SI
Hirji K, *see* Schag CAC
Hirsch-Ginsberg C, *see* Robertson LE
Hobbie WL, *see* Schwartz CL
Hochster H, *see* Wadler S
Hodson DI, *see* Browman GP
Hodson I, *see* Murray N
Hoffer PB, *see* Cooper DL
Hoffman A, *see* Dugan M
Hoffman R. Interleukin-3: A potentially useful agent for treating chemotherapy-related thrombocytopenia (editorial), 2057
Holdrinet A, *see* Carde P
Holland JC, *see* Kornblith AB
Holland JF, *see* Wadler S
Holli K, *see* Isola J
Hollis DR, *see* Kornblith AB
Holmlund J, *see* Curti BD
Holzmer MC, *see* Thompson DS
Hong WK, *see* Dimery IW
— *see* Huber MH
— *see* Lee JS
— *see* Lippman SM
Hoover HC Jr. Dr Hoover responds to Dr Moertel (letter), 586
—, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial, 390
Hoppe R, *see* Bloom JR
Hoppe RT, *see* Hancock SL
Horai T, *see* Furuse K
Horne MK, Mayo DJ, Wittes RE. Heparinized saline to flush groshong catheters (letter), 2458
Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steis RG, Glatstein E, Pizzo PA, Miser JS. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma, 1911
Horsfall DJ, *see* Seshadri R
Horton J, *see* Remick SC
Hoskins P, *see* O'Reilly SE
Hoskins PJ, Swenerton KD. Dodging the dogma: In reply (letter), 588
Høst H, *see* Abrahamsen JF
Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study, 2150
Howdle S, *see* O'Reilly SE
Howell SB, *see* Christen RD
— *see* Kim S
— *see* Kimura E
Hrushesky WJM, Bjarnason GA. Circadian cancer therapy, 1403
Hsu M-M, *see* Dugan M
Huart J, *see* Housset M
Hubbard JL, *see* Peereboom DM
Huber MH, Hong WK. Warfarin and small-cell lung cancer (letter), 383
— *see* Lee JS
Hudis C, *see* Crown J
Hudis CA, *see* Reichman BS
Hudson M, *see* Marina NM
Hudson MM, Greenwald C, Thompson E, Wilimas J, Marina N, Fairclough D, Kauffman W, Bozeman P, Mackert PW, Abromowitch M, Jenkins J, Boulden T, Kun L. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease, 100
—, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, Humphrey WA, Rupp C, Marina NM, Wilimas J, Link MP. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease, 1080
Huelskamp AM, *see* Kennedy MJ
Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients, 2127
Humblet Y, *see* D'Hondt V
Humphrey WA, *see* Hudson MM
Hunter CY, *see* Danhauser LL
Hurd D, *see* Peters WP
Hurd DD. Postremission therapy for the younger adult patient with acute myelogenous leukemia: Defining a role for transplantation (editorial), 1636
Hursey J, *see* Janik J
Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH, Pratt CB. Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group study, 2324
— *see* Sandoval C
Husband J, *see* Hill M
Hutchins GD, *see* Wahl RL
Hutchins LF, *see* Gandara DR
Hutter J, *see* List AF
Huvos A, *see* Meyers PA
Hvizdala E, *see* Katz JA

Iannitto E, *see* Gobbi PG
Iasonni V, *see* Garaventa A
Ichikura T, Tomimatsu S, Okusa Y, Uefuji K, Tamakuma S. Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer, 1894
Infante M, *see* Pastorino U
Ingle JN, *see* Loprinzi CL
— *see* Witzig TE
Ingwersen A, *see* Wolfrom C
Intergroup Rhabdomyosarcoma Study Committee, *see* Heyn R
International Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group, *see* Pappo AS
International Breast Cancer Study Group, *see* Gelber RD
Irvin R, *see* Burris H
Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi O-P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer, 36
The Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy, 2396
Ito Y, Wasserman R, Galili N, Reichard BA, Shane S, Lange B, Rovera G. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia, 546
Iyer R, *see* Pullen J

Jacaruso D, *see* Winick NJ
Jacob JL, *see* Reed E
Jacobs JP, Murray KJ, Schultz CJ, Wilson JF, Goswitz MS, Stevens CW, Cox JD. Central lymphatic irradiation for stage III nodular malignant lymphoma: Long-term results, 233
Jaffe ES, Longo DL. More on follicular lymphomas: In reply (letter), 1835
— *see* Pluda JM
— *see* Wilson WH
Jakacki R, *see* Packer RJ
Jakacki RI, Goldwein JW, Larsen RL, Barber G, Silber JH. Cardiac dysfunction following spinal irradiation during childhood, 1033
Jamal HH, *see* Berinstein NL
Jamis-Dow C, *see* Reichman BS
Janik J, Kopp WC, Smith JW II, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, Ewel CH, Hursey J, Urba WJ. Dose-related immunologic effects of levamisole in patients with cancer, 125
— *see* Reed E
Janik JE, *see* Curti BD
Jansen RLH, *see* Kruit WHJ
Japan Lung Cancer Photodynamic Therapy Study Group, *see* Furuse K
Jarque I, *see* Sanz MA
Jeffery RW, *see* Chlebowski RT
Jenkin RDT, *see* Anderson JR
Jenkins J, *see* Hudson MM
Jenkins JJ, *see* Heideman RL
Jensen MD, *see* Loprinzi CL
Jereb B, *see* Tournade MF
Jewell WR, *see* Rivkin SE
Jiménez R, *see* Bladé J
Jochimsen P, *see* Wolmark N
Jodrell DI, *see* Reyno LM
Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the Southeastern Cancer Study Group, 1223
—, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, Wagner H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: A pilot study of the Eastern Cooperative Oncology Group, 879
— *see* Hande KR
— *see* Waits TM
Jonat W, *see* Kaufmann M
Jones J, *see* Wolmark N
Jones QJ, *see* Dunn SM
Jones R, *see* Peters WP
Jordan E, *see* Grem JL
Jouet JP, *see* Facon T
Julian JA, *see* Grilli R
Julien JP, *see* Paridaens R
Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count, 679
Jürgens H, *see* Burdach S

Kadin M, *see* Shulman LN
Kaizer H, *see* Cassileth PA
Kales AN, *see* Grem JL
Kalish LA, *see* Adelstein DJ
Kallioniemi O-P, *see* Isola J
Kalousek D, *see* Woods WG
Kalter S, *see* Burris H
Kambe M, *see* Shimada Y
Kamen BA, Buchanan GR, Winick NJ. The epipodophyllotoxins. Both sides of the coin: In reply (letter), 1625
— *see* Weitman SD
— *see* Winick N
— *see* Winick NJ
Kaneko M, *see* Brodeur GM
Kanis JA, *see* Paterson AHG
Kantarjian H, *see* Quesnel B
— *see* Robertson LE
Kantarjian HM, *see* Giralt SA
Kaplan E, *see* Cella DF
Kaplan WD, *see* Kirn D
Karato A, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Oshita F, Nishio M, Kunikane H, Arioka H, Ohmatsu H, Nakashima H, Shiraishi J, Saijo N. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors, 2030
Kardinal CG, *see* Wolmark N

Karp JE, *see* Pluda JM
Kato H, *see* Furuse K
Katz JA, Hvizdala E, Shuster J, Falletta JM, Schwenn M, Murphy SB. Ten years' experience with LSA_2-L_2 therapy for childhood advanced lymphoblastic lymphoma (letter), 2054
Katzmann JA, *see* Witzig TE
Kauffman W, *see* Hudson MM
Kaufman DS, *see* Willett CG
Kaufman L, *see* Razavi D
Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W, Mahlke M, Neises M, Stosiek U, Stiglmayer R, Seeger F, Langnickel D, Nagel G, Gampe M, Maass H, Kubli F. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer, 454
Kawasaki H, *see* Saven A
Keating A, *see* Crump M
Keating MJ, *see* Gandhi V
— *see* Robertson LE
Keeney M, *see* Khojasteh A
Keiling R, *see* Fumoleau P
Keir M, *see* Newell DR
Kelalis P, *see* Green DM
Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer, 607
— *see* Scher HI
Kelsen DP, *see* Atiq OT
Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, Niedzwiecki D, Botet J, Budd A. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer, 330
Kemshead J, *see* Brodeur GM
Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer, 478
Kerbrat P, *see* Fumoleau P
— *see* Steward WP
Kerestes Z, *see* Levi JA
Kerkhofs H, *see* Bodis S
Kessinger A, *see* Vose JM
Kessler ML, *see* Robertson JM
Keung ACF, *see* Huizing MT
Keys HM, *see* Stehman FB
Khabbaz N, *see* Isola J
Khandekar JD, *see* Chlebowski RT
Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma, 2173
Khojasteh A, Chambers J, Khojasteh S, Keeney M. Cancer pain or "total" cancer pain? (letter), 1198
Khojasteh S, *see* Khojasteh A
Kim H, *see* Weber J
Kim JC, *see* Kim S
Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, Chamberlain MC. Extended CSF cytarabine exposure following intrathecal administration of DTC 101, 2186
— *see* Christen RD
Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60, 891
Kindl S, *see* Lazzarino M
Kinne D, *see* McCormick B
Kinne DW, *see* Rosen PP
Kinsella J, *see* Grossbard ML
Kinsella TJ, *see* Horowitz ME
Kinzie JJ, *see* Hazuka MB
Kirchner H, *see* de Riese WTW
Kirkpatrick A, *see* Giaccone G
Kirmani S, *see* Christen RD
Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP, Shulman LN. Large-cell and immunoblastic lymphoma of the mediastinum: Prognostic features and treatment outcome in 57 patients, 1336
Kitchen P, *see* Seshadri R
Kjeldsberg CR, *see* Anderson JR
Klasa R, *see* O'Reilly SE
Klastersky J, *see* Sculier JP
Klecker R, *see* Reichman BS
Klee FE, Osswald BR, Wysocki S. Testicular tumors, abdominal radiotherapy, and superior mesenteric artery syndrome (letter), 1626
Klein JL, *see* Bierman PJ
Kleine W, *see* Kaufmann M
Klijn JGM, *see* Foekens JA
— *see* Paridaens R
Klimo P, *see* O'Reilly SE
Klingebiel T, *see* Ladenstein R
Klintenberg C, *see* Stål O
Kluin-Nelemans HC, *see* Carde P
Knops GHJN, *see* Bär BMAM
Kobrinsky N, *see* Woods WG
Kodama N, *see* Furuse K
Koh H, *see* Hesketh P
Kohler DR, *see* Goldspiel BR
— *see* Wilson WH
Kohn E, *see* Reed E
Konaka C, *see* Furuse K
Konsker K, *see* Segna RA
Koolen MGJ, *see* Giaccone G
Kooy HM, *see* Loeffler JS
Kooy Y, *see* Weijl NI
Kopp WC, *see* Janik J
Korf BR, *see* West DC
Körholz D, *see* Burdach S
Kormanik PA, *see* Kim S
Korn EL, Simon R. Using the tolerable-dose diagram in the

design of phase I combination chemotherapy trials, 794
Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, Herndon JE II, Phillips CA, Abrams J, Aisner J, Norton L, Henderson C, Holland JC for the Cancer and Leukemia Group B. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer, 2081
Koscielniak E, *see* Burdach S
Kostashuk EC, *see* Murray N
Kosty M, *see* Saven A
Kouides PA, *see* Rapoport AP
Koustenis AG, *see* Goldspiel BR
Kovnar EH, *see* Gajjar AJ
— *see* Heideman RL
Kozakewich HPW, *see* West DC
Kozelsky TF, *see* Pisansky TM
Kozloff M, *see* Vokes EE
Krakoff IH, *see* Lee JS
Krance RA, *see* Heideman RL
Krebs LU, *see* Finn JW
Kreienberg R, *see* Kaufmann M
Kreissman SG, *see* West DC
Kris MG, *see* Pisters KMW
Kritz A, *see* Crown J
Krook JE, *see* Dinapoli RP
— *see* Witzig TE
Kroon HM, *see* van Holten-Verzantvoort ATM
Krown SE, *see* Minasian LM
Krozely MG, *see* Hande KR
Kruit WHJ, Bolhuis RLH, Goey SH, Jansen RLH, Eggermont AMM, Batchelor D, Schmitz PIM, Stoter G. Interleukin-2–induced thyroid dysfunction is correlated with treatment duration but not with tumor response, 921
Kubli F, *see* Kaufmann M
Kubota K, *see* Furuse K
Kuhn J, *see* Burris H
Kuhn JG, *see* Rothenberg ML
Kun L, *see* Hudson MM
Kun LE, *see* Gajjar AJ
— *see* Heideman RL
Kung FH, *see* Mendenhall NP
Kunikane H, *see* Karato A
Kupsky W, *see* Zerbini C
Kurtzberg J, *see* Peters WP
Kurzrock R, Estey E, Talpaz M. All-*trans* retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome, 1489
Kushner BH, LaQuaglia MP, Cheung N-KV. Rethinking management of localized neuroblastoma (letter), 1832
Kusunoki Y, *see* Furuse K
Kuttesch J, *see* Heideman RL
— *see* Pappo AS
Kuzniar B, *see* Berinstein NL
Kvaløy S, *see* Abrahamsen JF
Kyle RA, *see* Gertz MA

Lacava JA, *see* Perez JE
Ladenstein R, Lasset C, Hartmann O, Frappaz D, Garaventa A, Klingebiel T, Zucker JM, Coze C, Burdach S, Gadner H, Paolucci P, Pearson A, Pinkerton R, Chauvin F, Philip T. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation, 2330
Lai JL, *see* Quesnel B
Laluna F, *see* Ahlgren JD
Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group study, 440
— *see* O'Rourke NP
Lambert JM, *see* Grossbard ML
Lampert F, *see* Brodeur GM
Lampkin BC, *see* Wells RJ
Land V, *see* Pullen J
— *see* Winick NJ
Land VJ, *see* Pui C-H
Landman J, *see* Méresse V
Lange B, *see* Ito Y
— *see* Packer RJ
Lange BJ, *see* Woods WG
Lange W, *see* Finke J
Langhi M, *see* Perez JE
Langnickel D, *see* Kaufmann M
Langston JA, *see* Heideman RL
LaQuaglia M, *see* Meyers PA
LaQuaglia MP, *see* Kushner BH
Larsen RL, *see* Jakacki RI
Larsen SO, *see* Pedersen-Bjergaard J
Larson SM, *see* Czuczman MS
— *see* Oosterwijk E
— *see* Schwartz MA
Laskin MS, Lucchesi KJ, Morgan M. Paclitaxel rechallenge failure after a major hypersensitivity reaction (letter), 2456
Lasset C, *see* Ladenstein R
Lauer S, *see* Winick NJ
Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, Guaspari A, Brenckman WD Jr. A Randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer, 1888
Laurie JA, *see* Moertel CG
Lavally B, *see* West DC
Lawrence TS, *see* Robertson JM
Layfield LJ, *see* Xu F-J
Lazarous DF, *see* Gilbert L
Lazarus HM, *see* Cassileth PA
Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, Kindl S, Rosso R, Astori C, Buonanno MC, Magrini U, Bernasconi C. Primary mediastinal B-cell lymphoma with sclerosis: An aggressive tumor with distinctive clinical and pathologic features, 2306
Le Fur R, *see* Carde P
Leaf A, *see* Sparano JA
LeBail N, *see* Burris H
Lebwohl DE, *see* Reichman BS
Lecourt L, *see* Fumoleau P
Lee JJ, *see* Dimopoulos MA

Lee JS, Newman RA, Lippman SM, Huber MH, Minor T, Raber MN, Krakoff IH, Hong WK. Phase I evaluation of all-*trans*-retinoic acid in adults with solid tumors, 959
Lee JW, *see* Wells RJ
Lee REJ, *see* Brodeur GM
Lee S, *see* Dugan M
Lee T-C, *see* Cheng A-L
Lee TH, *see* Sugarbaker DJ
Lehoczky D, *see* Demeter J
Leichner PK, *see* Bierman PJ
Lemaire M, *see* Focan C
Lemerle J, *see* Tournade MF
Lenis G, *see* de Riese WTW
Lentjes E, *see* Weijl NI
Leonard CE, *see* Hazuka MB
Leone B, *see* Lorusso V
Leone BA, *see* Perez JE
Leone L, *see* Chahinian AP
Lepage E, *see* Fière D
Leung T, *see* Dugan M
Leventhal B, *see* Furman WL
Leventhal BG, *see* Mendenhall NP
LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, Gallagher SC, Muscoplat CC. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients, 1124
Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G, Stuart-Harris R, Snyder R, Byrne M, Kerestes Z, Margrie S for the Australasian Germ Cell Trial Group. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma, 1300
Levin B, *see* Ajani JA
Levin R, *see* Weber J
Levine EG, Raghavan D. MVAC for bladder cancer: Time to move forward again (editorial), 387
Levine HS, *see* Bukowski RM
Levine MN, *see* Browman GP
Levitt G, *see* Pein F
Levitt M, *see* Murray N
Lewis IJ, *see* Newell DR
Libert P, *see* Sculier JP
Libshitz HI, *see* Moulopoulos LA
Liedke S, *see* de Riese WTW
Liesveld JL, *see* Rapoport AP
Lietzau J, *see* Pluda JM
Lightdale CJ, *see* Smith JW
Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non–small-cell lung cancer, 1391
Liliemark J, *see* Juliusson G
Lillehei KO, *see* Hazuka MB
Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, Baker RR. Impact of axillary lymph node dissection on the therapy of breast cancer patients, 1536
Lin S, *see* Atiq OT
Linders EHP, *see* Bär BMAM
Link MP, *see* Hudson MM
Linn E, *see* Cella DF
Lippman SM, Hong WK. Not yet standard: Retinoids versus second primary tumors (editorial), 1204
— *see* Lee JS
Lipsett PA, *see* Campbell KA
Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy (editorial), 1199
Lipton A, *see* Vogelzang NJ
Lissner GS, *see* Tallman MS
List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia, 1652
Litzow MR, *see* Anderson JE
Livingston R, *see* Grunberg SM
Livingston RB, *see* Gandara DR
Lloyd S, *see* Cella DF
Lobelle JP, *see* Focan C
Lockhorst HM, Dekker AW. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma: In reply (letter), 1832
Loeffler JS, Alexander E III, Fine HA, Wen PY, Kooy HM, Black PMcL, Shea WM. Use of stereotactic radiosurgery in the treatment of malignant glioma: In reply (letter), 195
Loehrer PJ, *see* Fox EP
Lokich JJ, *see* Ahlgren JD
Lombardi F, *see* Tondini C
Longo DL. What's the deal with follicular lymphomas? (editorial), 202
— *see* Curti BD
— *see* Horowitz ME
— *see* Jaffe ES
— *see* Janik J
Longo W, *see* Robins HI
Longree L, *see* Focan C
Longueville J, *see* D'Hondt V
Look AT, *see* Brodeur GM
— *see* Gajjar AJ
López F, *see* Sanz MA
Lopez P, *see* Vandenberg TA
Loprinzi CL, Duffy J, Ingle JN. More postchemotherapy rheumatism: In reply (letter), 2052
—, Duffy J, Ingle JN. Postchemotherapy rheumatism (letter), 768
—, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia, 762
—, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate, 152
Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, De Lena M. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: A pilot study, 1952
— *see* Perez JE
Louie A, *see* Atkins MB
Love R, *see* Robins HI
Lovett D, *see* Warrell RP Jr
Lovett DR, *see* Schwartz MA

Lu Z, *see* Sparano JA
Lubejko BG, *see* Rowinsky EK
Lucchesi KJ, *see* Laskin MS
Luo X, *see* Pappo AS
Lynch MHE, *see* Petersen FB
Lynch TJ, *see* Sugarbaker DJ
Lyss AP, *see* Kornblith AB

Maass H, *see* Kaufmann M
Macdonald DR, *see* Schold SC Jr
Macdonald JS, *see* Moertel CG
MacDonald N, *see* Finn JW
Machiavelli M, *see* Perez JE
Mackert PW, *see* Hudson MM
Macklis RM, *see* West DC
MacVicar D, *see* Hill M
Madariaga J, *see* Hoover HC Jr
Madden T, *see* Marina NM
Madon E, *see* Amadori S
Magauran N, *see* Shulman LN
Magni A, *see* Formelli F
Magrini U, *see* Lazzarino M
Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients, 485
Mahaley MS Jr, *see* Schold SC Jr
Mahé B, *see* Moreau P
Mahjoubi R, *see* Cvitkovic E
Mahlke M, *see* Kaufmann M
Maier JA, *see* Dinapoli RP
Mailliard JA, *see* Loprinzi CL
Maioli M, *see* Pastorino U
Maki E, *see* Shepherd FA
Maldonado J, *see* Bladé J
Mamounas EP, *see* Wolmark N
Mancini A, *see* Garaventa A
Mandeli J, *see* Wadler S
Mandeli JP, *see* Segna RA
Mandelli F, *see* Amadori S
— *see* Martelli M
Mandjes IM, *see* Huizing MT
Mani S, *see* Buzaid AC
Mansi J, *see* Hill M
Mansour EG, *see* Adelstein DJ
Marcus RB Jr, *see* Mendenhall NP
Margolin K, *see* Sparano JA
Margolin KA, *see* Atkins MB
— *see* Sosman JA
Margrie S, *see* Levi JA
Margueritte G, *see* Pein F
Marina N, *see* Hudson MM
Marina NM, Rodman J, Shema SJ, Bowman LC, Douglass E, Furman W, Santana VM, Hudson M, Wilimas J, Meyer W, Madden T, Pratt C. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors, 554
— *see* Hudson MM
Markowitz AB, *see* Danhauser LL
Marks LB, *see* Peters WP
Marolleau JP, Brice P, Morel P, Gisselbrecht C. Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas (letter), 590
Maroun JA, *see* Murray N
Marshall JL, DeLap RJ. An alternate method to overcoming central venous catheter blockage in patients receiving high-dose fluorouracil and leucovorin (letter), 1433
Marshall ME, *see* Grunberg SM
Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F. P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma, 2362
Martín G, *see* Sanz MA
Martin K, *see* Fischkoff S
Martin LA, *see* Curran WJ Jr
Martin P, *see* Petersen FB
— *see* Weaver CH
Martin PJ, *see* Anderson JE
— *see* Radich JP
Martínez J, *see* Sanz MA
Martinez JF, *see* Hauser AR
Martínez-Duncker D, *see* Estorch M
Martini N, *see* Pisters KMW
Martino RL, *see* Grunberg SM
Martino S, *see* Chlebowski RT
Marty M on behalf of the International Collaborative Cancer Group Steering Committee. Epirubicin and the risk of leukemia: Not substantiated? (letter), 1431
Marty ML, *see* Sanz MA
Mascotti G, *see* Formelli F
Masera G, *see* Amadori S
Mashal R, *see* Shulman LN
Maslak P, *see* Yahalom J
Masood S, *see* Gilbert L
Mastore M, *see* Silvestrini R
Mathias B, *see* Peters WP
Mathieu-Boue A, *see* Gandia D
Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study, 2226
— *see* Campbell LA
Mauch P, *see* Freedman AS
— *see* Kirn D
— *see* Shulman LN
— *see* Wheeler C
Mauer AM, *see* Miller AA
Maulard C, *see* Housset M
Maurer HM, *see* Heyn R
— *see* Pappo AS
Mauri C, *see* Gobbi PG
Mauz-Körholz C, *see* Burdach S
Maxwell RM, *see* Gellert GA
Mayo DJ, *see* Horne MK
Mazanet R, *see* Tepler I
— *see* Wheeler C
Mazumdar M, *see* Bajorin DF
— *see* Kelly WK
— *see* Minasian LM
McAtee N, *see* Grem JL

McCaffrey R, *see* Hesketh P
McCarron EG, *see* Yahalom J
McCarthy K, *see* Dimery IW
McCarthy P, *see* Wheeler C
McCarthy WH, *see* Dunn SM
McCaul K, *see* Seshadri R
McCauley M, *see* Tepler I
— *see* Wheeler C
McClain K, *see* Furman WL
McClay EF, *see* Christen RD
McCloskey E, *see* Paterson AHG
McClure L, *see* Horowitz ME
McCormick B, Begg CB, Norton L, Yao T-J, Kinne D. Timing of radiotherapy in the treatment of early-stage breast cancer (letter), 191
McCrae J, *see* Crump M
McCready R, *see* Hill M
McDonald GB, *see* Bearman SI
— *see* Radich JP
McEvilly JM, *see* Vokes EE
McGill F, *see* Wadler S
McGlave P, *see* Gamis AS
McGuire WP, *see* Peereboom DM
McHale M, *see* Cella DF
McIntyre OR, *see* Cooper MR
McKenna RW, *see* Winick NJ
McKinnis RA, *see* Laufman LR
McLaughlin P, *see* Pryzant RM
— *see* Robertson LE
McMaster ML, *see* Waits TM
McMurtrey M, *see* Ajani JA
McSharry JJ, *see* Remick SC
McVie GJ, *see* Giaccone G
Meadows AT, Robison L. Splenectomy and risk of secondary leukemia (letter), 2054
— *see* Anderson JR
Meerwaldt JH, *see* Carde P
Mehta RG, *see* Cobleigh MA
Meisenberg B, *see* Peters WP
Meistrich ML, *see* Pryzant RM
Mele C, *see* Waterhouse DM
Mellink WAM, *see* Bodis S
Meloni G, *see* Williams CD
Mendenhall NP, Cantor AB, Williams JL, Ternberg JL, Weiner MA, Kung FH, Marcus RB Jr, Ferree CR, Leventhal BG. With modern imaging techniques, is staging laparotomy necessary in pediatric Hodgkin's disease? A Pediatric Oncology Group study, 2218
Mensink EJBM, *see* Bär BMAM
Mentzer SJ, *see* Sugarbaker DJ
Mercuri M, *see* Picci P
Méresse V, Vassal G, Michon J, De Cervens C, Courbon B, Rubie H, Perel Y, Landman J, Chastagnier P, De Valck C, Hartmann O. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: A phase II study from the Société Française d'Oncologie Pédiatrique, 630
Merino M, *see* Gilbert L
Messemer J, *see* Murphy BR
Metch B, *see* Rivkin SE
Meyer W, *see* Marina NM
Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation, 449
Meyskens FL Jr. Retinoids as anticancer agents (letter), 588
Micetich KC, *see* Sparano JA
Michalak JC, *see* Loprinzi CL
Michallet M, *see* Fière D
Michaux J-L, *see* Fière D
Michel J, *see* Bodis S
— *see* Sculier JP
Michiels JJ, *see* Carde P
Michl I, Zielinski CC. More postchemotherapy rheumatism (letter), 2051
Michon J, *see* Méresse V
Mick R, *see* Vokes EE
Mier J, *see* Sosman JA
Mier JW, *see* Atkins MB
— *see* Sparano JA
Mignolet F, *see* Paridaens R
Milan S, *see* Hill M
Milano G, *see* Dassonville O
Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM. Pharmacodynamics of prolonged oral etoposide in patients with advanced non–small-cell lung cancer, 1179
Miller JA, *see* Grem JL
Miller KD, *see* Lin PP
Miller L, *see* Woods WG
Miller TP, *see* Dana BW
Milpied N, *see* Moreau P
Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F, Sakai S. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer, 1602
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up, 1368
Minn F, *see* Cobleigh MA
Minor T, *see* Lee JS
Minsky B. In rectal carcinoma, colostomy or no colostomy: Is this the question?: In reply (letter), 193
Minton JP, *see* Rivkin SE
Miser JS, *see* Horowitz ME
Mittelman A, *see* Feldman EJ
Mixon A, *see* Weber J
Modeas C, *see* Chahinian AP
Moertel CG. Vaccine adjuvant therapy for colorectal cancer: "Very dramatic" or ho-hum? (editorial), 385
—, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy, 2386
Moglia D, *see* Formelli F
Mommen P, *see* Sculier JP
Monconduit M, *see* Carde P
Monnier A, *see* Fumoleau P
Montcuquet P, *see* Fumoleau P
Montgomery M, *see* LeVeque FG
Monti C, *see* Picci P
Moon RC, *see* Cobleigh MA
Moore M, *see* Crown J

Moorman CGM, *see* Tournade MF
Morawetz R, *see* Schold SC Jr
Moreau P, Bataille R, Mahé B, Milpied N, Harousseau JL. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma (letter), 1832
Morel P, *see* Facon T
— *see* Marolleau JP
Morgan M, *see* Laskin MS
Mori M, *see* Bearman SI
— *see* Radich JP
Moro MJ, *see* Bladé J
Morra E, *see* Lazzarino M
Morrison WH, *see* Dimery IW
Mortel R, *see* Stehman FB
Mortensen EL, *see* Ovesen L
Morton DL, Wen D-R, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck, 1751
Morton RF, *see* Loprinzi CL
Moscow JA, *see* Gilbert L
Motzer RJ, *see* Bajorin DF
— *see* Minasian LM
— *see* Seidman AD
Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone, 1311
Moynihan T, *see* Grossman SA
Muenz LR, *see* Hoover HC Jr
Muggia FM. How to improve survival after diagnosis of gastric cancer? It's back to the drawing board (editorial), 1437
Muldal A, *see* Vandenberg TA
Müll R, *see* D'Hondt V
Muntz H, *see* Tepler I
Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH. Surgical salvage of chemorefractory germ cell tumors, 324
Murphy SB. Secondary acute myeloid leukemia following treatment with epipodophyllotoxins (editorial), 199
— *see* Katz JA
Murray C, *see* Crump M
Murray K, *see* Curran WJ Jr
Murray KJ, *see* Jacobs JP
Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun JA, Wilson KS for the National Cancer Institute of Canada Clinical Trials Group. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer, 336
Muscoplat CC, *see* LeVeque FG
Musella R, *see* Carde P
Muto M, *see* Tepler I
Myers J, *see* Czuczman MS

Nadler LM, *see* Freedman AS
— *see* Grossbard ML
Naftolin F, *see* Magriples U
Nagel G, *see* Kaufmann M
Nakao I, *see* Shimada Y
Nakashima H, *see* Karato A
Namer M, *see* Fumoleau P
Narni F, *see* Gobbi PG
Natale RB, *see* Antman K
— *see* Gandara DR
Nathwani BN, *see* Dana BW
Neal J, *see* Dugan M
Needles MN, *see* Packer RJ
Neefe JR, *see* Gandara DR
Neff JR, *see* Picci P
Neijt JP, *see* van Holten-Verzantvoort ATM
Neises M, *see* Kaufmann M
Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma, 166
Nelson DF, *see* Curran WJ Jr
Nelson DL, *see* Pluda JM
Nelson J, *see* Rothenberg ML
Nelson JS, *see* Curran WJ Jr
Nelstrop AE, *see* Lambert HE
Nesbit ME, *see* Wells RJ
Neuberg D, *see* Freedman AS
— *see* Saphner T
Neudorf S, *see* Woods WG
Nevasaari K, *see* Blomqvist C
New York Gynecologic Oncology Group, *see* Wadler S
Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MCG on behalf of the United Kingdom Children's Cancer Study Group. Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula, 2314
Newman RA, *see* Lee JS
Newton WA, *see* Heyn R
— *see* Pappo AS
Ngai A, *see* Dugan M
Ngan BY, *see* Berinstein NL
Nicholson HS, *see* Packer RJ
Niederhuber JE, *see* Campbell KA
Niedzwiecki D, *see* Atiq OT
— *see* Kemeny N
Niell HB, *see* Miller AA
Nielsen D, *see* Pedersen-Bjergaard J
Niloff J, *see* Tepler I
Nishio M, *see* Karato A
Nobles E, *see* Shulman LN
Noel P, *see* Gertz MA
Nome O, *see* Abrahamsen JF
Nomura F, *see* Minami H
Noordijk EM, *see* Bodis S
— *see* Carde P
Nordenskjöld B, *see* Stål O
Norris BD, *see* Vandenberg TA
Norton L, *see* Crown J
— *see* Kornblith AB
— *see* McCormick B
— *see* Peters WP
— *see* Reichman BS
— *see* Rosen PP

Novak LJ, *see* Gaynon PS
Novak MJ, *see* Reyno LM
Noyon R, *see* van Leeuwen FE
Nürnberger W, *see* Burdach S
Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia, 1618
Nylen P, *see* Hesketh P

O'Boyle K, *see* Sosman JA
O'Brien JP, *see* Yahalom J
O'Brien MER, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule, 2112
O'Brien RT, *see* Tubergen DG
O'Brien S, *see* Robertson LE
O'Bryan RM, *see* Rivkin SE
Ochoa AC, *see* Curti BD
Ochoa J, *see* Curti BD
Ochs J, *see* Heideman RL
O'Dell M, *see* Seidman AD
O'Donnell J, *see* Weissman D
— *see* Weissman DE
Oesterling JE, *see* Pisansky TM
Oettgen HF, *see* Oosterwijk E
O'Fallon JR, *see* Dinapoli RP
Ogawa N, *see* Shimada Y
Ohe Y, *see* Karato A
Ohmatsu H, *see* Karato A
Ohyama S, *see* Hermans J
Ojeda B, *see* Estorch M
Oken MM, *see* Adelstein DJ
— *see* Cassileth PA
Okunaka T, *see* Furuse K
Okusa Y, *see* Ichikura T
Old LJ, *see* Czuczman MS
— *see* Oosterwijk E
— *see* Schwartz MA
Oliver RTD. Second tumors after radiation treatment of testicular germ cell tumors, 2286
Omura GA. Oncology (the study of cancer) is more than chemotherapy (letter), 1837
— *see* Johnson DH
Onetto N, *see* O'Reilly SE
— *see* Peereboom DM
— *see* Trimble EL
Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, Old LJ. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250, 738
O'Quigley J, *see* Christen RD
Orav EJ, *see* Healey EA
Ore L, *see* Wolmark N
O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy, 2250
—, Gelmon KA, Onetto N, Parente J, Rubinger M, Page RA, Plenderleith IH. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil, 2411
Orlandi E, *see* Lazzarino M
O'Rourke NP, Lambert HE. Secondary cytoreduction: Can it be justified? (letter), 2050
O'Rourke T, *see* Grunberg SM
Orringer MB, *see* Forastiere AA
Ortega F, *see* Bladé J
Osanto S, *see* Weijl NI
Osborne CK, *see* Rivkin SE
O'Shaughnessy JA, *see* Goldspiel BR
— *see* Savarese DMF
Oshita F, *see* Karato A
Osswald BR, *see* Klee FE
Otterson GA, *see* Savarese DMF
Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study, 2043
Oxman AD, *see* Grilli R
Oxman TE, *see* Silberfarb PM
Ozer H, *see* Cooper MR
Ozols RF, *see* Reed E

Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood, 850
Packman CH, *see* Rapoport AP
Paesmans M, *see* Sculier JP
Page RA, *see* O'Reilly SE
Palau J, *see* Sanz MA
Pandya KJ, *see* Saphner T
Panje WR, *see* Vokes EE
Pantalony D, *see* Crump M
Paolucci P, *see* Ladenstein R
Papapoulos SE, *see* van Holten-Verzantvoort ATM
Pape H, *see* Burdach S
Pappo AS, Crist WM, Kuttesch J, Rowe S, Ashmun RA, Maurer HM, Newton WA, Asmar L, Luo X, Shapiro DN for the Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma, 1901
Paradiso A, *see* Lorusso V
Parente J, *see* O'Reilly SE
Paridaens R, Heuson JC, Julien JP, Veyret C, Van Zyl J, Klijn JGM, Sylvester R, Mignolet F for the European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: A double-blind randomized study, 1723
Paris A, *see* Perez JE

Parker BA, Santarelli M, Green MR, Anderson JR, Cooper MR, Case D Jr, Barcos M, Peterson BA, Gottlieb AJ. AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: A Cancer and Leukemia Group B study, 248
Parker K, *see* Hesketh P
Parkinson DR, *see* Edmonson JH
— *see* Weber J
Partesotti G, *see* Gobbi PG
Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Rosmentz N, Clerici M, Soresi E, Valente M, Belloni PA, Ravasi G. Adjuvant treatment of stage I lung cancer with high-dose vitamin A, 1216
Pater JL, *see* Murray N
— *see* Reyno LM
Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer, 59
Patt YZ. Hepatic artery chemotherapy for colorectal liver metastases: Yet more controversy: In reply (letter), 2053
—. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues (editorial), 815
Patterson PU, *see* Dunn SM
Paulli M, *see* Lazzarino M
Paulussen M, *see* Burdach S
Payne D, *see* Murray N
Pazdur R, *see* Ajani JA
Pearce R, *see* Williams CD
Pearce T, *see* Remick SC
Pearl P, *see* Aisner J
Pearson A, *see* Ladenstein R
Pearson ADJ, *see* Brodeur GM
— *see* Newell DR
— *see* Skinner R
Pedersen-Bjergaard J, Gjedde SB, Philip P, Rørth M, Sigsgaard TC, Nielsen D, Hansen M, Dombernowsky P, Larsen SO. Epirubicin and the risk of leukemia: Not substantiated?: In reply (letter), 1432
Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK. Successful re-treatment with taxol after major hypersensitivity reactions, 885
— *see* Rowinsky EK
Pein F, Pinkerton R, Tournade MF, Brunat-Mentigny M, Levitt G, Margueritte G, Rubie H, Sommelet D, Thyss A, Zücker JM. Etoposide in relapsed or refractory Wilms' tumor: A phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group, 1478
Peng Y-M, *see* Feldman EJ
Perel Y, *see* Méresse V
Perez CA, *see* Johnson DH
Perez EA, *see* Gandara DR
Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Lacava JA, Rodriguez R, Cuevas MA, Paris A, Acuña LR, Langhi M, Lorusso V, De Lena M. Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer, 461
Perez-Tamayo C, *see* Forastiere AA
Pession A, *see* Garaventa A
Peters C, *see* Burdach S
Peters LC, *see* Hoover HC Jr
Peters LJ, *see* Dimery IW
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer, 1132
Petersdorf E, *see* Weaver CH
Petersen FB, Lynch MHE, Clift RA, Appelbaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P, Storb R, Rowley S, Sullivan KM, Witherspoon R, Weiden P, Thomas ED, Fisher L, Hansen JA, Buckner CD. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission, 1353
— *see* Anderson JE
— *see* Radich JP
— *see* Weaver CH
Petersen L, *see* Schag CAC
Peterson BA, *see* Parker BA
Peterson FB, *see* Weaver CH
Petrelli NJ, Rustum YM. Fluorouracil and leucovorin: There is a choice (letter), 1434
— *see* Wolmark N
Petros W, *see* Peters WP
Pfeifle DM, *see* Dinapoli RP
Pfister DG, *see* Bajorin DF
Philip P, *see* Pedersen-Bjergaard J
Philip T, *see* Brodeur GM
— *see* Ladenstein R
Phillips CA, *see* Kornblith AB
Phillips J, *see* Yahalom J
Phillips PC, *see* Packer RJ
Phillips TL, *see* Curran WJ Jr
Pianca C, *see* Garaventa A
Piccart M, *see* Peereboom DM
— *see* Razavi D
Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, Baldini N, Ferrari S, Mercuri M, Ruggieri P, Caldora P, Benassi MS, Fabbri N, Monti C, Campanacci M. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities, 1763
Piedbois P, *see* Buyse M
Pierce L, *see* Gilbert L
Pieresca C, *see* Gobbi PG
Pierson J, *see* Anderson JR
Piga A, *see* Giovagnoni A
Pinedo HM, *see* Huizing MT
Pinkel D. Intravenous mercaptopurine: Life begins at 40, 1826
Pinkerton CR, *see* Newell DR
Pinkerton R, *see* Ladenstein R
— *see* Pein F

Pinkus G, *see* Kirn D
— *see* Shulman LN
Pinkus GS, *see* Shivdasani RA
Pippert GC, *see* Vose JM
Piro LD, *see* Saven A
Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, Oesterling JE. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer, 2158
Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non–small-cell lung cancer following preoperative chemotherapy: Implications for the design of future non–small-cell lung cancer combined modality trials, 1757
Pitini V, *see* Gobbi PG
Pizzo PA, *see* Horowitz ME
Planting AST, *see* Giaccone G
Plaxe SC, *see* Christen RD
Plenderleith IH, *see* O'Reilly SE
Plezia P, *see* Feldman EJ
Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, Yarchoan R. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy, 1099
Plunkett W, *see* Gandhi V
Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA. Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses, 136
Polinsky ML, *see* Schag CAC
Poo W-J, *see* Buzaid AC
Poplack DG, *see* Savarese DMF
Portengen H, *see* Foekens JA
Portlock CS, *see* Yahalom J
Portuese E, *see* Remick SC
Porzsolt F, Tannock I. Goals of palliative cancer therapy, 378
Postmus PE, *see* Giaccone G
Potter D, *see* LeVeque FG
Powell D, *see* Remick SC
Powell N, *see* Fox SM
Powles TJ, *see* Paterson AHG
Prados M, *see* Packer RJ
Prasad U, *see* Dugan M
Pratt C, *see* Marina NM
Pratt CB, *see* Furman WL
— *see* Hurwitz CA
Press O, *see* Weaver CH
Press OW, *see* Anderson JE
Price L, *see* Newell DR
Pritchard J, *see* Brodeur GM
Pritchard KI. Informed consent in compliance studies (letter), 2457
— *see* Vandenberg TA
Pryzant RM, Meistrich ML, Wilson G, Brown B, McLaughlin P. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas, 239
Przepiorka D, *see* Giralt SA
Pugh RP, *see* Antman K
Pugh W, *see* Robertson LE
Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, Hancock ML, Shuster JJ, Steuber CP, Crist WM, Civin CI, Carroll AJ. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia, 1361
— *see* Rivera GK
— *see* Sandoval C
— *see* Winick N
Pullen DJ, *see* Pui C-H
Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Iyer R, Backstrom L, van Eys J, Harris M, Ravindranath Y, Sullivan M. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study, 839
Purl S, *see* Cella DF
Putnam JB, *see* Ajani JA
Pyesmany AF, *see* Gaynon PS

Quadri SM, *see* Bierman PJ
Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature, 2370
Quinlivan S, *see* Reichman BS
— *see* Seidman AD

Raber MN, *see* Lee JS
Rabinovich M, *see* Lorusso V
Rabinovich MG, *see* Perez JE
Rabinowe SN, *see* Freedman AS
Rademaker AW, *see* Cobleigh MA
Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, McDonald GB, Mori M, Schoch G, Hansen JA. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation–containing regimens, 304
Raemaekers JMM, *see* Bodis S
Ragab AH, *see* Heyn R
— *see* Hurwitz CA
Raghavan D, *see* Levi JA
— *see* Levine EG
Raimondi SC, *see* Pui C-H
— *see* Sandoval C
Ramaioli A, *see* Dassonville O
Ramsay NKC, *see* Gamis AS
Raney RB, *see* Heyn R
Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF. One hundred autotransplants for relapsed or refractory

Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome, 2351
Ratain MJ, *see* Vokes EE
Ravasi G, *see* Pastorino U
Ravikumar TS, *see* Salem RR
Ravindranath Y, *see* Hurwitz CA
— *see* Pullen J
Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde M-P, Beauduin M, Piccart M. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: A double-blind, placebo-controlled study assessing the usefulness of alprazolam, 1384
Reaman G, *see* Packer RJ
Reaman GH, *see* Gaynon PS
Recht A, Coleman CN, Harris JR, Come SE, Gelman RS. Timing of radiotherapy in the treatment of early-stage breast cancer: In reply (letter), 192
— *see* Abner AL
Redmond C, *see* Wolmark N
Redner A, *see* Schwartz MA
Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC, Ozols RF, VanderMolen L, Kohn E, Jacob JL, Cornelison TL. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer, 2118
Reed EC, *see* Vose JM
Régnier R, *see* Bodis S
Regnier R, *see* Carde P
Reich L, *see* Crown J
Reichard BA, *see* Ito Y
Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer, 1943
Reiffers J, *see* Fière D
Reis MD, *see* Berinstein NL
Reisman A, *see* Dugan M
Relling MV, *see* Hurwitz CA
Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, Portuese E, Wighton T, Powell D, Pearce T, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma, 1691
— *see* Adelstein DJ
Retchin SM, *see* Desch CE
Rey A, *see* Tournade MF
Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer, 1156
Reynolds CP, *see* Matthay KK
Reynolds M, *see* Douglass EC
Rice PA, *see* Curti BD
Richards W, *see* Sugarbaker DJ
Rieke JW, *see* LeVeque FG
Ries F, *see* Focan C
— *see* Sculier JP
Rigal-Huguet F, *see* Carde P
— *see* Fière D
Riggi M, Riva A. Therapy-related leukemia: What is the role of 4-epi-doxorubicin? (letter), 1430
Rimer BK, *see* Demark-Wahnefried W
Rimm IJ, *see* Wheeler C
Rinaldi D, *see* Burris H
Rios MB, *see* Giralt SA
Rissanen P, *see* Blomqvist C
Ritter J, *see* Creutzig U
Ritz J, *see* Freedman AS
Riva A, *see* Riggi M
Rivera G, *see* Rodman JH
— *see* Winick NJ
Rivera GK, Pui C-H, Crist WM. The epipodophyllotoxins: Both sides of the coin (letter), 1624
Rivkin SE, Green S, Metch B, Jewell WR, Costanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node–positive and estrogen receptor–negative patients: A Southwest Oncology Group study, 1710
— *see* Antman K
Rixe O, *see* Khayat D
Roach RW, *see* Gandara DR
Roald B, *see* Brodeur GM
Roberson PK, *see* Anderson JR
Robert NJ, *see* Saphner T
Robertson JM, Lawrence TS, Dworzanin LM, Andrews JC, Walker S, Kessler ML, DuRoss DJ, Ensminger WD. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy, 1286
Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Richter's syndrome: A report on 39 patients, 1985
Robertson MJ, *see* Freedman AS
Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C, Rushing D, Love R, Spriggs D. Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients, 1787
Robison L, *see* Meadows AT
Robson ME, *see* Grem JL
Rocca A, *see* Tondini C
Rock MK, *see* Rothenberg ML
Rockette H, *see* Wolmark N
Rodman J, *see* Marina NM
Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients, 287
Rodriguez G, *see* Burris H
Rodriguez GI, *see* Rothenberg ML
Rodriguez R, *see* Perez JE

Rogers D, *see* Garaventa A
Roldan A, *see* Hill M
Romero A, *see* Perez JE
Romond EH, *see* Wolmark N
Rondelli R, *see* Amadori S
Roozendaal KJ, *see* Giaccone G
Rørth M, *see* Pedersen-Bjergaard J
Rose DP, *see* Chlebowski RT
Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up, 2090
Rosenberg SA, *see* Pockaj BA
— *see* Weber J
Rosenbluth RJ, *see* Saphner T
Rosenfield AT, *see* Nelson BE
Rosenthal DI, *see* Glatstein E
Rosing H, *see* Huizing MT
Rosmentz N, *see* Pastorino U
Rosner G, *see* Peters WP
Ross M, *see* Peters WP
Rosso R, *see* Lazzarino M
Roth BJ, *see* Murphy BR
Roth JA, *see* Ajani JA
Roth S, *see* Carde P
Rothenberg M, *see* Reed E
Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD. Phase I and pharmacokinetic trial of weekly CPT-11, 2194
Rouesse J, *see* Steward WP
Rougraff BT, *see* Picci P
Rousselet G, Bachouchi M, Busson P, de Vathaire F, Wakasugi H, Schwaab G, Azli N, Armand J-P, Cvitkovic E, Tursz T. Clinical Implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma, 2143
— *see* Cvitkovic E
Rovera G, *see* Ito Y
Rowe JM, *see* Rapoport AP
Rowe S, *see* Pappo AS
Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting, 2010
—, Donehower RC, Peereboom DM. Paclitaxel rechallenge failure after a major hypersensitivity reaction: In reply (letter), 2456
— *see* Peereboom DM
Rowley S, *see* Petersen FB
— *see* Weaver CH
Rozenblit A, *see* Wadler S
Rozman C, *see* Bladé J
Rubens RD. Age and the treatment of breast cancer (editorial), 3
Rubie H, *see* Méresse V
— *see* Pein F
Rubin JS, *see* Wadler S
Rubinger M, *see* O'Reilly SE
Rubinstein L, *see* Atkins MB
Rubinstein LV, *see* Sparano JA
Rubio D, *see* Bladé J
Ruckdeschel JC, *see* Grossman SA
— *see* Remick SC
Rude R, *see* Nussbaum SR
Ruggieri P, *see* Picci P
Runowicz C, *see* Wadler S
Rupp C, *see* Hudson MM
Rupp IP, *see* Asselin BL
Rushing D, *see* Robins HI
Russell EJ, *see* Tallman MS
Russell R, *see* Browman GP
Russo P, *see* Bajorin DF
Rustin GJS, *see* Lambert HE
Rustum YM, *see* Petrelli NJ
Rutqvist L-E, *see* Stål O
Rutten EHJM, *see* Carde P
Ryan J, *see* Packer RJ
Ryan LM, *see* Edmonson JH
Ryan MB, *see* Ajani JA

Sacco JF, *see* Nussbaum SR
Sadura A, *see* Murray N
Sagman U, *see* Shepherd FA
Saijo N, *see* Karato A
Saito H, *see* Minami H
Saka H, *see* Minami H
Sakai S, *see* Minami H
Sakata Y, *see* Shimada Y
Salem RR, Ward BA, Ravikumar TS. A new peripherally implanted subcutaneous permanent central venous access device for patients requiring chemotherapy, 2181
Sallan SE, *see* Asselin BL
— *see* Lipshultz SE
— *see* Zerbini C
Salmon S, *see* List AF
Saltz L, *see* Atiq OT
Salvadori B, *see* Silvestrini R
San Miguel JF, *see* Bladé J
Sandeman T, *see* Levi JA
Sanders J, *see* Woods WG
Sanders JE, *see* Anderson JE
— *see* Petersen FB
— *see* Radich JP
Sandler AB, *see* Buzaid AC
Sandoval C, Pui C-H, Bowman LC, Heaton D, Hurwitz CA, Raimondi SC, Behm FG, Head DR. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation, 1039
Sandstedt B, *see* Tournade MF
Sanford RA, *see* Gajjar AJ
— *see* Heideman RL
Sanger WG, *see* Anderson JR
Sangiorgi L, *see* Picci P
Santana VM, *see* Marina NM
Santarelli M, *see* Parker BA
Santini J, *see* Dassonville O

Sanz GF, *see* Sanz MA
Sanz MA, de la Rubia J, Sanz GF, Martín G, Martínez J, Jarque I, Sempere A, Gomis F, Senent L, Soler MA, López F, Arilla MJ, Carpio N, Guinot M, Palau J, Tudela M, Marty ML. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: A report from a single institution, 1661
— *see* Bladé J
Saphner T, Troxel AB, Tormey DC, Neuberg D, Robert NJ, Pandya KJ, Edmonson JH, Rosenbluth RJ, Abeloff MD. Phase II study of goserelin for patients with postmenopausal metastatic breast cancer, 1529
Sarafian B, *see* Cella DF
Sarosdy MF, *see* Bajorin DF
Sartor O, *see* Borner MM
Sartorius SE, *see* Rowinsky EK
Sasaki Y, *see* Karato A
Sasako M, *see* Hermans J
Sather HN, *see* Gaynon PS
— *see* Tubergen DG
Sathya J, *see* Browman GP
Savage HE, *see* Vlock DR
Savarese DMF, Denicoff AM, Berg SL, Hillig M, Baker SP, O'Shaughnessy JA, Chow C, Otterson GA, Balis FM, Poplack DG, Cowan KH. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor, 1795
Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies, 671
Sawada T, *see* Brodeur GM
Sawka CA, *see* Berinstein NL
Schag CAC, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer, 783
Schaid DJ, *see* Loprinzi CL
— *see* Witzig TE
Schantz SP, *see* Vlock DR
Schattenberg A, *see* Bär BMAM
Scheinberg DA, *see* Czuczman MS
— *see* Schwartz MA
Scheithauer BW, *see* Dinapoli RP
Schellong G, *see* Creutzig U
Scher HI, Geller NL, Curley T, Tao Y. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC, 400
—, Kelly WK. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer, 1566
— *see* Bajorin DF
— *see* Kelly WK
— *see* Seidman AD
Schermann J, *see* Kaufmann M
Schiffer C, *see* Cooper MR
Schmitt CL, *see* Robins HI
Schmitz PIM, *see* Kruit WHJ
Schmoll H-J, *see* Bokemeyer C
Schneider J, *see* Crown J
Schneider M, *see* Dassonville O
Schneider NR, *see* Winick NJ
Schneider PD. Hepatic artery chemotherapy for colorectal liver metastases: Yet more controversy (letter), 2052
Schneider R, *see* Warrell RP Jr
Schnipper LE, *see* Tepler I
— *see* Wheeler C
Schnitt SJ, *see* Abner AL
— *see* Healey EA
Schnurr P, *see* Silberfarb PM
Schoch G, *see* Anderson JE
— *see* Radich JP
Schoenfelder J, *see* Vogel CL
Schold SC Jr, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD, Mahaley MS Jr. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma, 77
Schonfeld EP. Physician advocacy deficit (letter), 1838
Schroder J, *see* Weijl NI
Schultz CJ, *see* Jacobs JP
Schwaab G, *see* Rousselet G
Schwade JG, *see* Curran WJ Jr
Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer, 1906
Schwartz EL, *see* Sparano JA
Schwartz G, *see* Tepler I
— *see* Wheeler C
Schwartz M, *see* Kelly WK
Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias, 294
Schwartz PE, *see* Magriples U
— *see* Nelson BE
Schwartzentruber DS, *see* Weber J
Schwenn M, *see* Katz JA
Scott CB, *see* Curran WJ Jr
Scott JG, *see* Crump M
Scott RM, *see* Zerbini C
Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, Van Cutsem O, Berchier MC, Ries F, Michel J, Sergysels R, Mommen P, Klastersky J. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: A phase III randomized study conducted by the European Lung Cancer Working Party, 1858
Sebban C, *see* Fière D
Seeger F, *see* Kaufmann M
Seeger RC, *see* Brodeur GM
— *see* Campbell LA
— *see* Matthay KK
Seewaldt V, Cain JM, Greer BE, Tamimi H, Figge DC. Bowel complications with taxol therapy (letter), 1198
Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy, 434
Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer

RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, Fair WR, Begg C, Bosl GJ. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer, 408
— *see* Reichman BS
Seiter K, *see* Kemeny N
Selch M, *see* Matthay KK
Selch MT, *see* Black KL
Sella A, *see* Vassilopoulou-Sellin R
Sempere A, *see* Sanz MA
Senda K, *see* Minami H
Senent L, *see* Sanz MA
Sergysels R, *see* Sculier JP
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P for the South Australian Breast Cancer Study Group. Clinical significance of HER-2/*neu* oncogene amplification in primary breast cancer, 1936
Setlur V, *see* Seshadri R
Shaffer D, *see* Burris H
Shaffer K, *see* Kirn D
Shalinsky DR, *see* Christen RD
Sham J, *see* Dugan M
Shamberger RC, *see* West DC
Shane S, *see* Ito Y
Shapiro DN, *see* Pappo AS
Sharfman WH, *see* Curti BD
— *see* Janik J
Sharkey IM, *see* Skinner R
Sharma J, Von Hoff DD, Weiss GR. *Salmonella arizonae* peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer (letter), 2288
Shaw JM, *see* Tallman MS
Shea R, *see* Isola J
Shea WM, *see* Loeffler JS
Sheets E, *see* Tepler I
Sheinfeld J, *see* Bajorin DF
Sheldon JS, *see* Dunn SM
Shellito PC, *see* Willett CG
Shema SJ, *see* Marina NM
Shemano I, *see* Vogel CL
Shepard KV, *see* Finn JW
Shepherd FA, Ginsberg RJ, Haddad R, Feld R, Sagman U, Evans WK, DeBoer G, Maki E for the University of Toronto Lung Oncology Group. Importance of clinical staging in limited small-cell lung cancer: A valuable system to separate prognostic subgroups, 1592
Sherman M, *see* Rapoport AP
Sherret H, *see* Crump M
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11 a new camptothecin derivative, in metastatic colorectal cancer, 909
Shimokata K, *see* Minami H
Shina D, *see* Woods WG
Shinkai T, *see* Karato A
Shipp MA, *see* Kirn D
Shiraishi J, *see* Karato A
Shiraki M, *see* Edmonson JH
Shiu MH, *see* Atiq OT
Shiu W, *see* Dugan M
Shivdasani RA, Hess JL, Skarin AT, Pinkus GS. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma, 802
Shpall E, *see* Peters WP
Shulman HM, *see* Bearman SI
Shulman L, *see* Abner AL
Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G, Tung N, Kadin M. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome, 937
— *see* Kirn D
Shuster J, *see* Katz JA
— *see* Pullen J
— *see* Winick NJ
Shuster JJ, *see* Pui C-H
— *see* Winick NJ
Siegel BS, *see* Gellert GA
Siegel JE. Postchemotherapy rheumatism: Is this a menopausal symptom? (letter), 2051
Siegel S, *see* Anderson JR
Sigsgaard TC, *see* Pedersen-Bjergaard J
Sigurdson ER, *see* Kemeny N
Sikic BI. Modulation of multidrug resistance: At the threshold (editorial), 1629
Silber JH, Fridman M. Age effects of radiation-associated neurotoxicity in children: In reply (letter), 196
— *see* Jakacki RI
Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer, 997
Silberman M, *see* Cella DF
Silingardi V, *see* Gobbi PG
Silver B, *see* Abner AL
Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy, 1150
Simes RJ, *see* Coates A
Simon M, *see* Facon T
Simon R, *see* Korn EL
— *see* Smith M
Simone JV. Autologous bone marrow transplantation in childhood cancer (editorial), 1439
Sinclair PR, *see* Ahlgren JD
Singer J, *see* Weaver CH
Sitzmann JV, *see* Campbell KA
Skarin AT, *see* Shivdasani RA
Skingley P, *see* Browman GP
Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children, 173
Skoog L, *see* Stål O
Slamon DJ, *see* Kimura E
Slanina J, *see* Finke J
Sleeboom HP, *see* van Holten-Verzantvoort ATM
Smartt HH, *see* Dunn SM
Smetsers TFCM, *see* Bär BMAM
Smith AM, *see* Crump M

Smith DE. Additional cases of postchemotherapy rheumatism (letter), 1625
Smith H, *see* Wadler S
Smith IE, *see* O'Brien MER
Smith J, *see* Reed E
Smith JW, Brennan MF, Botet JF, Gerdes H, Lightdale CJ. Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma, 2380
Smith JW II, *see* Curti BD
— *see* Janik J
Smith L, *see* Burris H
Smith LS, *see* Rothenberg ML
Smith M, Simon R. Age effects of radiation-associated neurotoxicity in children (letter), 195
Smith S, *see* Burris H
Smith SD, *see* Winick NJ
Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women, 771
— *see* Desch CE
Snyder R, *see* Levi JA
Sobczak ML, *see* Gray JR
Sogani P, *see* Bajorin DF
Soiffer RJ, *see* Freedman AS
Soler MA, *see* Sanz MA
Somers R, *see* Carde P
— *see* Steward WP
— *see* van Leeuwen FE
Sommelet D, *see* Pein F
Soper JT, *see* Xu F-J
Soresi E, *see* Pastorino U
Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, Ernest ML, Fisher SG, Mier J, Vachino G, Caliendo G. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: Clinical and immunologic effects, 1496
— *see* Atkins MB
Soubrane C, *see* Khayat D
South Australian Breast Cancer Study Group, *see* Seshadri R
Sover E, *see* Grem JL
Sparano J, *see* Atkins MB
Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, Doroshow JH, Aronson FR, Rubinstein LV, Mier JW. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma, 1969
—, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: Evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation, 1609
—, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy, 1071
Spector N, *see* Freedman AS
Spector NL, *see* Grossbard ML
Speyer J, *see* Wadler S
Spiegel D, *see* Bloom JR
Spier C, *see* List AF
Spiers ASD, DeFelice JM. Palindromic baldness: Cytotoxic drugs correct alopecia (letter), 1838
Spinolo J, *see* Vose JM
Splinter TAW, *see* Giaccone G
Spooner D, *see* Steward WP
Sposto R, *see* Anderson JR
Spriggs D, *see* Robins HI
Spurr CL, *see* Wolmark N
Squicciarini P, *see* Silvestrini R
Sridhara R, *see* Reyno LM
Stadtmauer EA, *see* Cassileth PA
Stål O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist L-E, Skoog L, Sullivan S, Wingren S, Nordenskjöld B. S-phase fraction is a prognostic factor in stage I breast carcinoma, 1717
Stehman FB, Bundy BN, Thomas G, Keys HM, d'Ablaing G III, Fowler WC Jr, Mortel R, Creasman WT. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a Gynecologic Oncology Group trial, 1523
Steiger BW, *see* LeVeque FG
Stein RS, *see* Waits TM
Steinberg SM, *see* Gilbert L
— *see* Grem JL
— *see* Horowitz ME
— *see* Pockaj BA
— *see* Wilson WH
Steinherz PG, *see* Gaynon PS
Steis RG, *see* Horowitz ME
— *see* Janik J
Stepanavage M, *see* Nussbaum SR
Stephens RL, *see* Bukowski RM
Steuber CP, *see* Pui C-H
Stevens CW, *see* Jacobs JP
Stevens MCG, *see* Newell DR
Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, Van Oosterom AT, Warwick J, Greifenberg B, Thomas D, vanGlabbeke M. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 15
Stewart AF, *see* Nussbaum SR
Stewart I, *see* Cella DF
Stewart M, *see* Thorne AC
Stiggelbout AM, *see* van Leeuwen FE
Stiglmayer R, *see* Kaufmann M
Stoppa AM, *see* Quesnel B
Storb R, *see* Anderson JE
— *see* Petersen FB
— *see* Weaver CH

Stosiek U, *see* Kaufmann M
Stoter G, *see* Kruit WHJ
Stram DO, *see* Matthay KK
Straus DJ, *see* Czuczman MS
— *see* Yahalom J
Strauss GM, *see* Sugarbaker DJ
Strawderman M, *see* Wheeler C
Strother D, *see* Furman WL
Strother DR, *see* Hurwitz CA
Stroud DN, *see* Hazuka MB
Stuart DS, *see* O'Reilly SE
Stuart-Harris R, *see* Levi JA
Su I-J, *see* Cheng A-L
Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma, 1172
Sullivan BA, *see* Laufman LR
Sullivan K, *see* Weaver CH
Sullivan KM, *see* Anderson JE
— *see* Petersen FB
Sullivan M, *see* Pullen J
Sullivan S, *see* Stål O
Sumich MD, *see* Dunn SM
Sun M, *see* Meyers PA
Sunderland M, *see* Rodman JH
— *see* Sparano JA
Surbone A, *see* Reichman BS
Surdyke MG, *see* Hoover HC Jr
Sutcliffe SB, *see* Crump M
Sutherland CM, *see* Wolmark N
Sutton DMC, *see* Crump M
Suzuki Y, *see* Chahinian AP
Swan F, *see* Dimopoulos MA
Swenerton KD, *see* Hoskins PJ
— *see* Reyno LM
Sylvester R, *see* Paridaens R
Symann M, *see* D'Hondt V
Sznol M, *see* Atkins MB
— *see* Curti BD
— *see* Janik J
— *see* Sosman JA
— *see* Sparano JA

Taccone A, *see* Garaventa A
Taguchi T, *see* Shimada Y
Takashima J, *see* Green DM
Takeshita Y, *see* Hoover HC Jr
Takifuji N, *see* Furuse K
Takvorian T, *see* Freedman AS
Talbot DC, *see* O'Brien MER
Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia, 690
Talpaz M, *see* Giralt SA
— *see* Kurzrock R
Tamakuma S, *see* Ichikura T
Tamaro P, *see* Garaventa A
Tamimi H, *see* Seewaldt V
Tamura T, *see* Karato A
Tan BC, *see* Dugan M
Tanguy A, *see* Bodis S
— *see* Carde P
Tanner MA, *see* Rapoport AP
Tannock I, *see* Porzsolt F
Tao Y, *see* Kemeny N
— *see* Scher HI
— *see* Seidman AD
Tarbell NJ, *see* Hudson MM
— *see* Zerbini C
Tattersall MHN, *see* Dunn SM
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer, 2167
Taylor CW, *see* Gandara DR
Taylor JA, *see* Grossbard ML
Taylor JJ, *see* Dunn SM
Taylor S IV, *see* Cella DF
— *see* Gilchrist KW
Tefft M, *see* Heyn R
ten Bokkel Huinink WW, *see* Huizing MT
ten Velde GJM, *see* Giaccone G
Teo P, *see* Dugan M
Tepler I, Cannistra SA, Frei E III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy, 1583
Tepler I, *see* Wheeler C
Ternberg JL, *see* Mendenhall NP
Testi AM, *see* Amadori S
Thill L, *see* Khayat D
Thirion B, *see* Foekens JA
Thomas CR Jr, *see* Cella DF
Thomas D, *see* Steward WP
Thomas ED, *see* Anderson JE
— *see* Petersen FB
Thomas G, *see* Stehman FB
Thomas J, *see* Bodis S
— *see* Carde P
Thompson D, *see* Levi JA
Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I/II study, 1322
Thompson E, *see* Hudson MM
Thorne AC, Stewart M, Gulati SC. Harvesting bone marrow in an outpatient setting using newer anesthetic agents, 320
Thyss A, *see* Carde P
— *see* Pein F
Tilly H, *see* Quesnel B
Tirelli U, *see* Carbone A
Toia M, *see* Yahalom J
Tolcher AW, *see* Goldspiel BR

Tolley EA, *see* Miller AA
Tomimatsu S, *see* Ichikura T
Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, Buzzoni R, Valagussa P, Bonadonna G. Combined modality treatment with primary chop chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas, 720
Tong W, *see* Atiq OT
Toomasi F, *see* Atiq OT
— *see* Reichman BS
Topalian SL, *see* Pockaj BA
— *see* Weber J
Tormey DC, *see* Cummings FJ
— *see* Gilchrist KW
— *see* Saphner T
Torres G, *see* Estorch M
Torromeo C, *see* Martelli M
Tortosa J, *see* Bladé J
Tosato G, *see* Pluda JM
Tourani JM, *see* Khayat D
Tournade MF, Com-Nougué C, Voûte PA, Lemerle J, de Kraker J, Delemarre JFM, Burgers M, Habrand JL, Moorman CGM, Bürger D, Rey A, Zucker JM, Carli M, Jereb B, Bey P, Gauthier F, Sandstedt B. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: A risk-adapted therapeutic approach in Wilms' tumor, 1014
— *see* Pein F
Townsend AJ, *see* Gilbert L
Trams G, *see* Kaufmann M
Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Acute nonlymphocytic leukemia after small-cell lung cancer (letter), 586
Triche T, *see* Horowitz ME
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103, 2405
Trissel LA, *see* Hauser AR
Tristan-Morales M, *see* Rothenberg ML
Trochanowski B, *see* Atiq OT
Troxel AB, *see* Saphner T
Trudeau ME, *see* Vandenberg TA
Truesdell S, *see* Schwartz CL
Trump DL, *see* Antman K
— *see* Grossman SA
— *see* Taylor CD
Tschetter LK, *see* Dinapoli RP
— *see* Loprinzi CL
Tsokos M, *see* Horowitz ME
Tsuchida Y, *see* Brodeur GM
Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial, 527
—, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report, 520
Tudela M, *see* Sanz MA
Tueni E, *see* Steward WP
Tulsky DS, *see* Cella DF
Tung N, *see* Kirn D
— *see* Shulman LN
Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease, 925
Turrisi AT, *see* Johnson DH
Tursz T, *see* Cvitkovic E
— *see* Rousselet G
— *see* Steward WP
Tutsch KD, *see* Robins HI

Uefuji K, *see* Ichikura T
Ueno W, *see* Ahlgren JD
Ulbright TM, *see* Fox EP
United Kingdom Children's Cancer Study Group, *see* Newell DR
Urba SG, *see* Forastiere AA
Urba WJ, *see* Curti BD
— *see* Janik J

Vachino G, *see* Sosman JA
Vahdat L, *see* Crown J
Valagussa P, *see* Tondini C
Valente M, *see* Pastorino U
Vallejo CT, *see* Perez JE
Van Cutsem O, *see* Sculier JP
Van de Velde CJH, *see* Hermans J
van den Belt-Dusebout AW, *see* van Leeuwen FE
Van Der Harst D, *see* Weijl NI
van der Kuij V, *see* Huizing MT
van Eys J, *see* Pullen J
Van Heer C, *see* Razavi D
van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P, Zwinderman AH. Palliative pamidronate treatment in patients with bone metastases from breast cancer, 491
van Kerkhoff EHM, *see* van Leeuwen FE
Van Kessel AAG, *see* Bär BMAM
van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EHM, Delemarre JFM, Somers R. Second tumors after radiation treatment of testicular germ cell tumors: In reply (letter), 2286
—, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EHM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients, 415
Van Luxemburg S, *see* Weijl NI
Van Oosterom AT, *see* Steward WP
van Putten WLJ, *see* Foekens JA
Van Rood JJ, *see* Weijl NI

van Zandwijk N, *see* Giaccone G
Van Zyl J, *see* Paridaens R
Vandenberg TA, Pritchard KI, Eisenhauer EA, Trudeau ME, Norris BD, Lopez P, Verma SS, Buckman RA, Muldal A. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study, 1241
VanderMolen L, *see* Reed E
Vandermoten G, *see* Sculier JP
vanGlabbeke M, *see* Steward WP
Varet B, *see* Fière D
Varghese A, *see* Bloom JR
Variakojis D, *see* Tallman MS
Vassal G, *see* Méresse V
Vassilopoulou-Sellin R, Sella A. Interleukin-2–induced thyroid dysfunction is correlated with treatment duration but not with tumor response (letter), 1626
Vena D, *see* Trimble EL
Vendrik CPJ, *see* Giaccone G
Venzon DJ, *see* Pluda JM
Verdonck L, *see* Bodis S
Verma SS, *see* Vandenberg TA
Vermey P, *see* van Holten-Verzantvoort ATM
Vernant J-P, *see* Fière D
Veronesi U, *see* Formelli F
— *see* Silvestrini R
Versteeg C, *see* Wells RJ
Vertosick FT Jr. Use of stereotactic radiosurgery in the treatment of malignant glioma (letter), 194
Verweij J, *see* Steward WP
Veyret C, *see* Paridaens R
Vick NA, *see* Schold SC Jr
Vietti TJ, *see* Hurwitz CA
Villablanca JG, *see* Campbell LA
Villalon A, *see* Dugan M
Villalona-Calero MA. Secondary acute myelogenous leukemia in children with Latin-American ancestry (letter), 2286
Visakorpi T, *see* Isola J
Vlamis V, *see* Bajorin DF
— *see* Kelly WK
— *see* Minasian LM
Vlock DR, Schantz SP, Fisher SG, Savage HE, Carey TE, Wolf GT for the Department of Veterans Affairs Laryngeal Cancer Study Group. Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck, 2427
Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer, 345
Vogelsang GB, *see* Kennedy MJ
Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial, 1809
— *see* Bajorin DF
— *see* Chahinian AP
Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, Berezin F. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis, 360
Volk H, *see* Cummings FJ
Volpe R, *see* Carbone A
Von Hoff D, *see* Burris H
Von Hoff DD, *see* Rothenberg ML
— *see* Sharma J
Vootiprux V, *see* Dugan M
Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma, 1846
—, Reed EC, Pippert GC, Anderson JR, Bierman PJ, Kessinger A, Spinolo J, Armitage JO. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: A randomized trial, 1306
— *see* Anderson JR
— *see* Bierman PJ
Voute PA, *see* Brodeur GM
Voûte PA, *see* Tournade MF
Vredenburgh JJ, *see* Peters WP
Vreeland F, *see* Burris H
Vriesendorp HM, *see* Bierman PJ
Vuillemin E, *see* Khayat D

Wada H, *see* Furuse K
Wade JL III, *see* Cobleigh MA
Wadler S, Beitler JJ, Rubin JS, Haynes H, McGill F, Rozenblit A, Goldberg G, Cohen C, Speyer J, Runowicz C. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York Gynecologic Oncology Group study, 1511
—, Haynes H, Beitler JJ, Goldberg G, Holland JF, Hochster H, Bruckner H, Mandeli J, Smith H, Runowicz C for the New York Gynecologic Oncology Group. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy, 1517
— *see* Sparano JA
Wagner H, *see* Johnson DH
— *see* Remick SC
Wagner H Jr, *see* Adelstein DJ
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, 2101
Wainstock J, *see* Lin PP
Waits TM, Greco FA, Greer JP, Johnson DH, Wolff SN, Stein RS, McMaster ML, Hainsworth JD. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high–dose-intensity combination chemotherapy, 943
Wakasugi H, *see* Rousselet G
Wakka JC, *see* Oosterwijk E
Wakui A, *see* Shimada Y
Walker R, *see* Packer RJ
Walker S, *see* Robertson JM

Wall J, *see* Burris H
Walsh TD, *see* Finn JW
— *see* Glare PA
Walsh W, *see* Murphy BR
Waltz T, *see* Saven A
Wampler GL, *see* Ahlgren JD
Wang C-H, *see* Cheng A-L
Ward BA, *see* Salem RR
Warnaar SO, *see* Oosterwijk E
Warrell RP Jr. All-*trans*-retinoic acid in acute promyelocytic leukemia: Let's get on with finding out how good it is: In reply (letter), 590
—, Lovett D, Dilmanian FA, Schneider R, Heelan RT. Low-dose gallium nitrate for prevention of osteolysis in myeloma: Results of a pilot randomized study, 2443
— *see* Nussbaum SR
Warwick J, *see* Steward WP
Waskerwitz MJ, *see* Tubergen DG
Wasserman R, *see* Ito Y
Waterhouse DM. Informed consent in compliance studies: In reply (letter), 2457
—, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring, 1189
Wayne AS, *see* West DC
Weathers TD, *see* Fox EP
Weaver CH, Appelbaum F, Peterson FB, Buckner CD. Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma (letter), 812
Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Dony K, Hansen JA, Petersdorf E, Rowley S, Storb R, Sullivan K, Witherspoon R, Weiden P, Buckner CD. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy, 1329
Weber B, *see* Wahl RL
Weber D, *see* Moulopoulos LA
Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies, 499
Weber RS, *see* Dimery IW
Weichselbaum RR, *see* Vokes EE
Weick JK, *see* Grunberg SM
Weiden P, *see* Petersen FB
— *see* Weaver CH
Weijl NI, Van Der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, Lentjes E, Van Rood JJ, Cleton FJ, Osanto S. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment, 1376
Weil M, *see* Khayat D
Weinberg D, *see* Zerbini C
Weiner MA, *see* Mendenhall NP
Weiner RS, *see* Cassileth PA
Weinstein AS, *see* Curran WJ Jr
Weinstein H, *see* Wheeler C
Weinstein HJ, *see* Hudson MM
Weisenburger DD, *see* Anderson JR
Weiss G, *see* Burris H
— *see* Gandara DR
Weiss GR, *see* Antman K
— *see* Atkins MB
— *see* Rothenberg ML
— *see* Sharma J
— *see* Sosman JA
— *see* Sparano JA
Weiss RB, *see* Antman K
— *see* Grem JL
— *see* Peters WP
Weissman D, O'Donnell J, Brady A. Oncology (the study of cancer) is more than chemotherapy/The center responds to the fringe: In reply (letter), 1837
Weissman DE, O'Donnell J, Brady A. A cry from the fringe (letter), 1006
Weitman SD, Glatstein E, Kamen BA. Back to the basics: The importance of concentration × time in oncology (editorial), 820
— *see* Hurwitz CA
Weitz S, *see* Isola J
Wellisch D, *see* Bloom JR
Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, Versteeg C, Hammond GD. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: A report from the Childrens Cancer Group, 538
Welt S, *see* Oosterwijk E
Wen D-R, *see* Morton DL
Wen PY, *see* Loeffler JS
Wenig B, *see* Vokes EE
Werner M, *see* de Riese WTW
West DC, Grier HE. Rethinking management of localized neuroblastoma: In reply (letter), 1834
—, Shamberger RC, Macklis RM, Kozakewich HPW, Wayne AS, Kreissman SG, Korf BR, Lavally B, Grier HE. Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents, 84
Wexler LH, *see* Horowitz ME
Weynants P, *see* D'Hondt V
Wharam M, *see* Heyn R
Wharam MD, *see* Winick NJ
Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm IJ, Tepler I, McCarthy P, Mauch P, Ault K, Gaynes L, McCauley M, Schnipper LE, Antin J. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide, 1085
— *see* Kirn D
— *see* Shulman LN
— *see* Tepler I
White DE, *see* Pockaj BA

Whitin JC, *see* Asselin BL
Wickerham DL, *see* Wolmark N
Wieand HS, *see* Pisansky TM
Wiernik PH, *see* Aisner J
— *see* Sparano JA
Wierzbicki R, *see* Murray N
Wighton T, *see* Remick SC
Wilgus LL, *see* Christen RD
Wilimas J, *see* Hudson MM
— *see* Marina NM
Willett CG, Fung CY, Kaufman DS, Efird J, Shellito PC. Postoperative radiation therapy for high-risk colon carcinoma, 1112
Willett WC. Dietary fat reduction among women with early breast cancer (editorial), 2061
Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry, 2243
Williams JL, *see* Mendenhall NP
Williams SD, *see* Fox EP
Williamson SK, *see* Grunberg SM
Wilson G, *see* Pryzant RM
Wilson JF, *see* Anderson JR
— *see* Jacobs JP
Wilson KS, *see* Murray N
Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma, 1573
— *see* Goldspiel BR
Winer E, *see* Peters WP
Winer EP, *see* Demark-Wahnefried W
Wingren S, *see* Stål O
Winick N, Buchanan GR, Kamen BA. Secondary acute myeloid leukemia in Hispanic children (letter), 1433
—, Pui C-H. Secondary acute myelogenous leukemia in children with Latin-American ancestry: In reply (letter), 2286
Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide, 209
—, Smith SD, Shuster J, Lauer S, Wharam MD, Land V, Buchanan G, Rivera G. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study, 271
— *see* Kamen BA
Winicour P, *see* Cella DF
Witherspoon R, *see* Petersen FB
— *see* Weaver CH
Wittes RE, *see* Goldspiel BR
— *see* Horne MK
— *see* Wilson WH
Witz F, *see* Fière D
Witzig TE, Ingle JN, Schaid DJ, Wold LE, Barlow JF, Gonchoroff NJ, Gerstner JB, Krook JE, Grant CS, Katzmann JA. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: Results from patients enrolled in two prospective randomized trials, 351
Wold LE, *see* Witzig TE
Wolf BC, *see* Remick SC
Wolf GT, *see* Vlock DR
Wolfe M, *see* Bukowski RM
Wolff S, *see* List AF
Wolff SN, *see* Waits TM
Wolfrom C, Hartmann R, Fengler R, Brühmüller S, Ingwersen A, Henze G. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia, 827
Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco PA, Jochimsen P. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03, 1879
Wolter J, *see* Cobleigh MA
Womens' Intervention Nutrition Study, *see* Chlebowski RT
Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, Barnard D, Benjamin D, DeSwarte J, Kalousek D, Shina D, Hammond GD, Lange BJ. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens Cancer Group pilot study, 1448
— *see* Wells RJ
Woodworth T, *see* Hesketh P
Wu K, *see* Peters WP
Wyllie RA, *see* Newell DR
Wynder EL, *see* Chlebowski RT
Wysocki S, *see* Klee FE
Wyvill K, *see* Pluda JM

Xu F-J, Yu Y-H, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, Layfield LJ, Bast RC Jr. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures, 1506

Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, Portlock CS, Straus DJ, Phillips J, Fuks Z. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease, 1062
Yakar D, *see* Curran WJ Jr
Yang JC, *see* Weber J
Yao T-J, *see* McCormick B
Yao TJ, *see* Reichman BS
Yarchoan R, *see* Pluda JM

Yellen SB, *see* Cella DF
Yen SSC, *see* Christen RD
Yeomans AC, *see* Danhauser LL
Yeung K-Y, *see* Ahlgren JD
York RM, *see* Chlebowski RT
Yoshino M, *see* Shimada Y
Young RC, *see* Reed E
Yu Y-H, *see* Xu F-J

Zahurak M, *see* Forastiere AA
Zaman MB, *see* Pisters KMW
Zanesco L, *see* Amadori S
Zanini M, *see* Tondini C
Zasadny K, *see* Wahl RL
Zee BC, *see* Murray N
Zerbini C, Gelber RD, Weinberg D, Sallan SE, Barnes P, Kupsky W, Scott RM, Tarbell NJ. Prognostic factors in medulloblastoma, including DNA ploidy, 616
Zhang R, *see* Sparano JA
Zielinski CC, *see* Michl I
Zimmer MB, *see* LeVeque FG
Zimmermann M, *see* Creutzig U
Zinzani PL, *see* Tura S
Zittoun R, *see* Bodis S
Zloty M, *see* Cooper DL
Zubizarreta A, *see* Bladé J
Zucker JM, *see* Ladenstein R
— *see* Tournade MF
Zücker JM, *see* Pein F
Zuckerman E, *see* Kornblith AB
Zwinderman AH, *see* van Holten-Verzantvoort ATM
Zyroff J, *see* Saven A

SUBJECT INDEX

ABVD regimen, MOPP regimen *v*, in early-stage HD, 2258-2272
Adenocarcinoma
of esophagus, etoposide, doxorubicin, cisplatin, GM-CSF regimen for, 22-28
of gastroesophageal junction, etoposide, doxorubicin, cisplatin, GM-CSF regimen for, 22-28
Adrenal cancer, mitotane, cisplatin regimen in, 161-165
Age, breast cancer and, 3-4
Alendronate sodium, in hypercalcemia, 1618-1623
Alkeran, in hybrid combination chemotherapy, for HD, 712-719
Alkylating agent, radiotherapy plus, secondary leukemia following, 1039-1045
All-*trans*-retinoic acid
graded hepatic toxicity of, 963
graded toxicity of, 961
maximum-tolerated dose of, 1492-1493
in myelodysplastic syndrome, 1489-1495
pharmacology of, 963-964
phase I study of, 959-966
response duration of, 963
response to, 1493
toxicities of, 961-963, 1491-1492
Alprazolam, following chemotherapy, 1384-1390
American Society of Clinical Oncology, presidential address of, 2298-2305
Aminoglutethimide, hydrocortisone plus, in estrogen suppression, 1723-1728
Aminoglutethimide, tamoxifen, megestrol acetate regimen
in ovarian cancer, 1957-1968
toxicities of, 1960
Aminohydroxybutylidene bisphosphonate, in hypercalcemia, 1618-1623
AML, *see* Leukemia, acute myeloblastic
Amyloidosis
death in, 917
immunoglobulin M monoclonal gammopathy and, 914-920
Waldenstrom's macroglobulinemia and, 914-920
Androgen suppression, continued, in hormone-refractory prostate cancer, 2167-2172
Anesthesia, in outpatient bone marrow harvest, 320-323
Anorexia, megestrol acetate in, 762-767
Anthracycline therapy, QT interval prolongation following, 1906-1910
Anti-B4-blocked ricin
in B-cell neoplasms, 726-737
clinical toxicities of, 732
hematologic toxicity of, 733
pharmacokinetics of, 731
7-day continuous infusion of, 726-737
Anti-CD3, IL-2 plus
clinical antitumor effects of, 1501-1502
clinical toxicity of, 1498-1500
immunologic activation associated with, 1499-1501
maximum-tolerated dose for, 1498
in renal cancer, 1496-1505
re-treatment with, 1499
treatment plan for, 1497-1498
Antibody(ies), monoclonal, *see* Monoclonal antibody(ies)
Antibody reactivity, in head and neck cancer, 2427-2433
Antifolate, novel, 9-11
Antimyosin studies, of myocyte cell damage, 1264-1268
Antineoplastic agent, circadian chronopharmacology of, 1405
Anxiety, euphemism *v* cancer terminology and, 989-996
Arithmetic construct, 580-581
Asparaginase
in combination chemotherapy, for acute lymphoblastic leukemia, 2234-2242
in continuation combination chemotherapy, for leukemia, 210
high-dose cytarabine plus, 538-545
in induction combination chemotherapy, for leukemia, 210
pharmacokinetics of, 1780-1786
Astler-Coller staging, in colorectal cancer, 1113
Astrocytoma
2-chlorodeoxyadenosine in, 671-678
Serratia marcescens extract plus radiotherapy for, 1746-1750
Audiotape, in cancer consultation, 2279-2285

Autotransplantation
for advanced HD, 2351-2361
engraftment in, 2354-2355
Axillary lymph node dissection
in breast cancer, 1536-1544
morbidity due to, 1539
AZT therapy, in HIV-infected patients, NHL and, 1099-1107

B-cell neoplasm, anti-B4-blocked ricin for, 726-737
Bacillus Calmette-Guerin, immunomodulating adjuvant, in colorectal cancer, 390-399
Basal metabolic rate, in breast cancer, weight gain associated with, 1424
Beta-2 microglobulin, serum, in HD, prognostic role of, 1108-1111
Biologic rhythm, major, 1404
Biomarker, Ki-67 immunostaining as, in renal cell cancer, 1804-1808
Bisphosphonate therapy, breast cancer and, 491-498
Bladder, continuous irrigation of, mesna *v*, 1306-1310
Bladder cancer
methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 387-389
transitional-cell, chemoradiotherapy of, 2150-2157
Bleomycin
in combination chemotherapy
for elderly, 2362-2369
for good-prognosis germ cell cancer, 1300-1305
for poor-prognosis NHL, 943-949
sperm count following, 239-247
in combined modality therapy, for HD, 100-108
in hybrid combination chemotherapy, for HD, 712-719
in M-BACOD regimen, cost of, 1698
BMT, *see* Bone marrow transplantation
Body mass, increase in, megestrol acetate-induced, 152-154
Bone marrow
assessment of, in neuroblastoma, 1469
circadian variation of, 1406
Bone marrow harvest, outpatient, 320-323
Bone marrow transplantation
in acute myelogenous leukemia, 1636-1638
following adult acute lymphoblastic leukemia therapy, 1990-2001
allogeneic, following interferon alfa, in chronic myelogenous leukemia, 1055-1061
allogeneic *v* autologous, in acute myelogenous leukemia, 1046-1054
autologous
in acute myeloid leukemia, 1353-1360
in acute myeloid leukemia remission, 314-319
in childhood cancer, 1439-1440
conditioning regimens for, 2247
cyclophosphamide, carmustine, etoposide regimen plus, 1329-1335
melphalan, etoposide regimen plus, in HD, 704-711
for neuroblastoma, 2226-2233
in NHL remission, 931-936
in pediatric *v* adult HD, 2243-2249
in relapsed HD, 1062-1070
relapse sites following, 2226-2233
TBI plus, in pediatric sarcoma, 1911-1918
timing of, 1356
toxic complications of, 2245
plus combination chemotherapy, for NHL, 1085-1091
dexamethasone, cytarabine, thioguanine, etoposide, daunorubicin regimen plus
in acute myeloid leukemia, 1448-1457
in myelodysplastic syndrome, 1448-1457
for HD, 2342-2350
hepatic venoocclusive disease following, 1729-1736
high-dose consolidation regimen plus, for breast cancer, 1132-1143
outpatient, 320-323
postremission chemotherapy plus, in acute myelogenous leukemia, 1046-1054
procedure for, 2343
second allogeneic, 304-313
in stage IV neuroblastoma, 2330-2341
unrelated-donor, in Philadelphia chromosome-positive CML, 834-838
see also Autotransplantation and Peripheral stem-cell transplantation
Bone marrow transplantation, yttrium 90-labeled antiferritin, high-dose chemotherapy regimen, in poor-prognosis HD, 698-703
Bone metastasis(es)
of breast cancer, oral clodronate for, 59-65
pamidronate for, 491-498
Bone plasmacytoma, solitary, MRI in, 1311-1315
Brain metastasis(es)
management of, 369-373
surgery plus radiotherapy for, 369-373
Brain radiotherapy, whole-, surgery plus, 369-373
Breast cancer
adjuvant chemotherapy in, weight gain associated with, 1418-1429
adjuvant therapy for, 580-585
advanced, weekly intravenous vinorelbine in, 1245-1253
age and, 3-4
axillary lymph node dissection in, 1536-1544
bone metastases of, oral clodronate for, 59-65
carboplatin in, 2112-2117
cathepsin D in, prognostic value of, 899-908
chemoendocrine therapy in, 584
PET monitoring of, 2101-2111
contralateral, 1545-1552
risk factors for, 1548
cyclophosphamide, cisplatin, carmustine, BMT consolidation regimen in, 1132-1143
cyclophosphamide, doxorubicin, 5-FU, GM-CSF regimen in, 2411-2416
cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone regimen in, 1710-1716
cyclosporine-induced GVHD in, 478-484
early, dietary fat reduction in, 2061-2062, 2072-2080
early premenopausal, adjuvant therapy of, cost-effectiveness of, 771-776
in elderly, adjuvant therapy for, cost-effectiveness of, 777-782
elderly node-positive, tamoxifen in, 29-35
estrogen receptor-negative, adjuvant therapy in, cost-effectiveness of, 777-782
estrogen receptor-positive, adjuvant therapy in, cost-effectiveness of, 771-776
estrogen suppression in, 1723-1728
estrogen-receptor status in, 584
estrogenic recruitment in, 1723-1728
HER-2-*neu* oncogene amplification in, 1936-1942

metastatic
fenretinide plus tamoxifen in, 474-477
high-dose myelosuppressive chemotherapy in, 1144-1149
ifosfamide plus mitoxantrone in, 461-466
paclitaxel plus G-CSF in, 1943-1951
tamoxifen in, 474-477
weekly edatrexate in, 1241-1244
node-negative
cathepsin D in, 36-43
contralateral breast cancer and, 2092-2094
histologic type and prognosis in, 2098
non-mammary malignant neoplasms and, 2094-2095
prognosis in, 2090-2100
recurrence following, 2091-2092
recurrence probability in, 2098
survival following, 2095-2096
tumor size and prognosis in, 2098
node-positive
cyclophosphamide, methotrexate, 5-FU regimen in, 454-460
DNA ploidy in, 351-359
doxorubicin, cyclophosphamide regimen in, 454-460
doxorubicin, cyclophosphamide, tamoxifen regimen in, 454-460
percent S-phase in, 351-359
tumor necrosis in, 1929-1935
node-positive receptor-negative, prolonged chemotherapy in, 1710-1716
ovarian ablation in, 582-583
pi-class glutathione S-transferase expression in, 49-58
postmenopausal, dietary fat reduction in, 2072-2080
postmenopausal metastatic, goserelin in, 1529-1535
prechemotherapy estrogenic recruitment in, 1723-1728
PS2 protein in, prognostic value of, 899-908
psychosocial distress in, 783-793
psychosocial support therapy following, 66-69
recurrent, salvage mastectomy in, 44-48
S-phase fraction in, 1717-1722
sleep assessment in, 997-1004
tamoxifen in, 583
tamoxifen-treated, cell kinetics in, 1150-1155
Burkitt's lymphoma, 1676
Busulfan, cyclophosphamide, peripheral-blood stem-cell transplantation regimen, in AML, 1661-1667
Butchart staging, of malignant mesothelioma, 1173

CA-125
in benign disease, 1508-1509
in occult disease, 1508-1509
radioimmunoassay of, 1507
in residual ovarian cancer, 1506-1510
Cachexia, megestrol acetate in, 762-767
Cancer
by another name, 989-996
psychosocial outcomes of, 979-988
research, *see* Clinical cancer research
v euphemism, 989-996
Cancer consultation, recall of, 2279-2285
Cancer therapy
dietary counseling during, 2043-2049
oral intake during, 2043-2049
palliative, goals of, 378-381
Carboplatin
in breast cancer, 2112-2117
cisplatin *v*, in high-dose chemotherapy regimen, 2112-2117
in combined modality therapy, for Ewing's sarcoma, 1482-1488
cyclophosphamide plus
in advanced ovarian cancer, 1156-1164
hematologic toxicities of, 1586
nonhematologic toxicities of, 1586-1587
peripheral-blood progenitor cells for, 1583-1591
tumor responses to, 1587-1588
dose-intensity of, 2124
dosing of, 441, 2115
dosing reductions of, 2123-2124
etoposide plus
in germ cell cancer, 598-606
toxicity of, 601
GM-CSF plus
dosing of, 2119
in recurrent ovarian cancer, 2118-2126
hematologic toxicity of, 2114-2115
ifosfamide plus, in ovarian cancer, 1952-1956
maximum-tolerated dose of, 796
in myelosuppressive chemotherapy, for metastatic breast cancer, 1144-1149
nonhematologic toxicity of, 2114-2115
paclitaxel plus, dose-escalation schedules for, 800
pediatric dosing of, 2314-2323
pharmacokinetics of, in children, 2314-2323
pharmacokinetics *v* pharmacodynamics of, 2316
pharmacologic-based dosing of, 2295-2296
survival following, 443-445
tolerable-dose diagram for, 797
toxicity of, 442-443
vincristine plus, for glioma, 850-856
whole-body hyperthermia plus, 1787-1794
clinical response to, 1792
hematologic toxicity of, 1790
Herpes simplex I following, 1790-1791
pharmacokinetics following, 1791-1792
toxicity of, 1789-1790
Carboplatin, etoposide, epirubicin regimen
IL-3 following, 2063-2071
in SCLC, 2063-2071
Carboplatin, ifosfamide, etoposide regimen
phase I study of, 554-560
for relapsed pediatric solid tumors, 554-560
Cardiac disease
in childhood cancer survivors, 1199-1203
following childhood spinal irradiation, 1033-1038
following HD therapy, 1208-1215
nonfatal, following radiotherapy, 1211-1212
Cardiotoxicity, of anthracycline therapy, screening for, 1906-1910
Carmustine
in combination chemotherapy
for multiple melanoma, 1165-1171
for NHL, 1085-1091
in combined modality therapy
for lymphoid malignancies, 1329-1335
toxicity of, 1331
diaziquone *v*, for anaplastic glioma, 77-83
in hepatic arterial combination chemotherapy, for colorectal cancer, 330-335

in high-dose consolidation regimen, for breast cancer, 1132-1143
PCNU *v*, for glioma, 1316-1321
radiotherapy plus, for glioma, 857-862
Cathepsin D
in node-negative breast cancer, 36-43
prognostic value of, in breast cancer, 899-908
CD23 serum level
assay for, 2144
in nasopharyngeal cancer, 2143-2149
Central venous access device
P.A.S. Port, 2181-2185
peripherally implanted subcutaneous, for chemotherapy, 2181-2185
Cervical cancer
cisplatin, radiation, WR2721 regimen in, 1511-1516
radiation in, hydroxyurea *v* misonidazole plus, 1523-1528
Chemoendocrine therapy, in breast cancer, 584
PET monitoring of, 2101-2111
Chemoimmunotherapy
for head and neck cancer, 360-368
of metastatic melanoma, 2173-2180
Chemoradiotherapy
for acute lymphoblastic leukemia, 2234-2242
BMT plus, in lymphoid malignancies, 1329-1335
of childhood rhabdomyosarcoma, second cancer following, 262-270
dose-intensity of, 1226
in follicular large-cell lymphoma, 218-224
for glioma, 1316-1321
of head and neck cancer, 2136-2142
high-dose, for malignant glioma, 1458-1465
in multimodality regimen, for stage III neuroblastoma, 84-90
in nasopharyngeal carcinoma, 1919-1928
neoadjuvant, in bladder cancer, 2150-2157
in NHL, sperm count following, 239-247
in ovarian cancer, 440-448
preoperative, for esophageal cancer, 1118-1123
in primary hepatobiliary cancer, 1286-1293
in relapsed acute lymphoblastic leukemia, 271-278
in SCLC, 1223-1229
secondary tumor following, 1706
survival following, 1227
toxicity of, 1225-1226
of transitional-cell bladder cancer, 2150-2157
Chemotherapy
adjuvant, weight gain following, 1418-1429
in advanced NSCLC, survival following, 1866-1872
anticipatory nausea in, alprazolam for, 1384-1390
circadian dosing of, 1403-1417
combination
cost analysis of, 1697
in early premenopausal breast cancer, cost-effectiveness of, 771-776
in multiple melanoma, 1165-1171
oral *v* intravenous, 1691-1702
rheumatism associated with, 768-770
tolerable-dose design of, 794-801
cranial irradiation plus, in relapsed acute lymphoblastic leukemia, 271-278
dosing of, concentration and time in, 820-821
estrogen recruitment prior to, in breast cancer, 1723-1728
extended intrathecal, in acute lymphoblastic leukemia, 839-849
in gastric cancer, following curative surgery, 1441-1447
high-dose, in relapsed HD, 1062-1070
high-dose rapidly cycled myelosuppressive, in metastatic breast cancer, 1144-1149
hybrid combination, in HD, 712-719
infusional, in resistant NHL, 1071-1079
in NHL, sperm count following, 239-247
oral, in AIDS-related NHL, 1691-1702
oral combination, quality of life and, 1696-1697
oral extended, in NSCLC, 1598-1601
poly-, in breast cancer, 583
preoperative, in NSCLC, 1757-1762
prolonged, in node-positive receptor-negative breast cancer, 1710-1716
prolonged maintenance, in SCLC, 1230-1240
radiotherapy plus, *see* Chemoradiotherapy
regional, devices for, 822-826
repetitive high-dose, peripheral-blood progenitor cells for, 1583-1591
secondary tumor following, 1706
thoracic radiotherapy alternating with, in SCLC, 879-884
thoracic radiotherapy plus, 1223-1229
thrombocytopenia related to, IL-3 for, 2057-2060
topoisomerase-targeting, 2030-2035
triple intrathecal, in relapsed acute lymphoblastic leukemia, 271-278
weekly *v* standard, in SCLC, 1858-1865
Chemotherapy, yttrium 90-labeled antiferritin, BMT regimen, in poor-prognosis HD, 698-703
2-Chlorodeoxyadenosine
in chronic lymphocytic leukemia, 679-689
dose escalation of, 671-678
in nonhematologic malignancies, 671-678
side effects of, 685
toxicity of, 673-675
1-(2-Chloroethyl)-3(2,6 dioxo-1-piperidyl)-1-nitrosourea, carmustine *v*, for glioma, 1316-1321
Chlorpromazine, in combination therapy, for cisplatin-induced nausea, 2391-2395
CHOP regimen, cost of, 1698, 1699
Circadian chronopharmacology, of antineoplastic agents, 1405
Circadian variation, of antineoplastic agents, 1403-1417
Cisplatin
in advanced ovarian cancer, 1952-1956
carboplatin *v*, in high-dose chemotherapy regimen, 2112-2117
circadian pharmacodynamics of, 1409-1410
in combination chemotherapy
for bladder cancer, 387-389
for urothelial cancer, 400-407
in combination induction chemotherapy, for limited SCLC, 1593
in combined modality therapy
for head and neck cancer, 2136-2142
for transitional-cell bladder cancer, 2150-2157
in continuous infusion combination chemotherapy, for neuroblastoma, 623-629
in dose-intensified combination chemotherapy, for urothelial cancer, 408-414
dose-intensity of, 403

dose-response relationship for, 406
etoposide plus
in germ cell cancer, 598-606
toxicity of, 601
5-FU plus, in resected gastric cancer, 425-433
in high-dose consolidation regimen, for breast cancer, 1132-1143
maximum-tolerated dose of, 796
mitomycin plus, in NSCLC, 873-878
mitomycin *v* doxorubicin plus, in malignant mesothelioma, 1559-1565
in multimodality regimen, for stage III neuroblastoma, 84-90
multiple-day, emesis due to, 2391-2395
in ovarian cancer, secondary cytoreduction following, 434-439
paclitaxel plus
dose escalations of, 2013
neutropenia due to, 2015
in preoperative combination chemotherapy, for esophageal adenocarcinoma, 22-28
tolerable-dose diagram for, 798
vindesine plus, in NSCLC, 1757-1762
in weekly combination chemotherapy, for SCLC, 1858-1865
Cisplatin, 5-FU regimen, intraperitoneal, systemic 5-FU plus, 425-433
hematologic toxicity following, 428
pH of, 429
sclerosing encapsulating peritonitis following, 425-433
toxicity of, 427-428
Cisplatin, 5-FU, folinic acid, interferon alfa-2b regimen, in head and neck cancer, 360-368
Cisplatin, 5-FU, radiotherapy regimen, in nasopharyngeal carcinoma, 1919-1928
Cisplatin, cyclophosphamide induction regimen, for stage III neuroblastoma, 84-90
Cisplatin, interleukin-2, interferon alfa-2a regimen
for metastatic melanoma, 2173-2180
toxicity of, 2176-2177
Cisplatin, mitotane regimen, in adrenal cancer, 161-165
Cisplatin, paclitaxel, G-CSF regimen
hematologic toxicity of, 2013
muscular toxicity of, 2015-2016
neuromuscular toxicity of, 2013-2015
neutropenia due to, 2015
pharmacologic study of, 2010-2020
Cisplatin, radiation, WR2721 regimen
in cervical cancer, 1511-1516
clinical outcome of, 1514-1515
hypocalcemic effects of, 1517-1522
ionized calcium levels following, 1520
parathyroid hormone levels following, 1519
total calcium levels following, 1518
toxicities of, 1513-1514
Cisplatin, vinblastine, bleomycin regimen
in good-prognosis germ cell cancer, 1300-1305
response to, 1302-1303
toxicity of, 1302
Cisplatin, vinblastine, mitomycin regimen, in NSCLC, 1757-1762
Cisplatin, vincristine, 5-FU regimen, in hepatoblastoma, 96-99
Cisplatin, vindesine, mitomycin regimen, in NSCLC, 1757-1762
Clinical cancer investigator(s)
academia and, 1641
categories of, 1639
scientific contributions of, 1641
training of, 1640-1641
Clinical cancer research
of acute lymphocytic leukemia cure, 1641-1642
administration of, 1646-1647
ambiance of, 1640
biomedical research *v*, 1648
of cancer cause, 1641
competitive grant funding of, 1642-1643
definitions for, 1639
discovery in, 1647-1648
investigator-initiated, 1643
recommendations in, 1648-1649
regulations for, 1645
spin-off discoveries of, 1642
therapeutic pilot study in, 1645-1646
third-party payment for, 1643-1645
Clinical trial(s)
of combination chemotherapy, dosing design for, 794-801
in curable neoplasms, ethics of, 593-596
third-party payment for, 1643-1645
Clock gene, 1403
CNS, leukemia, prevention of, 839-849
Colony-stimulating factor, granulocyte-macrophage, *see* Granulocyte-macrophage colony-stimulating factor
Colorectal cancer
Astler-Coller staging in, Gunderson-Sosin modification of, 1113
folinic acid-modulated 5-FU in, 1879-1887
hepatic arterial floxuridine in, 330-335
hepatic arterial floxuridine, mitomycin, carmustine regimen in, 330-335
hepatic arterial therapy in, 330-335
lomustine, vincristine, 5-FU regimen in, 1879-1887
metastatic
CPT-11 in, 909-913
5-FU in, 1888-1893
5-FU plus oral folinic acid in, 1888-1893
5-FU, folinic acid, interferon alfa-2a regimen in, 1737-1745
regional hepatic arterial chemotherapy in, 815-819
postoperative radiotherapy in, 1112-1117
vaccine adjuvant therapy in, 385-386, 390-399
Combination chemotherapy
dose-intensified, in urothelial cancer, 408-414
methotrexate in, overview of, 7-9
Combined modality therapy
for HD, 100-108
for improved survival, in stage III neuroblastoma, 84-90
for malignant glioma, 1458-1465
for malignant mesothelioma, 1172-1178
for stage I-II lymphoma, 720-725
thoracic irradiation timing in, for SCLC, 336-344
Communication, of euphemism *v* cancer terminology, 989-996
Compliance, patient, *see* Patient compliance
Computed tomography
in AIDS-related lymphomatous meningitis, 1980
for optimal cytoreduction, in ovarian cancer, 166-172
in HD, 2218-2225
in melanoma staging, 638-643
preoperative, in ovarian cancer, 166-172
staging laparotomy *v*, in HD, 2218-2225

Cost
of CHOP regimen, 1698, 1699
of M-BACOD regimen, 1698, 1699
of oral combination chemotherapy, in AIDS-related NHL, 1691-1702

Cost-effectiveness
of breast cancer adjuvant therapy, in elderly, 777-782
of combination chemotherapy, in early premenopausal breast cancer, 771-776
of palliative cancer therapy, 380

CPT-11
bile concentrations of, 2202
chemical structure of, 2195
dose-intensity determination for, 2198
dose-intensity relationship of, 2199
dosing modifications of, 2196
dosing of, 2195
etoposide plus
diarrhea due to, 2032
granulocytopenia due to, 2032
hematologic toxicity of, 2031-2032
in refractory solid tumors, 2030-2035
phase I study of, 2030-2035
therapeutic efficacy of, 2033
hematologic toxicity of. 2197
in metastatic colorectal cancer, 909-913
neutropenia due to, 2197
nonhematologic toxicity of, 2197-2198
in NSCLC, 1391-1392
pharmacokinetic analysis of, 2196
pharmacokinetic parameters of, 2201
pharmacokinetics of, 2199
plasma distribution of, 2202
response to, 911
toxicity of, 911
treatment schedule for, 910
weekly
pharmacokinetic trial of, 2194-2204
phase I trial of, 2194-2204

Cranial irradiation
in acute myelogenous leukemia, 279-286
in childhood acute lymphoblastic leukemia, 527-537
in CNS leukemia, 520-526
combination chemotherapy plus, in relapsed acute lymphoblastic leukemia, 271-278

CT, *see* Computed tomography

Cyclophosphamide
carboplatin plus
hematologic toxicities of, 1586
in advanced ovarian cancer, 1156-1164
nonhematologic toxicities of, 1586-1587
peripheral-blood progenitor cells for, 1583-1591
tumor responses to, 1587-1588
etoposide plus
oral, in NSCLC, 1598-1601
in refractory neuroblastoma, 630-637
response to, 634-635
high-dose, mesna *v* continuous bladder irrigation following, 1306-1310
in CHOP regimen, cost of, 1698
in combination chemotherapy
for breast cancer, 1253-1263
estrogen recruitment prior to, 1723-1728
for elderly, 2362-2369
for large-cell lymphoma, 2250-2257
for multiple melanoma, 1165-1171
for NHL, 1573-1582, 248-254
for SCLC, 1858-1865
second cancer following, 262-270
in combined modality therapy, secondary acute myeloid leukemia following, 1039-1045
in M-BACOD regimen, cost of, 1698
in multimodality regimen, for stage III neuroblastoma, 84-90
in myelosuppressive chemotherapy, for metastatic breast cancer, 1144-1149
in oral combination chemotherapy, for AIDS-related NHL, 1691-1702
in weekly combination chemotherapy, for SCLC, 1858-1865
maximum-tolerated dose of, 796
oral, cost of, 1698
sperm count following, 239-247
tolerable-dose diagram for, 797
Cyclophosphamide, busulfan, PBSCT regimen, in AML, 1661-1667
Cyclophosphamide, carmustine, etoposide, BMT regimen
in lymphoid malignancies, 1329-1335
prognostic factors in, for NHL, 1085-1091
Cyclophosphamide, cisplatin induction regimen, for stage III neuroblastoma, 84-90
Cyclophosphamide, cisplatin, carmustine, BMT consolidation regimen, in high-risk breast cancer, 1132-1143
Cyclophosphamide, cytarabine, mercaptopurine, thioguanine regimen, in acute lymphoblastic leukemia, 2234-2242
Cyclophosphamide, doxorubicin regimen, in breast cancer, 454-460
Cyclophosphamide, doxorubicin, 5-FU, GM-CSF regimen, in breast cancer, 2411-2416
Cyclophosphamide, doxorubicin, etoposide regimen
infusional, in resistant NHL, 1071-1079
prolonged, in SCLC, 1230-1240
secondary tumors following, 1235-1236
toxicity of, 1233
Cyclophosphamide, doxorubicin, tamoxifen regimen, in breast cancer, 454-460
Cyclophosphamide, doxorubicin, vincristine, regimen, thoracic radiotherapy plus, 1223-1229
Cyclophosphamide, doxorubicin, vincristine induction regimen, in limited SCLC, 1593
Cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate, folinic acid, cytarabine regimen, cost of, 1698, 1699
Cyclophosphamide, doxorubicin, vincristine, etoposide, cisplatin induction regimen, in limited SCLC, 1593
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, cost of, 1698, 1699
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, radiotherapy plus, in lymphoma, 720-725
Cyclophosphamide, doxorubicin, vincristine, prednisone, bleomycin regimen, sperm count following, 239-247
Cyclophosphamide, epirubicin, 5-FU regimen

in metastatic breast cancer, 467-473
monthly *v* weekly, 467-473
Cyclophosphamide, etoposide, doxorubicin, vincristine, bleomycin, methotrexate, folinic acid, prednisone regimen, in NHL, 943-949
Cyclophosphamide, methotrexate, 5-FU regimen, in breast cancer, 454-460
Cyclophosphamide, methotrexate, 5-FU, vincristine, prednisone regimen
in breast cancer, 1710-1716
prolonged, 1710-1716
toxicity of, 1714-1715
Cyclophosphamide, vincristine consolidation regimen, in relapsed acute lymphoblastic leukemia, 271-278
Cyclophosphamide, vincristine, methotrexate, daunomycin, prednisone induction, in childhood NHL, 1024-1032
Cyclophosphamide, vincristine, methotrexate, prednisone regimen, in childhood NHL, 1024-1032
Cyclophosphamide, vincristine, prednisone regimen, in adult acute lymphoblastic leukemia, 1990-2001
Cyclophosphamide, vincristine, procarbazine regimen, in HD, 100-108
Cyclosporine
blood levels of, 1654-1655
in combination chemotherapy, for acute leukemia, 1652-1660
GVHD induced by, in breast cancer, 478-484
hematologic toxicity of, 1656-1657
in multidrug resistance modulation, for acute leukemia, 1652-1660
nonhematologic toxicity of, 1655
Cystitis, hemorrhagic, mesna *v* continuous bladder irrigation for, 1306-1310
Cytarabine
circadian pharmacodynamics of, 1409
in combination chemotherapy
for acute lymphoblastic leukemia, 839-849, 2234-2242
for acute myeloid leukemia, 1448-1457
for myelodysplastic syndrome, 1448-1457
for NHL, 248-254
in continuation combination chemotherapy, for acute lymphoblastic leukemia, 210
fludarabine potentiation of, in acute myelogenous leukemia, 116-124
following intrathecal DTC 101, 2186-2193
high-dose, asparaginase plus, 538-545
in intrathecal combination regimen, for acute lymphoblastic leukemia, 271-278
intravenous, with intravenous mercaptopurine, 1829-1830
in M-BACOD regimen, cost of, 1698
mitoxantrone plus, in acute leukemia, 2002-2009
Cytarabine, cyclosporine, daunorubicin regimen, in leukemia, 1652-1660
Cytarabine, methotrexate, radiotherapy regimen, in AIDS-related lymphomatous meningitis, 1978-1984
Cytarabine, teniposide pulse regimen, in relapsed acute lymphoblastic leukemia, 271-278
Cytarabine, thioguanine, asparaginase, methotrexate, carmustine consolidation, in childhood NHL, 1024-1032
Cytokine plasma level, determination of, 2065
Cytokinetic rhythm, circadian, 1405-1406
Cytoreduction, optimal, CT for, 166-172
DAB486IL-2
adverse effects of, 1688
in cutaneous T-cell lymphoma, 1682-1690
pharmacokinetics of, 1685
safety of, 1686-1687
source of, 1683
therapy with, antibody status during, 1687
Dacarbazine
in combination chemotherapy, for advanced soft tissue sarcoma, 1276-1285
in combined modality therapy, for HD, 100-108
in multimodality regimen, for stage III neuroblastoma, 84-90
Dactinomycin
in combination chemotherapy, for Wilms' tumor, 1014-1023
in combined modality therapy
for Wilms' tumor, 1014-1023
secondary acute myeloid leukemia following, 1039-1045
Dactinomycin, vincristine, cyclophosphamide, doxorubicin regimen, second cancer following, 262-270
Daunomycin, in combination chemotherapy, for NHL, 1024-1032
Daunorubicin
in combination chemotherapy
for acute leukemia, 1652-1660
for acute myeloid leukemia, 1448-1457
for myelodysplastic syndrome, 1448-1457
in induction combination chemotherapy, for acute lymphoblastic leukemia, 210
Dexamethasone
BMT plus
in acute myeloid leukemia, 1448-1457
in myelodysplastic syndrome, 1448-1457
in combination chemotherapy
for acute lymphoblastic leukemia, 2234-2242
for cisplatin-induced nausea, 2391-2395, 2396-2404
in M-BACOD regimen, cost of, 1698
Dexamethasone, cytarabine, thioguanine, etoposide, daunorubicin regimen, 1448-1457
Diarrhea, 5-FU-induced, octreotide *v* loperamide for, 148-151
Diaziquone, carmustine *v*, for anaplastic gloima, 77-83
Diet, fat-reduction, 2072-2080
in early breast cancer, 2061-2062
Dietary counseling
in breast cancer, for therapy-induced weight gain, 1423-1424
during cancer therapy, 2043-2049
Dietary intake, in breast cancer, weight gain associated with, 1423-1424
Diphenhydramine, in combination therapy, for cisplatin-induced nausea, 2396-2404
DNA ploidy
in literature, 621
in medulloblastoma prognosis, 616-622
in node-positive breast cancer, 351-359
in rhabdomyosarcoma prognosis, 1901-1905
Dose
tolerable, for combination chemotherapy trials, 794-801
see also specific agent
Down syndrome, acute lymphoblastic leukemia and, 1361-1367
Doxorubicin
in advanced soft tissue sarcomas, 1269-1275
in CHOP regimen, cost of, 1698

circadian pharmacodynamics of, 1409-1410
cisplatin plus, in malignant mesothelioma, 1559-1565
in combination chemotherapy
estrogen recruitment prior to, 1723-1728
for acute lymphoblastic leukemia, 2234-2242
for bladder cancer, 387-389
for breast cancer, 2411-2416
for low-grade lymphoma, 644-651
for multiple melanoma, 1165-1171
for NHL, 1573-1582
for poor-prognosis NHL, 943-949
for urothelial cancer, 400-407
for Wilms' tumor, 1014-1023
second cancer following, 262-270
sperm count following, 239-247
in combination induction, chemotherapy
for limited SCLC, 1593
for relapsed acute lymphoblastic leukemia, 271-278
in combined modality therapy
for SCLC, 1223-1229
for stage I-II lymphoma, 720-725
for Wilms' tumor, 1014-1023
secondary acute myeloid leukemia following, 1039-1045
dose-escalation diagram for, 797
in dose-intensified combination chemotherapy, for urothelial cancer, 408-414
dose-intensity of, 403
dose-response relationship for, 406
dosing of, 1279
epirubicin *v*, dosing intensity of, 1260
ifosfamide plus, in advanced soft tissue sarcomas, 1269-1275
infusional, in combination chemotherapy, for resistant NHL, 1071-1079
maximum-tolerated dose of, 796
in M-BACOD regimen, cost of, 1698
in multimodality regimen, for stage III neuroblastoma, 84-90
myocyte cell damage following, 1265
indium 111 antimyosin monoclonal antibody study of, 1264-1268
paclitaxel plus, dose-escalation schedules for, 799
in preoperative combination chemotherapy, for esophageal adenocarcinoma, 22-28
in prolonged combination chemotherapy, for SCLC, 1230-1240
resistance to, progesterone modulation of, 2417-2426
tolerable-dose diagram for, 797
Doxorubicin, bleomycin, vinblastine, dacarbazine regimen, in early-stage HD, 2258-2272
Doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, in HD, 100-108
Doxorubicin, cisplatin, etoposide, ifosfamide regimen
continuous infusion, in neuroblastoma, 623-629
dose escalation in, 624
myelosuppression toxicity of, 625
nonhematologic toxicities of, 627
response to, 627
Doxorubicin, cyclophosphamide regimen, in node-positive breast cancer, 454-460
Doxorubicin, cyclophosphamide tamoxifen regimen, in breast cancer, 454-460
Doxorubicin, cyclophosphamide, etoposide regimen, in SCLC, 1858-1865
Doxorubicin, dacarbazine, ifosfamide regimen
in advanced soft tissue sarcoma, 1276-1285
sarcoma survival following, 1279, 1282
Doxorubicin, etoposide, cyclophosphamide, cisplatin, vindesine, vincristine, methotrexate regimen, in SCLC, 1858-1865
Doxorubicin, etoposide, cyclophosphamide, vincristine, bleomycin, prednisone regimen
in elderly, 2362-2369
toxicity of, 2366
Doxorubicin, ifosfamide, GM-CSF regimen
in soft tissue sarcoma, 15-21
toxicity of, 17-18
Doxorubicin, methotrexate, vincristine, prednisone, folinic acid, cytarabine, cyclophosphamide, etoposide regimen
in NHL, 248-254
toxicities associated with, 250-254
Doxorubicin, prednisone pulse regimen, in relapsed acute lymphoblastic leukemia, 271-278
Doxorubicin, vincristine, cyclophosphamide, etoposide, prednisone regimen, in large-cell lymphoma, 2250-2257
Doxorubicinol, resistance to, progesterone modulation of, 2417-2426
Drug resistance
in recurrent lymphoma, 109-115
see also Multidrug resistance
DTC 101
dexamethasone plus, 2191
intrathecal administration of, cytarabine following, 2186-2193
toxicity of, 2191

Edatrexate
in NSCLC, 1395-1396
phase II study of, 1241-1244
response to, 1243-1244
toxicities due to, 1242
weekly, in metastatic breast cancer, 1241-1244
Elderly
doxorubicin, etoposide, cyclophosphamide, vincristine, bleomycin, prednisone regimen in, 2362-2369
large-cell lymphoma in, 2250-2257
node-positive breast cancer in, tamoxifen for, 29-35
Emesis, cisplatin-induced
metoclopramide, dexamethasone, diphenhydramine regimen in, 2396-2404
ondansetron, dexamethasone regimen in, 2396-2404
ondansetron, dexamethasone, chlorpromazine regimen in, 2391-2395
Endocrine therapy, *see* Hormonal therapy
Endometrial cancer, following tamoxifen, 485-490
Endoscopic ultrasonography, for gastric cancer recurrence, 2380-2385
Epidermal growth factor receptor
determination of, 1874
expression of, in head and neck cancer, 1873-1878
Epidoxorubicin, in hybrid combination chemotherapy, for HD, 712-719
Epipodophyllotoxins, secondary acute myeloid leukemia following, 199-201, 209-217
Epirubicin
in combination chemotherapy

for breast cancer, 1253-1263
following IL-3, 2063-2071
dose-response of, 1253-1263
doxorubicin *v*, dose-intensity of, 1260
high-dose, in NSCLC, 1397
in monthly combination chemotherapy, 467-473
in weekly combination chemotherapy, 467-473
Epirubicin, vincristine, cyclophosphamide, etoposide, prednisone regimen
in large-cell lymphoma, 2250-2257
toxicity of, 2252-2253
Epstein-Barr virus, HIV-associated systemic lymphomas linked to, 1674-1681
Esophageal cancer, preoperative chemoradiotherapy for, 1118-1123
Esophagus, adenocarcinoma of, etoposide, doxorubicin, cisplatin, GM-CSF regimen for, 22-28
Estrogen, suppression of, in breast cancer, 1723-1728
Estrogen recruitment, prechemotherapy, in breast cancer, 1723-1728
Ethinylestradiol, prechemotherapy, in breast cancer, 1723-1728
Etoposide
acute hypersensitivity reaction to, in HD, 1080-1084
following acute lymphoblastic leukemia, 209-217
carboplatin plus
in germ cell cancer, 598-606
toxicity of, 601
chemotherapy plus, secondary tumor following, 1706
chronic oral, in NSCLC, 1394-1395
cisplatin plus
in germ cell cancer, 598-606
toxicity of, 601
in combination chemotherapy
for acute myeloid leukemia, 1448-1457
for elderly, 2362-2369
following IL-3, 2063-2071
for large-cell lymphoma, 2250-2257
for myelodysplastic syndrome, 1448-1457
for NHL, 1085-1091, 248-254
for poor-prognosis NHL, 943-949
for relapsed pediatric solid tumors, 554-560
for SCLC, 1858-1865
in combination induction chemotherapy, for limited SCLC, 1593
in combined modality therapy
acute hypersensitivity to, 1080-1084
for Ewing's sarcoma, 1482-1488
for lymphoid malignancies, 1329-1335
in continuation combination chemotherapy, for acute lymphoblastic leukemia, 210
in continuous infusion combination chemotherapy, for neuroblastoma, 623-629
CPT-11 plus
diarrhea due to, 2032
granulocytopenia due to, 2032
hematologic toxicity of, 2031-2032
in refractory solid tumors, 2030-2035
phase I study of, 2030-2035
therapeutic efficacy of, 2033
cyclophosphamide plus
in refractory neuroblastoma, 630-637
oral, in NSCLC, 1598-1601
response to, 634-635
14-day infusion of, 1602-1608
dosing of, 1603
hematologic toxicity of, 1604
nonhematologic toxicity of, 1604
pharmacokinetics of, 1604-1605
response to, 1605
infusional, in combination chemotherapy, for resistant NHL, 1071-1079
low-dose infusional, response to, 1324-1326
low-dose oral, bioavailability of, 374-377
in lung cancer, phase I study of, 1602-1608
in myelosuppressive chemotherapy, for metastatic breast cancer, 1144-1149
oral, cost of, 1698
in oral combination chemotherapy, for AIDS-related NHL, 1691-1702
pharmacodynamic model of, 1184-1185
pharmacodynamics of, 1183-1184
pharmacokinetic studies of, 1603
pharmacokinetics of, 633
prolonged, toxicity of, 1324
in prolonged combination chemotherapy, for SCLC, 1230-1240
prolonged low-dose, 1322-1328
prolonged oral
in NSCLC, 1179-1188
pharmacodynamics of, 1179-1188
in relapsed Wilms' tumor, 1478-1481
secondary acute myeloid leukemia associated with, 209-217
secondary tumor following, 1706
in weekly combination chemotherapy, for SCLC, 1858-1865
Etoposide, doxorubicin, cisplatin, GM-CSF regimen
for esophageal adenocarcinoma, 22-28
toxicity of, 26
Etoposide, melphalan, autologous BMT regimen, in HD, 704-711
Etoposide, methotrexate, folinic acid maintenance regimen, for limited SCLC, 1593
Etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone regimen
dose-intensity of, 1579-1580
dosing of, 1575
in NHL, 1573-1582
response to, 1576-1578
toxicity of, 1578-1579
Ewing's sarcoma
autologous BMT plus TBI in, 1911-1918
chemotherapy response in, prognostic significance of, 1763-1769
histopathologic analysis in, 1763-1769
myeloablative radiochemotherapy in, 1482-1488
necrosis in, prognostic significance of, 1763-1769
peripheral blood stem-cell transplantation in, 1482-1488
preoperative chemotherapy in, 1763-1769

Family history, of cancer, rhabdomyosarcoma and, 265-266
Fat, dietary reduction of, 2072-2080
in early breast cancer, 2061-2062
Fenretinide
concentration of, in nipple discharge, 2040
distribution of, in human breast, 2039-2040
five-year administration of, 2036-2042
long-term elimination of, 2038-2039

plasma concentration of, 2040
tamoxifen plus, in metastatic breast cancer, 474-477
Floxuridine, hepatic arterial, in colorectal cancer, 330-335
Floxuridine, mitomycin, carmustine regimen
in colorectal cancer, 330-335
response to, 332-333
toxicity of, 333-334
Fludarabine, for cytarabine potentiation, in acute myelogenous leukemia, 116-124
Fluorodeoxyuridine, intraarterial hepatic, conformal radiotherapy plus, 1286-1293
Fluoropyrimidines, circadian pharmacodynamics of, 1410-1413
Fluorouracil
in chemoimmunotherapy, for head and neck cancer, 360-368
circadian pharmacodynamics of, 1410-1413
cisplatin plus, in resected gastric cancer, 425-433
in combination chemotherapy
for breast cancer, 2411-2416
for hepatoblastoma, 96-99
diarrhea associated with, octreotide *v* loperamide for, 148-151
folinic acid-modulated, in colon cancer, 1879-1887
infusional, interferon-alfa plus
pharmacokinetic analysis of, 1613-1614
response to, 1614
toxicity of, 1612-1613
interferon alfa-2b plus
in advanced cancer, 751-761
phase I study of, 751-761
toxic effects of, 754
levamisole plus, hepatic toxicity associated with, 2386-2390
lomustine, vincristine regimen plus, in colon cancer, 1879-1887
low-dose infusional, interferon-alfa plus, 1609-1617
maximum-tolerated dose of, 796
in metastatic colorectal cancer, 1888-1893
in monthly combination chemotherapy, for metastatic breast cancer, 467-473
oral folinic acid plus
in metastatic colorectal cancer, 1888-1893
toxicity of, 1890
in prolonged combination chemotherapy, 1710-1716
in weekly combination chemotherapy, for metastatic breast cancer, 467-473
Fluorouracil, cisplatin regimen, intraperitoneal, systemic 5-FU plus, 425-433
hematologic toxicity following, 428
pH of, 429
sclerosing encapsulating peritonitis following, 425-433
toxicity of, 427-428
Fluorouracil, cisplatin, radiotherapy regimen
bladder cancer metastases following, 2152-2153
bladder cancer pelvic recurrences following, 2152
bladder cancer survival following, 2153
in head and neck cancer, 2136-2142
in nasopharyngeal carcinoma, 1919-1928
protocol for, 2137
survival following, 2139, 2141
tolerance to, 2153
toxicity of, 2139
in transitional-cell bladder cancer, 2150-2157
Fluorouracil, cyclophosphamide, epirubicin regimen
in breast cancer, 1253-1263
toxicity of, 1255-1256
Fluorouracil, doxorubicin, cyclophosphamide regimen, estrogen recruitment prior to, 1723-1728
Fluorouracil, folinic acid, interferon alfa-2a regimen
clinical response to, 1739-1740
hematologic toxicity of, 1742
in metastatic colorectal cancer, 1737-1745
toxicity of, 1740-1743
Fluorouracil, methotrexate, cyclophosphamide regimen, in breast cancer, 454-460
Flutamide withdrawal syndrome, 1566-1572
Folinic acid
in chemoimmunotherapy regimen
for head and neck cancer, 360-368
for metastatic colorectal cancer, 1737-1745
in combination chemotherapy
for NHL, 248-254
for poor-prognosis NHL, 943-949
in combination maintenance chemotherapy, for limited SCLC, 1593
5-FU plus, in colon cancer, 1879-1887
in M-BACOD regimen, cost of, 1698
oral, 5-FU plus
in metastatic colorectal cancer, 1888-1893
toxicity of, 1890
5-FU, *see* Fluorouracil
Functional Assessment of Cancer Therapy scale, 570-579

G-CSF, *see* Granulocyte-colony stimulating factor
Gallium nitrate, for osteolysis, in myeloma, 2443-2450
Gallium scan, in mediastinal HD, 1092-1098
Gamma imaging, in AIDS-related lymphomatous meningitis, 1980
Gastric cancer
curative resection in, adjuvant therapy following, 1441-1447
following testicular cancer therapy, 415-424
improving survival in, 1437-1438
metastatic lymph nodes in, 1894-1900
nodal staging in, 1894-1900
recurrence of, endoscopic ultrasonography for, 2380-2385
resected, intraperitoneal cisplatin, 5-FU regimen in, 425-433
Gastroesophageal junction, adenocarcinoma of, etoposide, doxorubicin, cisplatin, GM-CSF regimen for, 22-28
Gastrointestinal cancer, following testicular cancer therapy, 415-424
Gastrointestinal mucosa, circadian variation of, 1406-1407
Gemcitabine, in NSCLC, 1396-1397
Germ cell cancer
chemorefractory, surgical salvage of, 324-329
etoposide plus carboplatin *v* cisplatin in, 598-606
good-prognosis, bleomycin in, 1300-1305
nonteratomatous, postchemotherapy retroperitoneal lymph node dissections in, 1294-1299
secondary neoplasia following, 1703-1709
Glioma
anaplastic, diaziquone *v* carmustine for, 77-83
carboplatin plus vincristine for, 850-856
carmustine *v* PCNU for, 1316-1321
malignant, high-dose chemoradiotherapy for, 1458-1465

radiotherapy plus carmustine for, 857-862
Serratia marcescens extract plus radiotherapy for, 1746-1750
Glucose metabolism, of breast cancer tumors, PET monitoring of, 2102-2111
GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
Goserelin
phase II study of, 1529-1535
in postmenopausal metastatic breast cancer, 1529-1535
Graft-versus-host disease, cyclosporine-induced, in breast cancer, 478-484
Granulocyte colony-stimulating factor
in dose-intensified combination chemotherapy
for urothelial cancer, 408-414
oxantrazole plus
cardiac toxicity of, 1799-1801
hematologic toxicity of, 1797-1799
nonhematologic toxicity of, 1799
phase I study of, 1795-1803
paclitaxel plus
in metastatic breast cancer, 1943-1951
myelotoxicity of, 1948
nonhematologic toxicity of, 1949
piroxantrone plus
cardiac toxicity of, 1799-1801
hematologic toxicity of, 1797-1799
nonhematologic toxicity of, 1799
phase I study of, 1795-1803
Granulocyte-colony stimulating factor, paclitaxel, cisplatin regimen
hematologic toxicity of, 2013
muscular toxicity of, 2015-2016
neuromuscular toxicity of, 2013-2015
neutropenia due to, 2015
pharmacologic study of, 2010-2020
Granulocyte-macrophage colony-stimulating factor
carboplatin plus
dosing of, 2119
febrile neutropenia due to, 2121
in recurrent ovarian cancer, 2118-2126
transfusion requirements due to, 2123
chemotherapy plus, for soft tissue sarcoma, 15-21
combination chemotherapy plus, in breast cancer, 2411-2416
etoposide, doxorubicin, cisplatin regimen plus, for esophageal adenocarcinoma, 22-28
ifosfamide, doxorubicin regimen plus, for soft tissue sarcoma, 15-21
peripheral-blood progenitor cell plus, 1585
platelet toxicity and, 2121-2123
side effects of, 2119-2120
WBC counts and, 2120
Growth factor-cytotoxin fusion protein
adverse effects of, 1688
in cutaneous T-cell lymphoma, 1682-1690
pharmacokinetics of, 1685
safety of, 1686-1687
source of, 1683
therapy with, antibody status during, 1687
Gunderson-Sosin modification, of Astler-Coller colorectal cancer staging, 1113
GVHD, *see* Graft-versus-host disease
HD, *see* Hodgkin's disease
Head and neck cancer
antibody reactivity in, 2427-2433
chemoradiotherapy of, 2136-2142
circulating immune complexes in, 2427-2433
cisplatin, 5-FU, folinic acid, interferon alfa-2b regimen in, 360-368
epidermal growth factor receptor expression in, 1873-1878
lymphatic mapping in, 1751-1756
quality-of-life questionnaire in, 863-872
Heat-shock protein, HSP-60, in ovarian cancer, 891-898
Hematopoietic stem-cell transplantation, *see* Peripheral stem-cell transplantation
Hepatic arterial infusion
in colorectal cancer, 330-335
complications associated with, 822-826
devices for, 822
in metastatic colorectal cancer, 815-819
Hepatic metastasis(es)
MRI monitoring of, 2451-2455
sonographic monitoring of, 2451
Hepatic venoocclusive disease
fatal outcome and, 1729-1736
following BMT, 1729
Hepatobiliary cancer, conformal radiotherapy plus regional chemotherapy in, 1286-1293
Hepatoblastoma, cisplatin, vincristine, 5-FU regimen in, 96-99
Hepatotoxicity, associated with 5-FU plus levamisole, 2386-2390
HER-2-*neu* oncogene, amplification of
analysis of, 1937
in breast cancer, 1936-1942
Histopathologic analysis, in Ewing's sarcoma, 1763-1769
HIV, *see* Human immunodeficiency virus
Hodgkin's disease
ABVD *v* MOPP regimen in, 2258-2272
autotransplantation in, 2351-2361
BMT for, 2342-2350
clinical staging *v* laparotomy in, 2258-2272
cyclophosphamide, vincristine, procarbazine regimen in, 100-108
doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen in, 100-108
etoposide, melphalan, autologous BMT regimen in, 704-711
hybrid combination chemotherapy in, 712-719
imaging in, 2218-2225
late relapse in, 225-232
late relapse outcomes in, 229
late relapse predisposing factors in, 230
mediastinal, gallium scans in, 1092-1098
pediatric, staging laparotomy in, 2218-2225
pediatric *v* adult, autologous BMT in, 2243-2249
poor-prognosis, yttrium 90-labeled antiferritin, chemotherapy, BMT regimen in, 698-703
psychosocial outcomes of, 979-988
relapsed
accelerated hyperfractionated total-lymphoid irradiation in, 1062-1070
autologous BMT in, 1062
high-dose chemotherapy in, 1062
serum beta-2-microglobulin, prognostic role of, 1108-1111
splenectomy in, secondary acute leukemia following, 925-930

therapy of
cardiac disease following, 1208-1215
pregnancy following, 507-512
second malignancies following, 255-261
Hormonal therapy
in chemoresistant ovarian cancer, 1957-1968
in early premenopausal breast cancer, cost-effectiveness of, 771-776
HSP-60, expression of, in ovarian cancer, 891-898
3H-Thymidine labeling index, as prognostic factor, in tamoxifen-treated breast cancer, 1150-1155
Human immunodeficiency virus
NHL development and, 1099-1107
systemic lymphomas associated with, Epstein-Barr virus linkage to, 1674-1681
Hydrocortisone
aminoglutethimide plus, in estrogen suppression, 1723-1728
in combination chemotherapy, for acute lymphoblastic leukemia, 839-849
in intrathecal combination regimen, for acute lymphoblastic leukemia, 271-278
Hydroxyurea
in combination chemotherapy, for NHL, 1024-1032
misonidazole *v*, in cervical cancer, 1523-1528
Hypercalcemia
alendronate sodium in, 1618-1623
aminohydroxybutylidene bisphosphonate in, 1618
Hypersensitivity reaction, paclitaxel, re-treatment following, 885-890
Hyperthermia, whole-body, carboplatin plus, 1787-1794
clinical response to, 1792
hematologic toxicity of, 1790
Herpes simplex I following, 1790-1791
pharmacokinetics following, 1791-1792
toxicity of, 1789-1790
Hypophosphatemic rickets, ifosfamide-induced, 176-177
Hypothyroidism, autoimmune, IL-2 and, 1376-1383

Ifosfamide
carboplatin plus, in ovarian cancer, 1952-1956
in combination chemotherapy
for advanced soft tissue sarcoma, 1276-1285
for relapsed pediatric solid tumors, 554-560
in continuous infusion combination chemotherapy, for neuroblastoma, 623-629
doxorubicin plus, in advanced soft tissue sarcomas, 1269-1275
hypophosphatemic rickets associated with, 176-177
mesna plus, pharmacology of, 179
metabolism of, 179-182
mitoxantrone plus
in metastatic breast cancer, 461-466
toxicity of, 464
nephrotoxicity associated with, 173-190
randomized trials of, in sarcomas, 1283
Ifosfamide, doxorubicin, GM-CSF regimen
in soft tissue sarcoma, 15-21
toxicity of, 17-18
IL-2, *see* Interleukin-2
IL-3, *see* Interleukin-3
Imaging, in pediatric HD, 2218-2225
Immune complexes, circulating, in head and neck cancer, 2427-2433
Immunoglobulin M monoclonal gammopathy, amyloidosis and, 914-920
Immunohistochemistry
for cathepsin D levels, 36-43
for pi-class glutathione S-transferase expression, 49-58
Immunologic effects, levamisole-induced, 125-135
Immunotherapy
in colorectal cancer, 385-386, 390-399
morbidity related to, 395
survival following, 396-397
Infection, IL-2–induced, 136-147
Insomnia, in lung cancer, 997-1004
Intercalating topoisomerase II inhibitor, alkylating agent, radiotherapy plus, secondary leukemia following, 1039-1045
Interferon, description of, 1609-1610
Interferon alfa
allogeneic BMT following, in chronic myelogenous leukemia, 1055-1061
infusional 5-FU plus
pharmacokinetic analysis of, 1613-1614
response to, 1614
toxicity of, 1612-1613
low-dose infusional 5-FU plus, 1609-1617
Interferon alfa-2a
in chemoimmunotherapy regimen, for metastatic colorectal cancer, 1737-1745
cisplatin, IL-2 regimen plus, for metastatic melanoma, 2173-2180
IL-2 plus
in advanced melanoma, 1969-1977
in metastatic renal cancer, 1809-1816
in renal cell cancer, 1368-1375
Interferon alfa-2b
in chemoimmunotherapy, for head and neck cancer, 360-368
combination chemotherapy plus, for multiple myeloma, 155-160
5-FU plus
in advanced cancer, 751-761
phase I study of, 751-761
toxic effects of, 754
IL-2 plus, in renal cell cancer, 661-670
Interleukin-2
in acute leukemia, 1817-1825
anti-CD3 plus
clinical antitumor effects of, 1501-1502
clinical toxicity of, 1498-1500
immunologic activation associated with, 1499-1501
in renal cancer, 1496-1505
maximum-tolerated dose for, 1498
re-treatment with, 1499
treatment plan for, 1497-1498
anti-CD3–activated T-killer cells plus
coagulopathy associated with, 655-656
lymphocytosis following, 656-657
metabolic acidosis following, 656
nitrate levels following, 657
therapy with, 652-660
tumor response to, 657-658
autoimmune hypothyroidism and, 1376-1383
biologic modifications induced following, 1820-1821
cisplatin, interferon alfa-2a regimen plus, for metastatic melanoma, 2173-2180

clinical use of, 1818-1820
high-dose, in advanced melanoma, 1969-1977
infectious complications associated with, 136-147
interferon alfa-2a plus, in advanced melanoma, 1969-1977
interferon alfa-2b plus, in renal cell cancer, 661-670
OKT3 plus
clinical antitumor effects of, 1501-1502
clinical toxicity of, 1498-1500
immunologic activation associated with, 1499-1501
in renal cancer, 1496-1505
maximum-tolerated dose for, 1498
re-treatment with, 1499
treatment plan for, 1497-1498
subcutaneous, interferon alfa-2a plus, in renal cancer, 1809-1816
thyroid dysfunction associated with, 921-924
Interleukin-2-diphtheria toxin fusion protein
adverse effects of, 1688
in cutaneous T-cell lymphoma, 1682-1690
pharmacokinetics of, 1685
safety of, 1686-1687
source of, 1683
therapy with, antibody status during, 1687
Interleukin-3
following carboplatin, etoposide, epirubicin regimen, 2063-2071
for chemotherapy-related thrombocytopenia, 2057-2060
hematologic recovery following, 2067-2068
in SCLC, 2063-2071
side effects of, 2065-2066
thrombocytopenia and, 2063-2071
Interleukin-6
B-cell activation by, 503-504
hematologic effects of, 502-503
immunologic effects of, 504
pharmacokinetics of, 501
phase I trial of, 499-506
toxicities of, 501-502
International Neuroblastoma Response Criteria, revisions of, 1466-1477
International Neuroblastoma Staging System, revisions of, 1466-1477
Investigators, clinical cancer, 1639-1651

Ketoroloc, in outpatient bone marrow harvesting, 320-323
Ki-67 immunostaining, in renal cell cancer, 1804-1808

Laparotomy, staging, *v* clinical staging, in HD, 2258-2272
Leucovorin, *see* Folinic acid
Leukemia
acute
IL-2 in, 1817-1825
mitoxantrone plus cytarabine in, 2002-2009
preclinical studies in, 1818
acute lymphoblastic
CNS relapse in, 271-278
Down syndrome and, 1361-1367
etoposide in, 209-217
extended intrathecal chemotherapy in, 839-849
high- *v* intermediate-dose methotrexate infusion in, 827-833
pediatric, improved therapy for, 2234-2242
secondary acute myeloid leukemia following, 209-217
36- *v* 4-hour methotrexate infusion in, 827-833
acute meyloid, therapy-related, 2370-2379
acute myeloblastic, busulfan, cyclophosphamide, PBSCT regimen in, 1661-1667
acute myelogenous
cranial irradiation in, 279-286
transplantation in, 1636-1638
acute myeloid
8:21 translocation in, 690-697
autologous BMT for, 1353-1360
dexamethasone, cytarabine, thioguanine, etoposide, daunorubicin, BMT regimen in, 1448-1457
intensively timed induction therapy plus BMT in, 1448-1457
remission of, autologous BMT in, 314-319
adult acute lymphoblastic, combination chemotherapy of, BMT following, 1990-2001
B-lineage acute lymphoblastic, residual disease in, 546-553
childhood acute lymphoblastic, delayed intensification in, 527-537
childhood acute myelogenous
postremission BMT in, 1046-1054
postremission chemotherapy in, 1046
childhood acute myeloid, high-dose cytarabine plus asparaginase in, 538-545
chronic lymphocytic
2-chlorodeoxyadenosine in, 679-689
Richter's syndrome and, 1985-1989
chronic myelogenous, allogeneic BMT following interferon alfa in, 1055-1061
chronic myeloid, donor leukocytes in, 513-519
CNS
cranial radiation in, 520-526
intrathecal methotrexate in, 520
prevention of, 520-526, 839-849
Philadelphia chromosome-positive chronic myelogenous, unrelated BMT donor in, 834-838
recurrent, second allogeneic BMT in, 304-313
secondary acute, following HD splenectomy, 925-930
secondary acute myeloid
following acute lymphoblastic leukemia, 209-217
following alkylating agent, intercalating topoisomerase II inhibitor, radiotherapy regimen, 1039-1045
following epipodophyllotoxins, 199-201, 209-217
risk of, 212-213
therapy-related, 1039-1045
Leukocyte donor, in chronic myeloid leukemia, 513-519
Levamisole
5-FU plus, hepatic toxicity associated with, 2386-2390
dose-related immunologic effects of, 125-135
Lomustine
in hybrid combination chemotherapy, for HD, 712-719
oral, cost of, 1698
Lomustine, etoposide, cyclophosphamide, procarbazine regimen, oral
cost analysis of, 1697-1699
in AIDS-related NHL, 1691-1702
quality of life and, 1696-1697
toxicity of, 1694-1695
Lomustine, procarbazine, methotrexate maintenace regimen, in limited SCLC, 1593
Lomustine, vincristine, 5-FU regimen, in colon cancer, 1879-1887
Loperamide, octreotide *v*, in 5-FU-induced diarrhea, 148-151
Lugano classification, of testicular cancer, 1704

Lung cancer
advanced non–small-cell, oral etoposide plus cyclophosphamide in, 1598-1601
chemoprevention, 1216-1222
early-stage, photodynamic therapy in, 1844-1845, 1852-1857
high-dose vitamin A in, 1216-1222
limited small-cell
mediastinal lymphadenopathy in, 1592-1597
staging in, 1592
thoracic irradiation timing in, 336-344
treatment protocols for, 1593
non–small-cell
advanced, chemotherapy in, 1866-1872
chronic oral etoposide in, 1394-1395
cisplatin intensity in, 873-878
CPT-11 in, 1391-1392
edatrexate in, 1395-1396
gemcitabine in, 1396-1397
high-dose epirubicin in, 1397
navelbine in, 1394
new agents for, 1391-1402
pathologic complete response in, 1757-1762
preoperative chemotherapy in, 1757-1762
prolonged oral etoposide in, 1179-1188
taxol in, 1393
taxotere in, 1393-1394
topotecan in, 1392-1393
photofrin II in, 1852-1857
sleep asessment in, 997-1004
small-cell
alternating chemotherapy and radiotherapy in, 879-884
chemoradiotherapy in, 1223-1229
doxorubicin, cyclophosphamide, etoposide regimen in, 1858-1865
doxorubicin, etoposide, cyclophosphamide, cisplatin, vindesine, vincristine, methotrexate regimen in, 1858-1865
IL-3 in, for SCLC, 2063-2071
prolonged maintenance chemotherapy in, 1230-1240
standard combination chemotherapy in, 1858-1865
weekly chemotherapy in, 1858-1865
Lymph node
assessment of, in neuroblastoma, 1469
metastatic, in gasric cancer staging, 1894-1900
Lymphadenectomy, selective cervical, for head and neck melanomas, 1751-1756
Lymphatic mapping, intraoperative, for head and neck melanomas, 1751-1756
Lymphoma
anaplastic large-cell, 1677, 1679
Burkitt's, 1676
cutaneous T-cell, cytotoxic fusion protein in, 1682-1690
cyclophosphamide, carmustine, etoposide, BMT regimen in, 1329-1335
follicular
circulating t(14,18)-positive cell following, 1668-1673
detecting occult disease in, 1344-1352
overview of, 202-208
follicular large-cell
chemoradiotherapy in, 218-224
prognosis of, 218-224
stage I and II, 219-221
stage III and IV, 219-222
HIV-associated systemic, variants of, 1674-1681
immunoblastic
relapse of, 1339-1340
survival in, prognostic factors for, 1340-1341
intermediate lymphocytic
cytogenetics of, 806-807
extranodal sites of, 804
features of, 802-811
immunophenotype of, 806
laboratory findings in, 803-804
natural history of, 807-808
pathology of, 804-805
presentation of, 803
prognosis of, 807-808
treatment of, 808-809
large-cell
doxorubicin, vincristine, cyclophosphamide, etoposide, prednisone regimen in, 2250-2257
epirubicin, vincristine, cyclophsophamide, etoposide, prednisone regimen in, 2250-2257
of mediastinum, 1336-1343
relapse of, prognostic factors for, 1339-1340
Richter's syndrome and, 1985-1989
survival in, prognostic factors for, 1340-1341
low-grade, doxorubicin-based therapy in, 644-651
nodular, total central lymphatic irradiation in, 233-238
non-Hodgkin's, *see* Non-Hodgkin's lymphoma
polymorphic B-cell immunoblastic, 1677
primary Ki-1 anaplastic large-cell, 937-942
primary large-cell, of mediastinum, 2291-2294
primary mediastinal B-cell, with sclerosis, 2306-2313
putative histiocytic, 1678
recurrent, drug resistance in, 109-115
residual, MRI in, 2273-2278
stage I-II, combined modality therapy in, 720-725
stage III nodular malignant, 233-238
Lymphomatous meningitis, AIDS-related, radiotherapy, methotrexate, cytarabine regimen in, 1978-1984
M-BACOD regimen, cost of, 1698, 1699
M195 monoclonal antibody
delivery of, 296
dose-escalation trial of, 294-303
effects of, 296-298
HAMA response of, 298
hematologic toxicity of, 298-300
nonhematologic toxicity of, 298
Magnetic resonance imaging
in AIDS-related lymphomatous meningitis, 1980
in liver metastasis monitoring, 2451-2455
in residual lymphoma, 2273-2278
in solitary bone plasmacytoma, 1311-1315
Marker, *see* Tumor marker
Mastectomy, salvage, in recurrent breast cancer, 44-48
Mdr-1 expression, as prognostic factor, in lymphoma, 109-115
Mechlorethamine, doxorubicin, cisplatin, dacarbazine, vincristine, cyclophosphamide regimen, in stage III neuroblastoma, 84-90

Mechlorethamine, lomustine, vindesine, Alkeran, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, bleomycin regimen, in HD, 712-719
Mechlorethamine, vincristine, procarbazine, prednisone regimen, in early-stage HD, 2258-2272
Mediastinum
  immunoblastic lymphoma of, 1336-1343
    relapse of, 1339-1340
    survival in, prognostic factors for, 1340-1341
  large-cell lymphoma of, 1336-1343
    relapse of, 1339-1340
    survival in, prognostic factors for, 1340-1341
  primary B-cell, with sclerosis, 2306-2313
  primary large-cell lymphoma of, 2291-2294
Medulloblastoma
  pediatric, tumor-cell ploidy in, 2211-2217
  prognostic factors in, 616-622
  survival in, 2211-2217
  treatment protocols in, 2212
Megatherapy
  protocols of, 2334
  regimens for, 2334
  in stage IV neuroblastoma, 2330-2341
Megestrol acetate
  body mass increase due to, 152-154
  in cancer anorexia, 762-767
  impact of, on quality of life, 2081-2089
  patient-reported side effects of, 2083-2084
  side effects of, 2084
  weight gain associated with, 152-154
Megestrol acetate, tamoxifen, aminoglutethimide regimen
  in ovarian cancer, 1957-1968
  toxicities of, 1960
Melanoma
  advanced, Il-2 *v* IL-2 plus interferon alfa-2a in, 1969-1977
  metastatic, cisplatin, IL-2, interferon alfa-2a regimen for, 2173-2180
  of head and neck, lymphatic mapping for, 1751-1756
  staging of, CT in, 638-643
Melphalan
  in combination chemotherapy, for multiple melanoma, 1165-1171
  in combined modality therapy, secondary leukemia following, 1039-1045
  prednisone plus, in multiple myeloma, 1165-1171
Melphalan, etoposide, autologous BMT regimen, in HD, 704-711
Melphalan, etoposide, carboplatin regimen, TBI plus, 1482-1488
Melphalan, prednisone regimen, in multiple myeloma, 155-160
Melphalan, prednisone, interferon alfa-2b regimen, in multiple myeloma, 155-160
Meningitis
  AIDS-related lymphomatous, radiotherapy, methotrexate, cytarabine regimen in, 1978-1984
  neoplastic, intrathecal methotrexate *v* thiotepa in, 561-569
Menopausal status, weight gain and, 1421
Mercaptopurine
  administration of, 1826
  clinical trials of, 1828
  in combination chemotherapy, for acute lymphoblastic leukemia, 2234-2242
  in continuation chemotherapy, for acute lymphoblastic leukemia, 210
  formulation of, 1826
  intravenous, 1826-1831
  intravenous administration of, 1827-1828
  intravenous cytrarabine plus, 1829-1830
  intravenous methotrexate plus, 1828-1829
  mode of action of, 1826
  pharmacokinetics of, 1826-1827
Mercaptopurine, methotrexate consolidation regimen, in relapsed acute lymphoblastic leukemia, 271-278
Mesna
  continuous bladder irrigation *v*, following high-dose cyclophosphamide, 1306-1310
  metabolism of, 182-183
Mesothelioma, malignant
  Butchart staging of, 1173
  doxorubicin plus cisplatin in, 1559-1565
  mitomycin plus cisplatin in, 1559-1565
  multimodality therapy in, 1172-1178
  node status in, 1172-1178
Meta-iodobenzylguanidine scintigraphy, in neuroblastoma testing, 1468-1469
Methotrexate
  in chemotherapy, benchmarks of, 6
  in choriocarcinoma therapy, 6
  in combination chemotherapy
    for NHL, 248-254, 1024-1032
    for poor-prognosis NHL, 943-949
  in combination maintenance chemotherapy, for limited SCLC, 1593
  in current therapy, 7-9
  high- *v* intermediate-dose, in acute lymphoblastic leukemia, 827-833
  historical overview of, 5-7
  intrathecal
    in childhood acute lymphoblastic leukemia, 527-537
    in CNS leukemia, 520-526
  intrathecal thiotepa *v*, in neoplastic meningitis, 561-569
  intravenous, with intravenous mercaptopurine, 1828-1829
  in M-BACOD regimen, cost of, 1698
  mechanism of action of, 8
  in prolonged combination chemotherapy, 1710-1716
  resistance to, 9
  36- *v* 4-hour infusion of, in acute lymphoblastic leukemia, 827-833
  in weekly combination chemotherapy, for SCLC, 1858-1865
Methotrexate, cyclophosphamide, 5-FU regimen, in breast cancer, 454-460
Methotrexate, cytarabine, radiotherapy regimen, in AIDS-related lymphomatous meningitis, 1978-1984
Methotrexate, hydrocortisone, cytarabine regimen
  in acute lymphoblastic leukemia, 839-849
  intrathecal, for acute lymphoblastic leukemia, 271-278
Methotrexate, mercaptopurine consolidation regimen, in relapsed acute lymphoblastic leukemia, 271-278
Methotrexate, mercaptopurine, asparaginase, etoposide, cytarabine regimen, in acute lymphoblastic leukemia, 210
Methotrexate, vinblastine, doxorubicin, cisplatin regimen
  dose-intensity of, 400-407

in bladder cancer, 387-389
in urothelial cancer, 400-407
Methotrexate, vinblastine, doxorubicin, cisplatin, G-CSF regimen
dose-escalation schedule for, 410
dose-limiting toxic effects of, 411
dose-modification scheme for, 410
dosing schema of, 409
febrile neutropenia following, 410
in urothelial cancer, 408-414
vascular toxicity following, 412
Methylprednisolone, pentoxifylline plus, 1332
Metoclopramide, dexamethasone, diphenhydramine regimen, in cisplatin-induced emesis, 2396-2404
Misonidazole, hydroxyurea *v*, in cervical cancer, 1523-1528
Mitomycin
cisplatin plus
in malignant mesothelioma, 1559-1565
in NSCLC, 873-878
in hepatic arterial combination chemotherapy, for colorectal cancer, 330-335
Mitomycin, doxorubicin, cisplatin regimen, in advanced soft tissue sarcomas, 1269-1275
Mitomycin, vinblastine, cisplatin regimen, in NSCLC, 1757-1762
Mitomycin, vindesine, cisplatin regimen, in NSCLC, 1757-1762
Mitotane, cisplatin regimen, in adrenal cancer, 161-165
Mitoxantrone
cytarabine plus, in acute leukemia, 2002-2009
dose level of
cardiotoxicity by, 2005
hepatic toxicity by, 2004
response by, 2004
dose-escalation schedule of, 2004
dosing of, in acute leukemia, 2002-2009
ifosfamide plus
in metastatic breast cancer, 461-466
toxicity of, 464
myocyte cell damage following, 1265-1266
indium 111 antimyosin monoclonal antibody study of, 1264-1268
in nasopharyngeal cancer, 70-76
pharmacokinetic studies of, 2005-2006
Monoclonal antibody(ies), indium 111 antimyosin, for myocyte cell damage studies, 1264-1268
Monoclonal antibody G250
biodistribution of, 744
phase I study of, 738-750
Monoclonal antibody M195
delivery of, 296
dose-escalation trial of, 294-303
effects of, 296-298
HAMA response of, 298
hematologic toxicity of, 298-300
nonhematologic toxicity of, 298
Monoclonal antibody OKB7, iodine 131-labeled
hematologic toxicity of, 2024
imaging of, 2023-2024
in NHL, 2021-2029
nonhematologic toxicity of, 2024
phamacology of, 2023
toxicity of, 2025
Monoclonal antibody OVX1, development of, 1506-1510
MOPP regimen, ABVD regimen *v*, in early-stage HD, 2258-2272
Morphine, immediate- *v* sustained-release, for cancer pain, 967-972
MRI, *see* Magnetic resonance imaging
Multidrug resistance
cyclosporine modulation of, in acute leukemia, 1652-1660
high-dose progesterone in, 2417-2426
modulation of, 1629-1635
in recurrent lymphoma, 109-115
Multiple myeloma
combination chemotherapy in, 1165-1171
melphalan, prednisone regimen in, 155-160, 1165-1171
melphalan, prednisone, interferon alfa-2b regimen in, 155-160
vincristine, carmustine, doxorubicin, prednisone regimen in, 1165-1171
vincristine, cyclophosphamide, melphalan, prednisone regimen in, 1165-1171
Murine tumor, circadian variation of, 1407
Myelodysplastic syndrome
all- *trans* retinoic acid, 1489-1495
dexamethasone, cytarabine, thioguanine, etoposide, daunorubicin, BMT regimen in, 1448-1457
intensively timed combination chemotherapy plus BMT in, 1448
Myeloma, osteolysis in, gallium nitrate for, 2443-2450
Myelosuppression, conventional chemotherapy and, 1-2
Myocyte(s), damage to
doxorubicin-associated, 1264-1268
indium 111 antimyosin monoclonal antibody studies of, 1264-1268
mitoxantrone-associated, 1264-1268

N-*myc* amplification, in neuroblastoma, 84-90
Nasopharyngeal cancer
chemoradiotherapy in, 1919-1928
mitoxantrone in, 70-76
undifferentiated
associated paraneoplastic syndromes of, 2434-2442
CD23 serum levels in, 2143-2149
Nausea
anticipatory, alprazolam for, 1384-1390
cisplatin-induced
metoclopramide, dexamethasone, diphenhydramine regimen in, 2396-2404
ondansetron in, 2391-2395
ondansetron, dexamethasone regimen in, 2396-2404
ondansetron, dexamethasone, chlorpromazine regimen in, 2391-2395
Navelbine, *see* Vinorelbine
Necrosis, in histopathologic response, definition of, 1763
Needle biopsies, in neuroblastoma diagnosis, 1468
Neopterin, 129-135
Nephrotoxicity, ifosfamide-induced, 173-190
assessment of, 178-179
biochemical manifestations of, 175
in children, 175-176
clinical manifestations of, 176
grading system for, 178
incidence of, 176
management of, 177
pathogenesis of, 183-185

reduction of, 186
reversibility of, 177
risk factors for, 185-186
subclinical manifestations of, 175
Neuroblastoma
biologic risk groups in, 1472-1473
BMT for, relapse sites following, 2226-2233
bone marrow assessment in, 1469
cortical bone involvement in, 1469
diagnosis of, 1467-1468
extent of, testing for, 1468-1470
liver involvement in, 1470-1471
lymph node assessment in, 1469
marrow involvement in, 1471
meta-iodobenzylguanidine scintigraphy in, 1468-1469
midline tumors, 1470
multifocal primary tumors, 1471
N-*myc* amplification in, 84-90
needle biopsies in, 1468
refractory
continuous infusion doxorubicin, cisplatin, etoposide, ifosfamide regimen in, 623-629
etoposide plus cyclophosphamide in, 630-637
response criteria revisions for, 1466-1477
Shimada classification of, 88
stage III, improved survival in, combined modality therapy for, 84-90
stage IV
BMT in, 2330-2341
megatherapy in, 2330
stages in, age limitations of, 1471
staging of, 1470-1471, 1771
staging revisions for, 1466-1477
therapy response in, 1471-1472
tumor marker in, 1469-1470
unresectable, treatment protocols for, 1771-1772
unresectable localized, 1770-1779
Neuromuscular toxicity, of paclitaxel, cisplatin, G-CSF regimen, 2013-2015
Neutropenia
due to CPT-11, 2197
due to paclitaxel, cisplatin, G-CSF regimen, 2015
febrile, following methotrexate, vinblastine, doxorubicin, cisplatin, G-CSF regimen, 411
NHL, *see* Non-Hodgkin's lymphoma
Node status, in malignant mesothelioma, 1172-1178
Non-Hodgkin's lymphoma
AIDS-related, oral combination chemotherapy in, 1691-1702
autotransplantation in, 2351-2361
childhood, long-term follow-up in, 1024-1032
cyclophosphamide, vincristine, methotrexate, daunomycin, prednisone induction in, 1024-1032
cyclophosphamide, vincristine, methotrexate, prednisone regimen in, 1024-1032
cytarabine, thioguanine, asparaginase, methotrexate, carmustine consolidation in, 1024-1032
doxorubicin, methotrexate, vincristine, prednisone, folinic acid, cytarabine, cyclophosphamide, etoposide regimen in, 248-254
etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone regimen in, 1573-1582
high–dose-intensity combination chemotherapy in, 943-949
in HIV-infected patients, 1099-1107
in remission, autologous BMT for, 931-936
iodine 131–labeled OKB7 in, 2021-2029
lomustine, etoposide, cyclophosphamide, procarbazine regimen in, 1691-1702
prognostic factors in, 1085-1091
relapsed, peripheral stem-cell transplantation in, 1841-1843
resistant, infusional cyclophosphamide, doxorubicin, etoposide regimen in, 1071-1079
therapy of, sperm count following, 239-247
thioguanine, cyclophosphamide, hydroxyurea, daunomycin, methotrexate, BCNU, cytarabine, vincristine, methotrexate maintenance regimen in, 1024-1032
unclassified, 1678
Non-mammary malignant neoplasm, following node-negative breast cancer, 2094-2095, 2099
NSCLC, *see* Lung cancer, non–small-cell
Nutrition
in early breast cancer, 2061-2062
fat reduction and, 2072-2080
Nutrition counseling, during cancer therapy, 2043-2049

Octreotide, loperamide *v*, in 5-FU-induced diarrhea, 148-151
OKT3, IL-2 plus
antitumor effects of, 1501-1502
clinical toxicity of, 1498-1500
immunologic activation associated with, 1499-1501
maximum-tolerated dose for, 1498
re-treatment with, 1499
in renal cancer, 1496-1505
treatment plan for, 1497-1498
Ondansetron, in cisplatin-induced nausea, 2391-2395
Ondansetron, dexamethasone regimen, in cisplatin-induced emesis, 2396-2404
Ondansetron, dexamethasone, chlorpromazine regimen, in cisplatin-induced nausea, 2391-2395
Osteolysis, gallium nitrate for, in myeloma, 2443-2450
Osteosarcoma, metastatic, 449-453
Ovarian ablation, in breast cancer, 582-583
Ovarian cancer
advanced
carboplatin plus ifosfamide in, 1952-1956
cisplatin in, 1952
cyclophosphamide plus carboplatin in, 1156-1164
carboplatin in, 440-448
carboplatin plus radiotherapy in, 440-448
chemoresistant, hormonal therapy in, 1957-1968
HSP-60 expression in, 891-898
megestrol acetate, tamoxifen, aminoglutethimide regimen in, 1957-1968
optimal cytoreduction in, CT for, 166-172
OVX1 in, 1506-1510
platinum-pretreated, paclitaxel in, 2127-2135
platinum-refractory, paclitaxel in, 2405-2410
receptor levels in, 1964
recurrent, carboplatin, GM-CSF regimen in, 2118-2126
residual

CA-125 in, 1506-1510
radioimmunoassay in, 1506-1510
secondary cytoreduction for, following cisplatin, 434-439
OVX1
in benign disease, 1508
levels of, in healthy individuals, 1507-1508
in nonovarian carcinomas, 1509
in occult disease, 1508
in ovarian cancer, 1506-1510
radioimmunoassay of, 1507
Oxantrazole, G-CSF plus
cardiac toxicity of, 1799-1801
hematologic toxicity of, 1797-1799
nonhematologic toxicity of, 1799
phase I study of, 1795-1803
Oxycodone, for cancer pain, 973-978

P.A.S. Port, for chemotherapy, 2181-2185
Paclitaxel
carboplatin plus, dose-escalation schedules for, 800
chemical structure of, 2128
cisplatin plus
dose escalations of, 2013
neutropenia due to, 2015
doxorubicin plus, dose-escalation schedules for, 799
G-CSF plus
in metastatic breast cancer, 1943-1951
myelotoxicity of, 1948
nonhematologic toxicity of, 1949
maximum-tolerated dose of, 796
metabolites of, pharmacokinetics of, 2127-2135
in NSCLC, 1393
pharmacodynamic analysis of, 2132
pharmacokinetic parameters of, 2132
pharmacokinetics of, 2127-2135, 2326
phase I trial of, 2324-2329
in platinum-refractory ovarian cancer, 2405-2410
re-treatment with, following hypersensitivity reaction, 885-890
toxicities of, 2130, 2327
Paclitaxel, cisplatin, G-CSF regimen
hematologic toxicity of, 2013
muscular toxicity of, 2015-2016
neuromuscular toxicity of, 2013-2015
neutropenia due to, 2015
pharmacologic study of, 2010-2020
Pain, cancer-induced
immediate- *v* sustained-release morphine in, 967-972
oxycodone for, 973-978
Palliative cancer therapy
approaches to, 378-379
assessment of, 379-380
in clinical trials, 380-381
cost-effectiveness of, 380
goals of, 378-381
Pamidronate, for bone metastases, 491-498
Patient compliance
microelectronic monitoring of, 1189-1197
monitoring of, pill counts for, 1189
predictors of, 1194-1195
in prolonged chemotherapy, 1710-1716
with tamoxifen, 1189
PBSCT, *see* Peripheral-blood stem-cell transplantation
PCNU, carmustine *v*, for glioma, 1316-1321
Pentoxifylline, methylprednisolone plus, 1332
Peripheral blood stem-cell transplantation
autologous, busulfan, cyclophosphamide regimen plus, 1661-1667
busulfan, cyclophosphamide regimen plus, in AML, 1661-1667
in Ewing's sarcoma, 1482-1488
GM-CSF plus, 1585
in high-dose carboplatin, cyclophosphamide regimens, 1583-1591
melphalan, etoposide, carboplatin, radiation regimen prior to, 1482-1488
in NHL, 1841-1843, 1846-1851
processing in, 1847
Peritoneal fibrosis, associated with intraperitoneal cisplatin, 5-FU regimen plus 5-FU, 429
Peritonitis, sclerosing encapsulating, associated with intraperitoneal cisplatin, 5-FU regimen plus 5-FU, 425-433
PET, *see* Positron Emission Tomography
Photodynamic therapy
in early-stage lung cancer, 1844-1845, 1852-1857
light sources for, 1853
photofrin II plus, in lung cancer, 1852
survival following, 1855
toxicity of, 1855-1857
Photofrin II
description of, 1853
photodynamic therapy plus, in lung cancer, 1844-1845, 1852-1857
Physical activity, in breast cancer, weight gain associated with, 1423-1424
Physician, as patient advocate, 1011-1013
Pi-class glutathione S-transferase expression
as prognostic factor, in lymphoma, 49-58
in breast cancer prognosis, 49-58
Pilocarpine, for xerostomia, 1124-1131
Piroxantrone, G-CSF plus
cardiac toxicity of, 1799-1801
hematologic toxicity of, 1797-1799
nonhematologic toxicity of, 1799
phase I study of, 1795-1803
Ploidy, DNA
in literature, 621
in medulloblastoma prognosis, 616-622
in node-positive breast cancer, 351-359
in rhabdomyosarcoma prognosis, 1901-1905
Polymerase chain reaction analysis
in detecting follicular lymphoma, 1344-1352
in residual leukemic disease, 546-553
Positron emission tomography
in breast cancer metabolic monitoring, 2101-2111
in chemohormonotherapy monitoring, 2101
Prednisone
in CHOP regimen, cost of, 1698
in combination chemotherapy
for adult acute lymphoblastic leukemia, 1990-2001
for elderly, 2362-2369
for large-cell lymphoma, 2250-2257
for multiple melanoma, 1165-1171
for multiple myeloma, 155-160

for NHL, 1573-1582, 248-254
for poor-prognosis NHL, 943-949
sperm count following, 239-247
in combination induction chemotherapy, for relapsed acute lymphoblastic leukemia, 271-278
in combined modality therapy, for stage I-II lymphoma, 720-725
in hybrid combination chemotherapy, for HD, 712-719
in prolonged combination chemotherapy, 1710-1716
melphalan plus, in multiple myeloma, 1165-1171
vincristine plus, in acute lymphoblastic leukemia, 2234-2242
Prednisone, doxorubicin pulse regimen, in relapsed acute lymphoblastic leukemia, 271-278
Prednisone, vincristine, daunorubicin, asparaginase regimen, in acute lymphoblastic leukemia, 210
Pregnancy, following HD therapy, 507-512
Procarbazine
in combination maintenance chemotherapy, for limited SCLC, 1593
in combined modality therapy, for HD, 100-108
in hybrid combination chemotherapy, for HD, 712-719
oral, cost of, 1698
in oral combination chemotherapy, for AIDS-related NHL, 1691-1702
Progestational agent, in chemoresistant ovarian cancer, 1957-1968
Progesterone
high-dose, for multidrug resistance, 2417-2426
pharmacokinetics of, 2422
Prognostic factor(s)
in AIDS-related NHL survival, hazards ratio for, 1698
beta-2 microglobulin as, in HD, 1108-1111
cathepsin D as
in breast cancer, 899-908
in node-negative breast cancer, 36-43
cell kinetics as, in tamoxifen-treated breast cancer, 1150-1155
DNA ploidy as
in medulloblastoma, 616-622
in node-positive breast cancer, 351-359
in rhabdomyosarcoma, 1901-1905
epidermal growth factor receptor as, in head and neck cancer, 1873-1878
in head and neck cancer, 1873-1878
hepatic venoocclusive disease as, following BMT, 1729-1736
HER-2-*neu* oncogene amplification as, in breast cancer, 1936-1942
mdr-1 as, in lymphoma, 109-115
in medulloblastoma, 2211-2217
in NHL, 1085-1091
percent S-phase as, in node-positive breast cancer, 351-359
pi-class glutathione S-transferase as, in lymphoma, 109-115
prostate-specific antigen as, in prostate cancer, 2158-2166
PS2 protein as, in breast cancer, 899-908
S-phase fraction as
in breast cancer, 1717-1722
in node-negative breast cancer, 36-43
splenectomy as, in HD, 925-930
tumor necrosis as, in node-positive breast cancer, 1929-1935
in Waldenstrom's macroglobulinemia, 1553-1558
Propofol, in outpatient bone marrow harvest, 320-323
Prostate cancer
clinical outcome prognosis in, 596-597, 607-615
hormone-refractory
continued testicular suppression in, 2167-2172
flutamide withdrawal syndrome in, 1566-1572
metastatic hormone-refractory, prostate-specific antigen in, 596-597, 607-615
potential prognostic factors in, 2162
prostate-specific antigen in, for prognosis, 2158-2166
Prostate-specific antigen
as pretherapy prognostic factor following radiotherapy, 2158-2166
in prostate cancer outcome prognosis, 596-597, 607-615
role of, in prostate cancer, 596-597, 607-615
PS2 protein, prognostic value of, in breast cancer, 899-908
Psychosocial distress, breast cancer patients with, 783-793
Psychosocial outcome
in HD, 979-988
in testicular cancer, 979-988
Psychosocial support therapy, following breast cancer, 66-69

QT interval, prolongation of, following anthracycline therapy, 1906-1910
Quality of life
assessment of, during cancer therapy, 2044-2045
following breast cancer, psychosocial support therapy for, 66-69
Functional Asessment of Cancer Therapy scale for, 570-579
megestrol acetate impact on, 2081-2089
oral combination chemotherapy for, in AIDS-related NHL, 1691-1702
following radiotherapy, in head and neck cancer, 863-872
Questionnaire, for quality-of-life assessment, in head and neck cancer, 863-872

Radiation
cyclophosphamide, doxorubicin, vincristine induction regimen plus, 1223-1229
hydroxyurea *v* misonidazole plus, in cervical cancer, 1523-1528
Radiation, cisplatin, WR2721 regimen
in cervical cancer, 1511-1516
clinical outcome of, 1514-1515
hypocalcemic effects of, 1517-1522
ionized calcium levels following, 1520
parathyroid hormone levels following, 1519
total calcium levels following, 1518
toxicities of, 1513-1514
Radiochemotherapy
myeloablative, in Ewing's sarcoma, 1482-1488
for PBSCT, 1482-1488
Radioimmunoassay, in residual ovarian cancer, 1506-1510
Radiotherapy
accelerated hyperfractionated total-lymphoid, in relapsed HD, 1062-1070
alkylating agent, intercalating topoisomerase II inhibitor plus, secondary acute myeloid leukemia following, 1039-1045
5-FU, cisplatin regimen plus, in nasopharyngeal carcinoma, 1919-1928
carboplatin following, in ovarian cancer, 440-448
carmustine plus, for glioma, 1316-1321, 857-862
cisplatin, 5-FU regimen plus, for head and neck cancer, 2136-2142
combination chemotherapy plus, for acute lymphoblastic leukemia, 2234-2242

conformal, intraarterial fluorodeoxyuridine plus, in hepatobiliary cancer, 1286-1293
cyclophosphamide, doxorubicin, vincristine, prednisone regimen plus, in lymphoma, 720-725
fluorouracil, cisplatin regimen plus, in transitional-cell bladder cancer, 2150-2157
in combined modality therapy, for HD, 100-108, 2258-2272
in HD, cardiac disease following, 1208-1215
interstitial and external-beam, for malignant glioma, 1458-1465
involved-field, in AIDS-related lymphomatous meningitis, 1978-1984
in nodular lymphoma, 233-238
PCNU plus, for glioma, 1316-1321
pelvic, sperm count following, 239-247
postoperative, in colon cancer, 1112-1117
quality of life following, for head and neck cancer, 863-872
secondary tumor following, 1706
Serratia marcescens extract plus
for glioma, 1746-1750
survival following, 1748
toxicity of, 1747-1748
of spinal cord, cardiac dysfunction following, 1033-1038
surgery plus, for brain metastasis, 369-373
of testicular cancer, second cancer following, 415-424
thoracic
chemotherapy alternating plus, in SCLC, 879-884
cyclophosphamide, doxorubicin, vincristine regimen plus, 1223-1229
total central lymphatic, 233-238
vincristine, dactinomycin, doxorubicin regimen plus, in Wilms' tumor, 1014-1023
xerostomia following, pilocarpine for, 1124-1131
see also Total-body irradiation
Radiotherapy, methotrexate, cytarabine regimen, in AIDS-related lymphomatous meningitis, 1978-1984
Rand Global Well-Being Subscale, 2085
Renal cell cancer
antibody localization in, 738-750
anti-CD3 plus IL-2 in, 1496-1505
IL-2 plus interferon alfa-2b in, 661-670
interferon alfa-2a in, 1368-1375
Ki-67 immunostaining in, 1804-1808
metastatic, subcutaneous IL-2 plus interferon alfa-2a in, 1809-1816
Researcher, clinical cancer, 1639-1651
Retinoic acid, all-*trans*, *see* All-*trans* retinoic acid
Retinoids, secondary cancer following, 1204-1207
Retroperitoneal lymph node dissection, postchemotherapy, in nonteratomatous germ cell cancer, 1294-1299
Rhabdomyosarcoma
autologous BMT plus TBI in, 1911-1918
family cancer history and, 265-266
prognosis in ploidy and, 1901-1905
therapy of, second cancer following, 262-270
Rheumatism, postchemotherapy, 768-770
Richter's syndrome, chronic lymphocytic leukemia and, 1985-1989
Rickets, hypophosphatemic, ifosfamide-induced, 176-177

S-phase fraction
as breast cancer prognostic factor, 1717-1722
in node-positive breast cancer, 351-359
Sarcoma
advanced soft tissue, chemotherapy of, 1269-1275
granulocytic, 8:21 translocation in, 690-697
osteogenic, metastatic, 449-453
pediatric, autologous BMT plus TBI in, 1911-1918
soft tissue
chemotherapy plus GM-CSF in, 15-21
doxorubicin, ifosfamide, GM-CSF regimen in, 15-21
SCLC, *see* Lung cancer, small-cell
Sclerosing encapsulating peritonitis, following intraperitoneal cisplatin, 5-FU plus 5-FU, 425-433
Screening, for late anthracycline cardiotoxicity, 1906-1910
Second cancer
following childhood rhabdomyosarcoma therapy, 262-270
following cyclophosphamide, doxorubicin, etoposide regimen, 1235-1236
following dactinomycin, vincristine, cyclophosphamide, doxorubicin regimen, 262-270
following HD therapy, 255-261
following node-negative breast cancer, 2094-2095, 2099
following retinoids, 1204-1207
following testicular cancer, 415-424, 1703, 1709
following various therapy modalities, 1706
Serratia marcescens extract, radiotherapy plus
for glioma, 1746-1750
survival following, 1748
toxicity of, 1747-1748
Shimada classification, of neuroblastoma, 88
SIOP staging, 1015
Sixth International Society of Pediatric Oncology staging, of Wilms' tumor, 1015
Sleep, assessment of
in breast cancer, 997-1004
in lung cancer, 997-1004
Sleeping disorder, chemotherapy-associated, alprazolam for, 1384-1390
Slot-blot technique, 1936-1942
SN-38
bile concentrations of, 2202
chemical structure of, 2195
pharmacokinetic parameters of, 2201
plasma concentrations of, 2202
Solid tumor, pediatric, tumor necrosis factor in, 2205-2210
Sperm count
following cyclophosphamide, 239-247
following pelvic radiotherapy, 239
Spinal cord, childhood irradiation of, cardiac dysfunction following, 1033-1038
Splenectomy, in HD, secondary acute leukemia following, 925-930
Staging laparotomy
clinical *v*, 2258-2272
CT *v*, in HD, 2218-2225
in pediatric HD, 2218-2225
Stomach cancer, *see* Gastric cancer
Suprachiasmatic nucleus, 1403-1404
Surgery
in chemorefractory germ cell cancer, 324-329
CT prior to, in ovarian cancer, 166-172
curative, in gastric cancer, adjuvant therapy following, 1441-1447
in Ewing's sarcoma, chemotherapy response following, 1763-1769

monitoring plus, second tumor following, 1706
second, in ovarian cancer, following cisplatin, 434-439
vincristine, dactinomycin, doxorubicin regimen plus, in Wilms' tumor, 1014-1023
whole-brain radiotherapy plus, for brain metastasis, 369-373
Survival
improved, combined modality therapy for, in stage III neuroblastoma, 84-90
tumor-cell ploidy and, in medulloblastoma, 2211-2217

Tamoxifen
in breast cancer, 583
cell kinetics following, 1150-1155
in elderly node-positive breast cancer, 29-35
endometrial cancer following, 485-490
fenretinide plus, 474-477
in metastatic breast cancer, 474
patient adherence to, 1189-1197
Tamoxifen, cyclophosphamide, doxorubicin regimen, in breast cancer, 454-460
Tamoxifen, megestrol acetate, aminoglutethimide regimen
in ovarian cancer, 1957-1968
toxicities of, 1960
Taxol, *see* Paclitaxel
Taxotere
antitumor activity of, 953, 955
neutropenia associated with, 952
nonhematologic toxicity of, 953
in NSCLC, 1393-1394
pharmacokinetics of, 956
structure of, 951
toxicities of, 954-955
2-hour *v* 6-hour intravenous infusion of, 950-958
TBI, *see* Total-body irradiation
Teniposide
dosing of, for targeted systemic exposure, 287-293
increased dose-intensity of, 287-293
Teniposide, cytarabine pulse regimen, in relapsed acute lymphoblastic leukemia, 271-278
Testicular cancer
contralateral, 415-424
Lugano classification of, 1704
psychosocial outcomes of, 979-988
second cancer following, 415-424, 1703-1709
Thermogenesis, in breast cancer, weight gain associated with, 1423-1424
Thioguanine, in combination chemotherapy
for acute lymphoblastic leukemia, 2234-2242
for acute myeloid leukemia, 1448-1457
for myelodysplastic syndrome, 1448-1457
Thioguanine, cyclophosphamide, hydroxyurea, daunomycin, methotrexate, BCNU, cytarabine, vincristine, methotrexate maintenance regimen, in NHL, 1024-1032
Thiotepa, intrathecal methotrexate *v*, in neoplastic meningitis, 561-569
Thoracic irradiation, timing of, in SCLC, 336-344
Thrombocytopenia
chemotherapy-related, 2057-2060
IL-3 and, 2063-2071
Thyroid gland, dysfunction of, IL-2 associated with, 921-924
Topotecan, in NSCLC, 1392-1393
Toremifene
response to, 347-348
in tamoxifen-refractory breast cancer, 345-350
toxicity of, 348-349
Total-body irradiation, autologous BMT plus, in pediatric sarcoma, 1911-1918
Tumors, ciracadian variations of, 1407-1409
Tumor marker(s)
CA-125 as, in ovarian cancer, 1506-1510
CD23 as, in nasopharyngeal cancer, 2143-2149
Ki-67 immunostaining as, in renal cell cancer, 1804-1808
in neuroblastoma, 1469-1470
OVX1 as, in ovarian cancer, 1506-1510
Tumor necrosis factor
characteristics of, 2205
in node-positive breast cancer, 1929-1935
in pediatric solid tumors, 2205-2210
phase I trial of, 2205-2210
toxicity of, 2206-2207

Ultrasonography
endoscopic, for gastric cancer recurrence, 2380-2385
in liver metastasis monitoring, 2451-2455
Undifferentiated carcinoma, of nasopharyngeal type, 2434-2442
Urothelial cancer
methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 400-407
methotrexate, vinblastine, doxorubicin, cisplatin, G-CSF regimen in, 408-414

Vaccine, in colorectal cancer, 385-386, 390-399
Venoocclusive disease, hepatic
fatal outcome and, 1729-1736
following BMT, 1729-1736
Vinblastine
in combination chemotherapy
for bladder cancer, 387-389
for good-prognosis germ cell cancer, 1300-1305
for urothelial cancer, 400-407
in combined modality therapy, for HD, 100-108
in dose-intensified combination chemotherapy, for urothelial cancer, 408-414
in hybrid combination chemotherapy, for HD, 712-719
Vinblastine, cisplatin, mitomycin regimen, in NSCLC, 1757-1762
Vinblastine, etoposide, prednisone, doxorubicin, radiotherapy, in HD, 1080-1084
Vincristine
carboplatin plus, for glioma, 850-856
in CHOP regimen, cost of, 1698
in combination chemotherapy
for elderly, 2362-2369
for hepatoblastoma, 96-99
for large-cell lymphoma, 2250-2257
for NHL, 1573-1582, 248-254
for poor-prognosis NHL, 943-949
second cancer following, 262-270
sperm count following, 239-247
in combination induction chemotherapy, for limited SCLC, 1593
in combined modality therapy

for HD, 100-108
for SCLC, 1223-1229
for stage I-II lymphoma, 720-725
secondary acute myeloid leukemia following, 1039-1045
in hybrid combination chemotherapy, for HD, 712-719
in induction combination chemotherapy, for acute lymphoblastic leukemia, 210
lomustine, 5-FU regimen plus, in colon cancer, 1879-1887
in M-BACOD regimen, cost of, 1698
in multimodality regimen, for stage III neuroblastoma, 84-90
prednisone plus, in acute lymphoblastic leukemia, 2234-2242
in prolonged combination chemotherapy, 1710-1716
in weekly combination chemotherapy, for SCLC, 1858-1865
Vincristine, carmustine, doxorubicin, prednisone regimen, in multiple myeloma, 1165-1171
Vincristine, cyclophosphamide consolidation regimen, in relapsed acute lymphoblastic leukemia, 271-278
Vincristine, cyclophosphamide, melphalan, prednisone regimen, in multiple melanoma, 1165-1171
Vincristine, cyclophosphamide, prednisone regimen, in adult acute lymphoblastic leukemia, 1990-2001
Vincristine, dactinomycin, doxorubicin regimen
radiotherapy plus, in Wilms' tumor, 1014-1023
surgery plus, 1014
Vincristine, dexamethasone, asparaginase, doxorubicin regimen, in acute lymphoblastic leukemia, 2234-2242
Vincristine, doxorubicin, prednisone regimen, in relapsed acute lymphoblastic leukemia, 271-278
Vindesine
cisplatin plus, in NSCLC, 1757-1762
in hybrid combination chemotherapy, for HD, 712-719
in weekly combination chemotherapy, for SCLC, 1858-1865
Vindesine, cisplatin, mitomycin regimen, in NSCLC, 1757-1762
Vinorelbine
hematologic toxicity of, 1248
nonhematologic toxicity of, 1248
in NSCLC, 1394
response to, 1249
weekly intravenous, in breast cancer, 1245-1252
Vitamin A
high-dose, in lung cancer, 1216-1222
patient compliance with, 1218-1219
survival following, 1219-1220
toxicity of, 1218-1219
Vomiting, cisplatin-induced
metoclopramide, dexamethasone, diphenhydramine regimen in, 2396-2404
ondansetron, dexamethasone regimen in, 2396-2404
ondansetron, dexamethasone, chlorpromazine regimen in, 2391-2395

Waldenstrom's macroglobulinemia
amyloidosis and, 914-920
clinical course of, 1554-1555
description of, 1553
hematologic findings in, 1554-1555
prognostic factors in, 1553-1558
treatment of, 1553
WBC count, GM-CSF and, 2120
Weight gain
associated with megestrol acetate, 152-154
basal metabolic rate and, in breast cancer, 1424
dietary intake and, in breast cancer, 1423-1424
dietary intervention for, in breast cancer, 1423-1424
during adjuvant chemotherapy, consequences of, 1421-1422
following adjuvant chemotherapy, in breast cancer, 1418-1429
menopausal status and, 1421-1422
physical activity and, in breast cancer, 1423-1424
thermogenesis and, in breast cancer, 1423-1424
Wilms' tumor
protocol compliance in, 1019-1020
protocol for, 1017
protocol violations in, 1019
relapse sites in, 1022
relapsed, etoposide in, 1478-1481
risk-adapted approach to, 1014-1023
SIOP staging of, 1015
stage I, treatment outcomes in, 91-95
treatment results in, 1020-1021
unilateral, 1009-1010
vincristine, dactinomycin, doxorubicin regimen in, 1014-1023
vincristine, dactinomycin, doxorubicin, radiation regimen in, 1014
Women's Intervention Nutrition Study, 2072-2080
WR2721
dosing of, in cervical cancer, 1512
hypocalcemic effects of, 1517-1522
WR2721, cisplatin, radiation regimen
in cervical cancer, 1511-1516
clinical outcome of, 1514-1515
hypocalcemic effects of, 1517-1522
ionized calcium levels following, 1520
parathyroid hormone levels following, 1519
total calcium levels following, 1518
toxicities of, 1513-1514

Xerostomia, pilocarpine for, 1124-1131

Yttrium 90–labeled antiferritin, chemotherapy, BMT regimen, in poor-prognosis HD, 698-703